2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy

The Task Force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)

Endorsed by: the International Society of Gender Medicine (IGM), the German Institute of Gender in Medicine (DGesGM), the European Society of Anaesthesiology (ESA), and the European Society of Gynecology (ESG)

Authors/Task Force Members: Vera Regitz-Zagrosek* (Chairperson) (Germany), Jolien W. Roos-Hesselink* (Co-Chairperson) (The Netherlands), Johann Bauersachs (Germany), Carina Blomström-Lundqvist (Sweden), Renata Cičková (Czech Republic), Michele De Bonis (Italy), Bernard Jung (France), Mark Richard Johnson (UK), Ulrich Kintscher (Germany), Peter Kranke1 (Germany), Irene Marthe Lang (Austria), Joao Morais (Portugal), Petronella G. Pieper (The Netherlands), Patrizia Presbitero (Italy), Susanna Price (UK), Giuseppe M. C. Rosano (UK/Italy), Ute Seeland (Germany), Tommaso Simoncini2 (Italy), Lorna Swan (UK), Carole A. Warnes (USA)

* Corresponding authors. Vera Regitz-Zagrosek, Charité Universitätsmedizin Berlin, Institute for Gender in Medicine, CCR, DZHK, partner site Berlin, Hessische Str 3-4, 10115 Berlin, Germany, Tel: +49 30 450 525 288, Fax: +49 30 450 7 525 288, E-mail: vera.regitz-zagrosek@charite.de. Jolien W. Roos-Hesselink, Department of Cardiology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 40, 3015CGGD, Rotterdam, Netherlands, Tel: +31 10 7032432, E-mail: j.roos@erasusmc.nl

ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies document reviewers: listed in the Appendix.

1 Representing the European Society of Anaesthesiology (ESA)
2 Representing the European Society of Gynecology (ESG)

ESC entities having participated in the development of this document:

Associations: Acute Cardiovascular Care Association (ACCA), European Association of Cardiovascular Imaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).

Councils: Council on Cardiovascular Nursing and Allied Professions, Council on Cardiovascular Primary Care, Council on Hypertension, Council on Valvular Heart Disease.

Working Groups: Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Grown-up Congenital Heart Disease, Myocardial and Pericardial Diseases, Pulmonary Circulation and Right Ventricular Function, Thrombosis.

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).

Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of health care or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and the patient’s caregiver where appropriate and/or necessary. Nor do the ESC Guidelines exempt health professionals from taking careful and full consideration of the relevant official updated recommendations or guidelines issued by the competent public health authorities in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

© The European Society of Cardiology 2018. All rights reserved. For permissions please email: journals.permissions@oup.com.
Document Reviewers: Christi Deaton (CPG Review Coordinator) (UK), Iain A. Simpson (CPG Review Coordinator) (UK), Victor Aboyans (France), Stefan Agewall (Norway), Emanuele Barbato (Italy), Pavel Calda (Czech Republic), Antonio Coca (Spain), Ioan Mircea Coman (Romania), Julie De Backer (Belgium), Victoria Delgado (The Netherlands), Giovanni Di Salvo (UK), Samantha Fitzsimmons (UK), Donna Fitzsimons (UK), Madalina Garbi (UK), Sofie Gevaert (Belgium), Gerhard Hindricks (Germany), Guillaume Jondeau (France), Jolanda Kluin (The Netherlands), Christos Lions (Greece), Theresa A. McDonagh (UK), Pascal Meier (UK/Switzerland), Philip Moons (Belgium), Antonis Pantazis (UK), Massimo Francesco Piepoli (Italy), Bianca Rocca (Italy), Marco Roffi (Switzerland), Stephan Rosenkranz (Germany), Andrea Sarkozy (Belgium), Evgeny Shlyakhto (Russia), Candice K. Silversides (Canada), Karen Sliwa (South Africa), Miguel Sousa-Uva (Portugal), Juan Tamargo (Spain), Sara Thorne (UK), Marc Van de Velde (Belgium), Bryan Williams (UK), Jose Luis Zamorano (Spain)

The disclosure forms of all experts involved in the development of these Guidelines are available on the ESC website www.escardio.org/guidelines

Online publish-ahead-of-print 25 August 2018

Table of Contents

Table of Contents .......................................................... 3166
List of tables ......................................................................... 3168
Abbreviations and acronyms .................................................. 3168
1. Preamble ........................................................................ 3169
2. Introduction ..................................................................... 3171
   2.1 Why do we need new Guidelines on the management of cardiovascular diseases in pregnancy? .................................................. 3171
   2.2 New format of the Guidelines ............................................. 3171
   2.3 Why these Guidelines are important? .............................. 3171
   2.4 Methods ........................................................................ 3171
   2.5 What is new? ................................................................ 3172
3. General considerations ..................................................... 3173
   3.1 Epidemiology ................................................................ 3173
   3.2 Physiological adaptations to pregnancy ........................... 3174
   3.3 Pre-pregnancy counselling .............................................. 3174
      3.3.1 Risk of maternal cardiovascular complications .......... 3174
      3.3.2 Risk of obstetric and offspring complications .......... 3174
      3.3.3 Pregnancy heart team ............................................. 3176
   3.4 Cardiovascular diagnosis in pregnancy ............................ 3176
      3.4.1 Electrocardiography ................................................ 3176
      3.4.2 Echocardiography .................................................. 3176
      3.4.3 Exercise testing ...................................................... 3177
   3.5 Genetic testing and counselling ....................................... 3177
   3.6 Foetal assessment ........................................................ 3178
      3.6.1 Screening for congenital heart disease ....................... 3178
      3.6.2 Assessing foetal wellbeing ...................................... 3178
   3.7 Interventions in the mother during pregnancy .................. 3178
      3.7.1 Percutaneous therapy ............................................. 3178
      3.7.2 Cardiac surgery with cardiopulmonary bypass ........... 3178
   3.8 Timing and mode of delivery: risk for mother and child .... 3179
      3.8.1 Timing of delivery .................................................. 3179
      3.8.2 Labour induction ................................................. 3179
      3.8.3 Vaginal or caesarean delivery ................................ 3179
      3.8.4 Delivery in anticoagulated women (not including mechanical valve; see section 5) .............................................. 3179
      3.8.5 Urgent delivery on therapeutic anticoagulation ......... 3179
      3.8.6 Haemodynamic monitoring during delivery .............. 3180
      3.8.7 Anaesthesia/analgesia .......................................... 3180
      3.8.8 Labour ............................................................... 3180
      3.8.9 Perimortem caesarean section ............................... 3180
3.4.4 Ionizing radiation exposure ......................................... 3177
3.4.5 Chest radiography and computed tomography .................. 3177
3.4.6 Cardiac catheterization .............................................. 3177
3.4.7 Magnetic resonance imaging ....................................... 3177
3.5 Genetic testing and counselling ....................................... 3177
3.6 Foetal assessment ........................................................ 3178
   3.6.1 Screening for congenital heart disease ....................... 3178
   3.6.2 Assessing foetal wellbeing ...................................... 3178
3.7 Interventions in the mother during pregnancy .................. 3178
   3.7.1 Percutaneous therapy ............................................. 3178
   3.7.2 Cardiac surgery with cardiopulmonary bypass ........... 3178
3.8 Timing and mode of delivery: risk for mother and child .... 3179
   3.8.1 Timing of delivery .................................................. 3179
   3.8.2 Labour induction ................................................. 3179
   3.8.3 Vaginal or caesarean delivery ................................ 3179
   3.8.4 Delivery in anticoagulated women (not including mechanical valve; see section 5) .............................................. 3179
   3.8.5 Urgent delivery on therapeutic anticoagulation ......... 3179
   3.8.6 Haemodynamic monitoring during delivery .............. 3180
   3.8.7 Anaesthesia/analgesia .......................................... 3180
   3.8.8 Labour ............................................................... 3180
   3.8.9 Perimortem caesarean section ............................... 3180

Keywords
Guidelines • Pregnancy • Cardiovascular disease • Risk assessment • Management • Congenital heart disease • Valvular heart disease • Hypertension • Heart failure • Arrhythmia • Pulmonary hypertension • Aortic pathology • Cardiomyopathy • Drug therapy • Pharmacology
3.10 Methods of contraception and termination of pregnancy, and in vitro fertilization ................................................................. 3180
3.10.1 Methods of contraception .................................................. 3181
3.10.2 Sterilization ........................................................................ 3181
3.10.3 Methods of termination of pregnancy ................................. 3181
3.10.4 In vitro fertilization .............................................................. 3181
3.11 Recommendations .................................................................. 3182
4. Congenital heart disease and pulmonary hypertension .............. 3182
4.1 Introduction ............................................................................ 3182
4.2 Pulmonary hypertension and Eisenmenger’s syndrome ............. 3183
4.2.1 Pulmonary hypertension ...................................................... 3183
4.2.2 Eisenmenger’s syndrome .................................................... 3183
4.2.3 Cyanotic heart disease without pulmonary hypertension .......... 3184
4.3 Specific congenital heart defects ................................................. 3184
4.3.1 Left ventricular outflow tract obstruction ............................... 3184
4.3.2 Atrial septal defect ............................................................. 3184
4.3.3 Ventricular septal defect ...................................................... 3184
4.3.4 Atrophicventricular septal defect ......................................... 3184
4.3.5 Coarctation of the aorta ....................................................... 3184
4.3.6 Pulmonary valve and right ventricular outflow tract disease .... 3184
4.3.7 Congenital aortic stenosis ................................................... 3185
4.3.8 Tetralogy of Fallot ............................................................. 3185
4.3.9 Ebstein’s anomaly ............................................................. 3185
4.3.10 Transposition of the great arteries ..................................... 3185
4.3.11 Congenitally corrected transposition of the great arteries ....... 3185
4.3.12 Fontan circulation ............................................................. 3186
4.4 Recommendations .................................................................... 3186
5. Aortic diseases ........................................................................... 3186
5.1 Maternal and offspring risk ....................................................... 3187
5.2 Specific syndromes .................................................................. 3187
5.2.1 Marfan syndrome ............................................................. 3187
5.2.2 Bicuspid aortic valve ......................................................... 3187
5.2.3 Vascular Ehlers–Danlos syndrome ..................................... 3187
5.2.4 Turner syndrome ............................................................. 3187
5.2.5 Other autosomal dominant aortopathies .............................. 3187
5.3 Management ........................................................................... 3187
5.3.1 Follow-up and medical therapy .......................................... 3187
5.3.2 Interventions ...................................................................... 3188
5.3.3 Delivery ............................................................................ 3188
5.4 Recommendations .................................................................... 3189
6. Valvular heart disease ................................................................. 3190
6.1 Stenotic valve lesions ............................................................... 3190
6.1.1 Mitral stenosis .................................................................... 3190
6.1.2 Valvular aortic stenosis ...................................................... 3190
6.2 Regurgitant lesions .................................................................. 3191
6.2.1 Mitral and aortic regurgitation .......................................... 3191
6.2.2 Tricuspid regurgitation ...................................................... 3191
6.3 Atrial fibrillation in native heart valve disease .......................... 3191
6.4 Prosthetic valves ..................................................................... 3191
6.4.1 Choice of valve prosthesis ................................................ 3191
6.4.2 Pregnancy risk with bioprostheses ..................................... 3192
6.5 Mechanical prostheses and anticoagulation .............................. 3192
6.5.1 Maternal risk .................................................................... 3192
6.5.2 Obstetric and offspring risk .............................................. 3192
6.5.3 Management ..................................................................... 3193
6.6 Recommendations .................................................................... 3195
7. Coronary artery disease ............................................................... 3197
7.1 Aetiology ................................................................................ 3197
7.2 Presentation and diagnosis ...................................................... 3197
7.3 Management .......................................................................... 3197
7.4 Pharmacotherapy .................................................................... 3197
7.5 Intervention ............................................................................ 3197
7.6 Pre-existing CAD .................................................................... 3197
7.7 Labour and delivery ................................................................. 3198
7.8 Recommendations .................................................................... 3198
8. Cardiomyopathies and heart failure ............................................. 3198
8.1 Peripartum cardiomyopathy ..................................................... 3198
8.1.1 Diagnosis .......................................................................... 3198
8.1.2 Prognosis and counselling ................................................ 3198
8.2 Dilated cardiomyopathy .......................................................... 3198
8.2.1 Prognosis and counselling ................................................ 3199
8.3 Management of heart failure during and after pregnancy ......... 3199
8.3.1 Acute/subacute heart failure and cardiogenic shock during or after pregnancy ................................................................. 3199
8.3.2 Bromocriptine and peripartum cardiomyopathy .................... 3201
8.3.3 Devices and transplantation .............................................. 3201
8.3.4 Anticoagulation ............................................................... 3201
8.3.5 Delivery and breastfeeding ............................................... 3201
8.4 Hypertrophic cardiomyopathy .................................................. 3201
8.4.1 Management .................................................................... 3201
8.4.2 Delivery ........................................................................... 3202
8.5 Recommendations .................................................................... 3202
9. Arrhythmias ................................................................................ 3203
9.1 Introduction ............................................................................ 3203
9.2 Maternal risk .......................................................................... 3203
9.3 Obstetric and offspring risk ...................................................... 3203
9.4 Supraventricular tachycardia .................................................... 3203
9.5 Atrial fibrillation and atrial flutter .......................................... 3203
9.5.1 Anticoagulation ............................................................... 3203
9.6 Ventricular tachycardia ............................................................ 3203
9.7 Bradycarrhythmias ................................................................. 3204
1. Preamble

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other societies and organisations. Because of the impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.

Members of this Task Force were selected by the ESC, including representation from its relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management of a given condition according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk–benefit ratio. The level of evidence and the
strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined in Tables 1 and 2.

The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. These forms were compiled into one file and can be found on the ESC website (http://www.escardio.org/guidelines). Any changes in declarations of interest that arise during the writing period were notified to the ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry.

The ESC CPG supervises and coordinates the preparation of new Guidelines. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the Guidelines are approved by all the experts involved in the Task Force. The finalized document is approved by the CPG for publication in the European Heart Journal. The Guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.

The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recommendations including condensed pocket guideline versions, summary slides, booklets with essential messages, summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.). These versions are abridged and thus, if needed, one should always refer to the full text version, which is freely available via the ESC website and hosted on the EHJ website. The National Societies of the ESC are encouraged to endorse, translate and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.

Surveys and registries are needed to verify that real-life daily practice is in keeping with what is recommended in the guidelines, thus completing the loop between clinical research, writing of guidelines, disseminating them and implementing them into clinical practice.

Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do...
Table 2  Level of evidence

<table>
<thead>
<tr>
<th>Level of evidence</th>
<th>Data derived from multiple randomized clinical trials or meta-analyses.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level of evidence B</td>
<td>Data derived from a single randomized clinical trial or large non-randomized studies.</td>
</tr>
<tr>
<td>Level of evidence C</td>
<td>Consensus of opinion of the experts and/or small studies, retrospective studies, registries.</td>
</tr>
</tbody>
</table>

not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription.

2. Introduction

2.1 Why do we need new Guidelines on the management of cardiovascular diseases in pregnancy?

Since the previous version of these Guidelines was published in 2012, new evidence has accumulated, particularly on diagnostic techniques, risk assessment, and the use of cardiovascular drugs. This made a revision of the recommendations necessary.

2.2 New format of the Guidelines

The new Guidelines have been adapted to facilitate their use in clinical practice and to meet readers’ demands by focusing on condensed, clearly presented recommendations. At the end of each section, ‘recommendations’ summarize the essentials. ‘Gaps in the evidence’ are listed in section 13 to propose topics for future research. The Guidelines document is harmonized with the simultaneously published chapter on the management of cardiovascular diseases (CVDs) in pregnancy of the ESC Textbook of Cardiology (http://oxfordmedicine.com/view/10.1093/med/9780199566990.001.0001/med-978019566990-chapter-33). Background information and a detailed discussion of the data that have provided the basis for the recommendations can be found in the relevant book chapter.

2.3 Why these Guidelines are important

Pregnancy is complicated by maternal disease in 1–4% of cases. New data about the prevalence and incidence of pregnancy-related heart disease are limited from most parts of the world. Sudden adult death syndrome, peripartum cardiomyopathy (PPCM), aortic dissection, and myocardial infarction (MI) were the most common causes of maternal death in the UK over the period 2006–08. Knowledge of the risks associated with CVDs during pregnancy and their management in pregnant women who suffer from serious pre-existing conditions is of pivotal importance for advising patients before pregnancy. Since all measures concern not only the mother but the foetus as well, the optimum treatment of both must be targeted. A therapy favourable for the mother can be associated with potential harm to the developing child and, in extreme cases, treatment measures that protect the survival of the mother can cause the death of the foetus. On the other hand, therapies to protect the child may lead to a sub-optimal outcome for the mother. Because prospective or randomized studies are frequently absent, recommendations in these Guidelines mostly correspond to evidence level C. Therefore, registries and prospective studies are urgently needed to improve current knowledge. At the European level, the Registry Of Pregnancy And Cardiac disease (ROPAC) registry of the ESC and the European Surveillance of Congenital Anomalies network are providing data on epidemiology and drug exposure in pregnancy.

2.4 Methods

The current Guidelines are based on the previously published ESC Guidelines on the management of CVDs during pregnancy, the literature found in a systematic search from 2011–16 in the National Institutes of Health database (PubMed), and on recent publications and recommendations from the American Heart Association and the American College of Cardiology. Furthermore, we considered related Guidelines of the ESC published in 2012–15 on the topics of congenital heart disease, aortic disease, valvular heart disease, coronary artery disease (CAD), hypertension, pericardial diseases, pulmonary hypertension (PH), infective endocarditis (IE), ventricular arrhythmias, and acute coronary syndromes, and on the topics of cancer treatment and cardiovascular toxicity, dyslipidaemias, atrial fibrillation (AF), and CVD prevention published in 2016 (https://www.escardio.org/Guidelines/Clinical-Practice-Guidelinehomepage).
### 2.5 What is new in the 2018 CVD in Pregnancy Guidelines? (Figure 1)

#### Selected revised recommendations and selected new recommendations

<table>
<thead>
<tr>
<th>Comment/comparison with 2011 version</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strengthening mWHO classification of maternal risk.</td>
<td>It is recommended to perform risk assessment in all women with cardiac diseases of childbearing age and before conception, using the mWHO classification of maternal risk(^{11}) (IC).</td>
</tr>
<tr>
<td>Upgrade in class of recommendation; patients with severe MS should undergo intervention before pregnancy.</td>
<td>Intervention is recommended before pregnancy in patients with MS and valve area &lt;1.0 cm(^2) (IC).</td>
</tr>
<tr>
<td>In 2011, OACs were recommended during the second and third trimesters until the 36th week. Now, separate recommendations for women with low and high dose are given for VKA use during the second and third trimesters.</td>
<td>During the second and third trimesters until the 36th week, VKAs are recommended in women needing a low dose (low-dose VKA: warfarin &lt;5 mg/day, phenprocoumon &lt;3 mg/day, or acenocoumarol &lt;2 mg/day) (IC).</td>
</tr>
<tr>
<td>Sotalol deleted.</td>
<td>Flecainide or propafenone are recommended for prevention of SVT in patients with WPW syndrome(^{12}) (IC).</td>
</tr>
<tr>
<td>Changed in high-risk patients from UFH to LMWH. Dosing based on body weight introduced.</td>
<td>LMWH is the drug of choice for the prevention and treatment of VTE in all pregnant patients(^{13}) (IB). It is recommended that the therapeutic dose of LMWH is based on body weight(^{14}) (IC).</td>
</tr>
<tr>
<td>Changes: dose adjustment of UFH or LMWH dose within 36 h now recommended.</td>
<td>In pregnant women on LMWH or UFH, it is recommended to perform weekly anti-Xa level monitoring or aPTT monitoring with dose adjustment (within 36 h) (IC).</td>
</tr>
<tr>
<td>Upgrade of recommendation: IIb to IIa.</td>
<td>Catheter ablation with electroanatomical systems should be considered in experienced centres in case of drug-refractory and poorly tolerated SVT(^{15–17}) (IIaC).</td>
</tr>
<tr>
<td>Change from D-dimers to imaging as the first line of investigation, as D-dimers are unreliable in pregnancy.</td>
<td>If compression ultrasound is negative, magnetic resonance venography should be considered to diagnose VTE(^{18}) (IIaC).</td>
</tr>
<tr>
<td>FDA categories A–X were used for all drugs in 2011.</td>
<td>Decision-making based on former FDA categories is no longer recommended (IIIC).</td>
</tr>
<tr>
<td>‘Pre-pregnancy surgery’ is now deleted. Now also information on Turner syndrome with aortic diameter corrected for BSA</td>
<td>Pregnancy is not recommended in patients with severe dilatation of the aorta (heritable thoracic aortic disease such as Marfan syndrome &gt;45 mm, bicuspid aortic valve &gt;50 mm, &gt;27 mm/m(^2) BSA, or Turner syndrome ASI &gt;25 mm/m(^2) BSA)(^{19,20}) (IIIC).</td>
</tr>
</tbody>
</table>

#### Selected new recommendations

- Right heart catheterization is recommended to confirm the diagnosis of PAH. This can be performed during pregnancy but with very strict indications\(^{10}\) (IC).
- LMWH in therapeutic dose is recommended in pregnant patients with chronic thrombo-embolic pulmonary hypertension (IC).
3. General considerations

3.1 Epidemiology

In the western world, the risk of CVD in pregnancy has increased due to increasing age at first pregnancy. According to World Atlas, the 10 countries where mean age at first birth is highest record a mean age between 28.8–31.2 years. The mild increase in maternal age does not justify an increase in CVD during pregnancy because of maternal age. However, pregnancies in the late reproductive years (or between ages of 40–50 years) are more frequently associated with an increasing prevalence of cardiovascular risk factors, especially diabetes, hypertension, and obesity. Additionally, an increasing number of women with congenital heart disease reach childbearing age. In western countries, maternal heart disease is the major cause of maternal death during pregnancy.

Hypertensive disorders are the most frequent cardiovascular disorders during pregnancy, occurring in 5–10% of all pregnancies (see section 10). Among the other disease conditions, congenital heart disease is the most frequent CVD present during pregnancy in the western world (75–82%). Rheumatic valvular disease dominates in non-western countries, comprising 56–89% of all CVDs in pregnancy. Peripartum intensive care unit (ICU) admissions are increasing in frequency, with affected women-who suffer from serious pre-existing conditions, are older, and present with multiple comorbidities and also congenital heart disease-being more frequently admitted to ICU.
admitted than in previous years. The admission rate to ICUs was 6.4 per 1000 deliveries, corresponding to 1 admission per 156 deliveries, in Vienna, Austria during the period 2011–14. A 5% mortality rate was also observed in the study and is considered as appropriate in comparison to the literature. Cardiomyopathies are rare, but represent severe causes of cardiovascular complications in pregnancy.

3.2 Physiological adaptations to pregnancy

Pregnancy induces changes in the cardiovascular system to meet the increased metabolic demands of the mother and foetus. Plasma volume and cardiac output (CO) reach a maximum of 40–50% above baseline at 32 weeks of gestation, while 75% of this increase has occurred by the end of the first trimester. The increase in CO is achieved by an increase in stroke volume in the first-half of pregnancy and a gradual increase in heart rate thereafter. Atrial and ventricular diameters increase while ventricular function is preserved. In women with heart disease, left ventricular (LV) and right ventricular (RV) adaptation to pregnancy can be suboptimal. Maternal cardiac dysfunction is related to impaired uteroplacental flow and suboptimal foetal outcome. Systemic and pulmonary vascular resistances decrease during pregnancy.

Pregnancy is a hypercoagulable state associated with increased risk of thrombo-embolism. Increased activity of liver enzyme systems, glomerular filtration rate, and plasma volume, protein binding changes, and decreased serum albumin levels contribute to changes in the pharmacokinetics of many drugs. Uterine contractions, positioning (left lateral vs. supine), pain, anxiety, exertion, haemorrhage, and uterine involution cause significant haemodynamic changes during labour and post-partum. Anaesthesia, haemorrhage, and infection may induce additional cardiovascular stress. Blood pressure (BP) and CO increase during labour and post-partum. In conclusion, the physiological adaptations to pregnancy influence the evaluation and interpretation of cardiac function and clinical status.

3.3 Pre-pregnancy counselling

All women with known cardiac or aortic disease who wish to embark on pregnancy require timely pre-pregnancy counselling. Informed maternal decision-making is crucial and there is a clear need for individualized care, taking into account not only the medical condition but also the emotional and cultural context, psychological issues, and ethical challenges. Especially in patients with a high-risk or possible contraindication for pregnancy, the risk of pregnancy and the necessity of careful planning of pregnancy should be discussed at a young age. However, it is also important to explain that many women can go through pregnancy with low-risks.

For risk estimation, as a minimum, an electrocardiogram (ECG), echocardiography, and an exercise test should be performed. In case of aortic pathology, complete aortic imaging by computed tomography (CT) scanning or magnetic resonance imaging (MRI) is necessary for appropriate pre-conception counselling. Peak heart rate and peak oxygen uptake are both known to be predictive of maternal cardiac events in pregnancy. A pregnancy exercise capacity >80% is associated with a favourable pregnancy outcome.

Several aspects must be discussed, including long-term prognosis, fertility and miscarriage rates, risk of recurrence of congenital disease, drug therapy, estimated maternal risk and outcome, expected foetal outcomes, and plans for pregnancy care and delivery. A multidisciplinary management plan should be constructed and discussed with the patient. In addition, attention to unhealthy habits including being overweight, smoking, and consuming alcohol is important, as these can have a clear impact on maternal and foetal outcomes. Pregnancy is a very suitable time for recommending a healthy lifestyle, including smoking cessation.

3.3.1 Risk of maternal cardiovascular complications

The risk of complications in pregnancy depends on the underlying cardiac diagnosis, ventricular and valvular function, functional class, presence of cyanosis, pulmonary artery pressures, and other factors. Comorbidities, including for example rheumatoid and musculoskeletal diseases as well as mental disorders, should also be taken into account. Therefore, risk estimation should be individualized.

To assess the maternal risk of cardiac complications during pregnancy, the condition of the woman should be assessed, taking into account medical history, functional class, oxygen saturation, natriuretic peptide levels, echocardiographic assessment of ventricular and valvular function, intrapulmonary pressures and aortic diameters, exercise capacity, and arrhythmias. Disease-specific risk should be assessed using the modified World Health Organization (mWHO) classification (Table 3) and as described in the respective sections dealing with specific diseases in these Guidelines. Risk estimation should be further refined by taking into account predictors that have been identified in studies that included large populations with various diseases, such as the CARPREG (CARDiac disease in PREGnancy), ZAHARA, and ROPAC (Registry Of Pregnancy And Cardiac disease) studies (Table 4).

The mWHO classification is currently the most accurate system of risk assessment, although it is probably more appropriate for developed, rather than developing, countries. The general principles of this classification, and follow-up and management during pregnancy according to this mWHO classification, are presented in Table 3. Indications for intervention (surgical or catheter) do not differ in women who contemplate pregnancy compared with other patients. The few exceptions to this rule are women with at least moderate mitral stenosis and women with aortic dilatation. See also the disease-specific sections of these Guidelines. Fertility treatment is contraindicated in women with mWHO class IV, and should be carefully considered in those who have mWHO class III disease or who are anti-coagulated.

The risk estimation needs to be re-evaluated during each pre-pregnancy visit, because the risk of complications may change over time. Natriuretic peptide levels are associated with the occurrence of cardiac events, with N-terminal pro B-type natriuretic peptide (NT-proBNP) >128 pg/mL at 20 weeks pregnancy being predictive of events later in the pregnancy. Pre-eclampsia is associated with HF in women with heart disease.

3.3.2 Risk of obstetric and offspring complications

Women with cardiac disease have an increased risk of obstetric complications, including premature labour, pre-eclampsia, and post-partum haemorrhage. Offspring complications occur in 18–30% of patients with heart disease, with neonatal mortality between 1–4%. Maternal and
### Table 3  Modified World Health Organization classification of maternal cardiovascular risk

<table>
<thead>
<tr>
<th>Diagnosis (if otherwise well and uncomplicated)</th>
<th>mWHO I</th>
<th>mWHO II</th>
<th>mWHO II–III</th>
<th>mWHO III</th>
<th>mWHO IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small or mild pulmonary stenosis</td>
<td>Small increased risk of maternal mortality and no/mild increased risk in morbidity</td>
<td>Intermediate increased risk of maternal mortality or moderate to severe increase in morbidity</td>
<td>Significantly increased risk of maternal mortality or severe morbidity</td>
<td>Extremely high risk of maternal mortality or severe morbidity</td>
<td></td>
</tr>
<tr>
<td>Patent ductus arteriosus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitral valve prolapse</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Successfully repaired simple lesions (atrial or ventricular septal defect, patent ductus arteriosus, anomalous pulmonary venous drainage)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atrial or ventricular ectopic beats, isolated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk</th>
<th>mWHO I</th>
<th>mWHO II</th>
<th>mWHO II–III</th>
<th>mWHO III</th>
<th>mWHO IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>No detectable increased risk of maternal mortality and no/mild increased risk in morbidity</td>
<td>Small increased risk of maternal mortality or moderate increase in morbidity</td>
<td>Intermediate increased risk of maternal mortality or moderate to severe increase in morbidity</td>
<td>Significantly increased risk of maternal mortality or severe morbidity</td>
<td>Extremely high risk of maternal mortality or severe morbidity</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Maternal cardiac event rate</th>
<th>2.5–5%</th>
<th>5.7–10.5%</th>
<th>10–19%</th>
<th>19–27%</th>
<th>40–100%</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Counselling</th>
<th>Yes</th>
<th>Yes</th>
<th>Yes</th>
<th>Yes: expert counselling required</th>
<th>Yes: pregnancy contraindicated if pregnancy occurs, termination should be discussed</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Care during pregnancy</th>
<th>Local hospital</th>
<th>Local hospital</th>
<th>Referral hospital</th>
<th>Expert centre for pregnancy and cardiac disease</th>
<th>Expert centre for pregnancy and cardiac disease</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Minimal follow-up visits during pregnancy</th>
<th>Once or twice</th>
<th>Once per trimester</th>
<th>Bimonthly</th>
<th>Monthly or bimonthly</th>
<th>Monthly</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Location of delivery</th>
<th>Local hospital</th>
<th>Local hospital</th>
<th>Referral hospital</th>
<th>Expert centre for pregnancy and cardiac disease</th>
<th>Expert centre for pregnancy and cardiac disease</th>
</tr>
</thead>
</table>

ASI = aortic size index; EF = ejection fraction; HTAD = heritable thoracic aortic disease; mWHO = modified World Health Organization classification; NYHA = New York Heart Association; WHO = World Health Organization.
3.3.3 Pregnancy heart team

In women with a moderate or high-risk of complications during pregnancy (mWHO II–III, III, and IV), pre-pregnancy counselling and management during pregnancy and around delivery should be conducted in an expert centre by a multidisciplinary team: the pregnancy heart team. The minimum team requirements are a cardiologist, obstetrician, and anaesthetist, all with expertise in the management of high-risk pregnancies in women with heart disease. Additional experts that may be involved, depending on the individual situation, are a geneticist, cardiothoracic surgeon, paediatric cardiologist, foetal medicine specialist, neonatologist, haematologist, nurse specialist, pulmonary specialist, and others where appropriate. In this team patients from other centres can also be discussed, so not every hospital needs to have its own pregnancy heart team. The conclusions and recommendations should be filed and made available 24 h per day.

3.4 Cardiovascular diagnosis in pregnancy

During pregnancy it can be more difficult to diagnose HF, for example, because the physiological changes that occur during pregnancy (section 3.2) may mimic CVD. However, many disorders can be identified by taking a careful history and a thorough physical examination. When disproportionate or unexplained dyspnoea occurs during pregnancy and/or when a new pathological murmur (all audible diastolic murmurs are abnormal) is heard, echocardiography is indicated. BP should be measured using a standardized method (section 10). Proteinuria should be sought, especially with a history or family history of hypertension or pre-eclampsia. Oxytocin should be performed in patients with congenital heart disease.

3.4.1 Electrocardiography

In most pregnant patients, the heart rotates to the left with a 15°–20° leftward axis deviation on the ECG. Common additional findings include transient ST/T wave changes, a Q wave and inverted T waves in lead III, an attenuated Q wave in lead aVF, and inverted T waves in V1, V2, and occasionally V3. Changes may mimic LV hypertrophy and other structural heart diseases. Holter monitoring should be performed in patients with known previous paroxysmal/persistent arrhythmia [ventricular tachycardia (VT), AF, or atrial flutter] or reporting palpitations.

3.4.2 Echocardiography

Transthoracic echocardiography is the preferred imaging method in pregnancy. This reproducible, widely available, relatively cheap diagnostic modality can be used both in the outpatient clinic and at the
cardiology ward, and also at the emergency department, ICU, and obstetric ward, and should be used with a low threshold. During pregnancy, some changes in echo parameters are expected, such as mild dilatation of the chambers, a change in LV wall thickness, and an increase in valve gradients. Transoesophageal echocardiography is relatively safe; however, the risk of vomiting/aspiration and sudden increases in intra-abdominal pressure should be considered, and foetal monitoring performed.

3.4.3 Exercise testing
Physiological exercise testing is an integral part of follow-up in adult congenital heart disease and valve disease, and should be performed in patients with known heart disease who plan pregnancy. This Task Force recommends submaximal exercise testing (80% of predicted maximal heart rate) in asymptomatic patients with suspected heart disease if already pregnant. There is no evidence that it increases the risk of spontaneous miscarriage. Stress echocardiography using bicycle ergometry may improve diagnostic specificity. Dobutamine stress is rarely indicated during pregnancy and, because pregnancy in itself is a stress test, its use should be avoided when other options are available.

3.4.4 Ionizing radiation exposure
The potential risks of ionizing radiation exposure to the foetus depend on the stage of pregnancy and the absorbed dose. Risks are highest during organogenesis and the early foetal period, less in the second trimester, and least in the third trimester. Malformations are typically associated with the central nervous system. Early in pregnancy (including 0–8 days pre-implantation), the high incidence of spontaneous abortion makes the evaluation of radiation-induced pre-natal death difficult, although it occurs at other stages of gestation with doses >250 mGy. Observed radiation-induced abnormalities (typically at doses of 100–200 mGy) include growth restriction, intellectual disability, malignancies, and neurological effects. The periods of greatest vulnerability include growth retardation at 8–56 days, microcephaly at 14–105 days, and intellectual deficit/seizures/severe mental impairment at 56–105 days. An increased risk of childhood cancer with in utero doses of approximately 20 mGy has been reported, with an estimated 1–2 cases of childhood cancer occurring per 3000 children exposed to 10 mGy of radiation in utero. If possible, procedures should be delayed until at least the completion of the period of major organogenesis (>12 weeks after menses).

All medical radiation doses must be kept ‘as low as reasonably achievable’. If ionizing radiation is required, risks and benefits should be communicated to the mother, and informed consent obtained. The radiation dose to the foetus should be kept as low as possible (preferably <50 mGy) with clear documentation, particularly if the foetus is in the field of view (see section 3.7.1).

3.4.5 Chest radiography and computed tomography
Although the foetal dose from chest radiography is <0.01 mGy, it should only be performed if other methods fail to clarify the cause of symptoms. Lung ultrasound is a promising alternative imaging modality, although its use in pregnancy has yet to be clarified. CT is usually not necessary for cardiac disease during pregnancy and is not recommended, except for the diagnosis or exclusion of pulmonary embolism (PE) or aortic pathology where other diagnostic tools are insufficient (section 10), and where low radiation CT with 0.01–0.66 mGy can be used.

3.4.6 Cardiac catheterization
Cardiac catheterization is seldom needed for diagnostic purposes, but can be necessary to guide interventional procedures.

The mean radiation exposure to the unshielded abdomen is 1.5 mGy, and <20% of this reaches the foetus. For example, successful closure of a patent foramen ovale was achieved with the Helex device in three patients in the second trimester. Radiation doses, as assessed by dose area product, were 260, 58, and 19 cGy/cm², with estimated uterine (foetal) doses of <0.005, <0.001, and <0.005 mGy, respectively. The radial approach by an experienced operator is preferable. Most electrophysiological studies should only be performed if arrhythmias are medically refractory and cause haemodynamic compromise. Electroanatomical mapping systems should be used to reduce the radiation dose (section 3).

3.4.7 Magnetic resonance imaging
MRI is advised if other non-invasive diagnostic measures are not sufficient for definitive diagnosis, and is preferred to ionizing radiation-based imaging modalities when possible. Evidence regarding gadolinium-based contrast in pregnancy is controversial and its use should be avoided if possible, especially in the first trimester. Excretion of gadolinium-based agents into breast milk is limited [<0.04% of an intravenous (i.v.) dose within the first 24 h, with 1–2% absorption]. Data suggest that it is safe to continue breastfeeding after the administration of such agents.

3.5 Genetic testing and counselling
The risk of inheriting cardiac defects is raised significantly in comparison with parents without CVD, where the risk is approximately 1%.

Heritability varies between 3 and 50% depending on the type of parental heart disease.

Children of parents with an autosomal dominant condition [e.g. Marfan syndrome, hypertrophic cardiomyopathy (HCM), or long QT syndrome (LQTS)] have an inheritance risk of 50%.

The final phenotype will also be determined by incomplete penetrance and pleiotropic effects, and may vary significantly. For defects that are inherited in a polygenic manner, recurrence risk is less clearly defined. Genetic testing in cardiomyopathies is not appropriate for pre-natal diagnosis in dilated cardiomyopathies, except for selected disorders or high-risk situations in the setting of expert teams after detailed clinical and family assessment.

In patients with venous thrombo-embolism (VTE), genetic testing is considered to be justified only for relatives of probands with a deficiency of natural anticoagulants or after recurrent VTES.
Genetic counselling by an expert in the specific genetic disorder is highly recommended for patients and their family members in the situations below, and has the rationale of identifying at-risk asymptomatic or disease-free relatives and guiding clinical surveillance for disease onset. It is advocated in patients with known genetic disorders, especially if treatment options are available.

Genetic counselling and parental testing may be useful:
- In cases of known carrier status of hereditary pulmonary arterial hypertension (PAH) or pulmonary veno-occlusive disease.
- In cardiomyopathies and channelopathies (e.g. LQTS).
- In congenital heart disease that is known to be associated with genetic abnormalities (e.g. conotruncal defects or bicuspid valve), when the patient has dysmorphic features, developmental delay/mental retardation, or when other non-cardiac congenital abnormalities are present in syndromes such as in Marfan or other heritable thoracic aortic disease (HTAD), 22q11 deletion, Williams–Beuren, Alagille, Noonan, and Holt–Oram syndromes.
- In thoracic aortic pathology.
- When other family members are affected.

3.5.1 Pre-natal diagnosis
Presently, options for pre-natal genetic testing are increasingly available for those patients with an identified genetic defect (either chromosomal defects such as insertions/deletions/translocations or single-gene defects). This includes (i) pre-gestational diagnosis or (ii) pre-natal diagnosis, chorionic villus sampling, or amniocentesis. Counselling should be provided by an experienced centre with an interdisciplinary expert team.

An individualized approach to each family is required to ensure autonomous choice and informed consent regarding pre-natal diagnostic testing within the local ethical and legal framework.

3.6 Foetal assessment
3.6.1 Screening for congenital heart disease
Measurement of nuchal fold thickness around the 12th week of pregnancy to screen for chromosome abnormalities also screens for foetal congenital heart disease. For major congenital heart disease, a 12-week ultrasound has a sensitivity and specificity of 85% (95% confidence interval) and 99% (95% CI 98–100%), respectively. The incidence of congenital heart disease with normal nuchal fold thickness is about 1/1000. The earlier diagnosis of a major malformation allows parents to consider all options, including termination of pregnancy.

All women with congenital heart disease should be offered foetal echocardiography in the 19th–22nd weeks of pregnancy, with 45% of all congenital cardiac malformations identified. Foetal echocardiography should be performed by experienced specialists.

When a foetal cardiac anomaly is suspected, it is mandatory to obtain the following:
- Full foetal echocardiography
- Detailed scanning to identify associated anomalies (digits and bones)
- Family history
- Maternal medical history: medical disorders, viral illness, or teratogenic medication
- Foetal karyotype (e.g. deletion in 22q11.2 with conotruncal anomalies)
- Referral to a foetal medicine specialist, paediatric cardiologist, geneticist, and neonatologist
- Delivery at an institution that can provide neonatal cardiac care.

3.6.2 Assessing foetal wellbeing
In the context of foetal growth restriction, the aim is to determine the optimal time for delivery, balancing foetal and neonatal risks. The chance of disability-free survival increases by ~2% per day between 24 and 28 weeks, and 1% per day thereafter until 32 weeks. Delivery should be determined by umbilical artery and ductus venosus blood flow patterns.

3.7 Interventions in the mother during pregnancy
3.7.1 Percutaneous therapy
If an intervention is absolutely necessary, the best time is after the 4th month in the second trimester. By this time, organogenesis is complete, the foetal thyroid is still inactive, and the uterine volume is still small, so there is a greater distance between the foetus and the chest than in later months. ST-elevation MI (STEMI) management in pregnancy mainly relies on primary percutaneous coronary intervention (PCI). Thrombolysis may be a bailout, just as in non-pregnant patients, and recombinant tissue plasminogen activator does not cross the placenta but may induce bleeding complications (substantial bleeding). Procedures should follow the ‘as low as reasonably achievable’ principle. Manoeuvres to minimize radiation are: (i) use echo guidance when possible; (ii) place the source as distant as possible from the patient and the receiver; (iii) use only low-dose fluoroscopy; (iv) favour anteroposterior projections; (v) avoid direct radiation of the abdominal region; (vi) collimate as tightly as possible to the area of interest; (vii) minimize fluoroscopy time; and (viii) utilize an experienced cardiologist. Abdominal shielding lowers the radiation dose to the foetus to some degree; however, the presence of lead in the field of the primary beam may on the other hand increase scattered radiation. As the benefit of shielding is limited, it should not interfere with an optimal intervention. Monitoring and recording of radiation exposure facilitates the future assessment of possible effects on the foetus. Unfractionated heparin (UFH) has to be given at 40–70 U/kg i.v., targeting an activated clotting time of 250 s (200–300 s) or an activated partial thromboplastin time (aPTT) two times that which is normal.

3.7.2 Cardiac surgery with cardiopulmonary bypass
Maternal mortality during cardiopulmonary bypass is now similar to that in non-pregnant women. However, foetal mortality remains high (~2%). Cardiac surgery is recommended only when medical therapy or interventional procedures fail and the mother’s life is
threatened. The best period for surgery is between the 13th and 28th weeks. With full maternal and foetal monitoring and attention to cardiopulmonary bypass, particularly the use of pulsatile perfusion, the risks to both the mother and the foetus can be minimized. Gestational age has a large impact on neonatal outcome. Caesarean delivery may be considered before cardiopulmonary bypass if gestational age is >26 weeks. Whether or not delivery is advantageous for the baby at this gestational age depends on gender, estimated weight, prior administration of corticosteroids before delivery, and the outcome statistics of the neonatal unit concerned. When gestational age is ≥28 weeks, delivery before surgery should be considered. Before surgery, a full course of betamethasone 12 mg intramuscularly 12 h apart) of corticosteroids should be administered to the mother, whenever possible. During cardiopulmonary bypass, foetal heart rate and uterine tone should be monitored, and cardiopulmonary bypass time should be minimized for better foetal outcomes.

3.8 Timing and mode of delivery: risk for mother and child

A delivery plan should be made with details of induction, management of labour, delivery, and post-partum surveillance. The emotional context, psychological care, and ethical challenges should also be taken into account. This delivery plan should be widely disseminated and placed in the patient’s hand-held notes. Specific expertise and collaborative management by a pregnancy heart team in specialist centres is mandatory for all moderate- and high-risk patients.

3.8.1 Timing of delivery

Induction of labour should be considered at 40 weeks of gestation in all women with cardiac disease; this reduces the risk of emergency caesarean section by 12% and the risk of stillbirth by 50% in women without heart disease, and the benefit is likely to be greater for women with heart disease who have higher rates of obstetric complications. Timing of induction will depend on cardiac status, obstetric evaluation including cervical assessment, foetal well-being, and foetal lung maturity.

3.8.2 Labour induction

Both misoprostol [25 µg, prostaglandin E₁ (PGE₁)] or dinoprostone [1–3 mg or slow-release formulation of 10 mg (PGE₂)] can be used safely to induce labour. Reassuringly, in women without heart disease, high-dose (600 µg) misoprostol has no effect on cardiac parameters, although there remains a theoretical risk of coronary vasospasm and arrhythmias. Dinoprostone may cause profound hypotension, but only when injected blindly into the myometrium, and this route of administration should be avoided. Mechanical methods such as a cervical ripening balloon might be preferable in patients where a drop in systemic vascular resistance would be detrimental. Artificial rupture of membranes and infusion of oxytocin can be used safely in women with heart disease.

3.8.3 Vaginal or caesarean delivery

The ROPAC data show that elective caesarean section carries no maternal benefit and results in earlier delivery and lower birth weight. Vaginal delivery is associated with less blood loss and lower risk of infection, venous thrombosis, and embolism, and should be advised for most women. Caesarean section should be considered for obstetric indications and for patients presenting in labour on oral anticoagulants (OACs), with aggressive aortic pathology, and in acute intractable HF. Caesarean section is advised in severe forms of PH (including Eisenmenger’s syndrome).

3.8.4 Delivery in anticoagulated women (not including mechanical valve; see section 5)

For women with a planned caesarean section, therapeutic low molecular weight heparin (LMWH) dosing can be simply omitted for 24 h prior to surgery. If delivery has to be performed earlier, then anti-Xa activity can guide the timing of the procedure. In high-risk women, therapeutic UFH can be restarted at 6 h post-delivery. In women at moderate or low-risk, a single prophylactic dose of LMWH for example, in the case of enoxaparin, 20 mg if weight is <50 kg, 40 mg if 50–90 kg, and for women with a raised body mass index (BMI) 0.5 mg/kg can be given at 6 h post-delivery, before restarting therapeutic LMWH 12 h later.

If vaginal delivery is planned, moderate- and high-risk patients can be converted to an infusion of UFH with regular checks of aPTT to optimize control, and the infusion stopped at least 4–6 hours prior to insertion of regional anaesthesia or anticipated delivery. For women at low-risk, therapeutic LMWH can be omitted for 24 h prior to anticipated delivery. Anticoagulation can be restarted as above.

3.8.5 Urgent delivery on therapeutic anticoagulation

Delivery in a patient taking therapeutic anticoagulation carries a high-risk of maternal haemorrhage. For UFH, protamine sulfate should be given, the exact dose depending on the mode of administration and time since the last dose of UFH (please refer to the European Medicines Agency statement: https://www.medicines.org.uk/emc/product/8). In the case of LMWH, protamine sulfate should be given; however, not only may antifactor Xa activity remain prolonged and bleeding tendency persist, but the half-life of LMWH is longer and absorption after subcutaneous injection is prolonged, such that repeated doses or an infusion of protamine sulfate may be required. If the patient is on OACs, caesarean section is preferred to reduce the risk of foetal intracranial haemorrhage.

Reversal of anticoagulation is better with four-factor prothrombin complex concentrate, best given as an individualized dose dependent on maternal weight, initial international normalized ratio (INR), and target INR (than fresh frozen plasma (12–15 mL/kg), and should be given prior to caesarean delivery to achieve an INR ≤1.5; however, none of the available algorithms have been validated in pregnant women. Vitamin K (5–10 mg i.v.) may also be given, but may take up to 8–12 h to reverse the INR and has a persistent effect making re-anticoagulation more difficult. The foetus may remain anticoagulated
for 8–10 days after discontinuation of maternal OACs, and may need to be given fresh frozen plasma as well as vitamin K.

3.8.6 Haemodynamic monitoring during delivery
Maternal BP and heart rate should be monitored in all patients with cardiac disease. In women with more severe heart disease, an arterial line provides more accurate data. Pulse oximetry and continuous ECG monitoring are advised to detect early signs of decompensation, and to identify those in whom delivery should be expedited. A Swan-Ganz catheter is of uncertain benefit, is associated with complications, and should be avoided in most cases. In some high-risk patients (PH), right atrial pressure monitoring may be considered.

3.8.7 Anaesthesia/analgesia
Epidural analgesia reduces labour pain and can be used to provide anaesthesia for caesarean section if necessary. However, it can cause systemic hypotension (10%) and must be carefully titrated, especially in patients with obstructive valve lesions or diminished ventricular function who may benefit from invasive BP monitoring. All i.v. fluids need to be used carefully.

3.8.8 Labour
Mobilization may facilitate foetal head descent and a lateral decubitus position can attenuate the haemodynamic impact of cava compression by the gravid uterus. The active phase of the second stage should be delayed for 2 h to allow maximal descent of the foetal head, as this will shorten the active phase of the second stage. Assisted delivery with forceps or a ventouse may be used to further reduce maternal effort, as indicated by the underlying cardiac lesion. Continuous electronic foetal heart rate monitoring is recommended.

3.8.9 Perimortem caesarean section
In the case of an acute life-threatening maternal event, immediate delivery should be considered. The aim of delivery is to improve the chance of successfully resuscitating the mother and, only secondarily, of improving foetal survival. It should be considered from 24 weeks of gestation, as prior to this time the degree of uterine vena cava compression is limited and the baby is not considered to be viable. The delivery should be performed within 4 min of the cardiac arrest.

3.8.10 Post-partum care
A slow i.v. infusion of oxytocin (2 U of oxytocin given over 10 min immediately after birth, followed by 12 mU/min for 4 h) reduces the risk of post-partum haemorrhage and has a minimal impact on cardiovascular parameters. PGE analogues [sulprostone (100–500 µg/h) and misoprostol (200–1000 µg)] can be used to treat post-partum haemorrhage; however, ergometrine and prostaglandin F analogues should be avoided. Sulprostone should be used with caution, given its association with cardiovascular or respiratory symptoms. Meticulous leg care, elastic support stockings, and early ambulation are important to reduce the risk of thromboembolism. The post-partum period is associated with significant haemodynamic changes and fluid shifts, particularly in the first 24–48 h after delivery, which may precipitate HF. Haemodynamic monitoring should therefore be continued for at least 24–48 h in those at risk. With preceding beta-blockade, infant monitoring for 48 h is recommended.

3.8.11 Breastfeeding
Lactation is associated with a low-risk of bacteraemia secondary to mastitis and should be encouraged in patients with heart disease whenever possible. Any specific concerns or contraindications are discussed in the disease section (i.e. section 8). Most drugs used in patients enter the milk and could thus contraindicate breastfeeding (see Table 7 for details of drugs and safety data). If needed, inhibition of lactation can be obtained with standard doses of cabergoline (0.25 mg every 12 h for 2 days), or bromocriptine (2.5 mg on the day of delivery, followed by 2.5 mg twice daily for 14 days) if cabergoline is not available.

3.9 Infective endocarditis
IE is rare, with an overall annual incidence estimated at 1 per 1000 in patients with congenital heart disease and between 3 and 12 per 1000 in patients with prosthetic valves.

3.9.1 Prophylaxis
The same measures apply as in non-pregnant patients. During delivery, the indication for prophylaxis has been controversial and, given the lack of convincing evidence, antibiotic prophylaxis is not recommended during vaginal or caesarean delivery. Non-specific hygiene and asepsis measures are also important to prevent endocarditis.

3.9.2 Diagnosis and risk assessment
The diagnosis of IE during pregnancy involves the same criteria as in the non-pregnant patient. The scarcity of data accounts for wide ranges in estimations of maternal and foetal mortality of 11–33 and 14–29%, respectively.

Unlike chronic valvular regurgitations, acute regurgitations due to IE are poorly tolerated and often cause severe HF. Cerebral and peripheral embolisms are also frequent. Every pregnant patient with IE should be discussed by an endocarditis team.

3.9.3 Treatment
IE should be treated in the same way as in the non-pregnant patient. Antibiotics should be given according to guidelines, guided by culture and antibiotic sensitivity results, considering the potential foetotoxic effects of antibiotics (see Table 7 for details of drugs and safety data). Antibiotics that can be given during all trimesters of pregnancy are penicillin, ampicillin, amoxicillin, daptomycin, erythromycin, mezlocillin, oxacillin, and cephalosporins. There is a definite risk to the foetus in all trimesters of pregnancy with aminoglycosides and to amoxicillin during the second trimester, especially for first-time mothers. In patients with congenital heart disease, surgery should be considered in the immediate post-partum period.

3.9.4 Delivery
IE is rare, with an overall annual incidence estimated at 1 per 1000 in patients with congenital heart disease, and between 3 and 12 per 1000 in patients with prosthetic valves.

IE is rare, with an overall annual incidence estimated at 1 per 1000 in patients with congenital heart disease, and between 3 and 12 per 1000 in patients with prosthetic valves.

IE is rare, with an overall annual incidence estimated at 1 per 1000 in patients with congenital heart disease, and between 3 and 12 per 1000 in patients with prosthetic valves.

IE is rare, with an overall annual incidence estimated at 1 per 1000 in patients with congenital heart disease, and between 3 and 12 per 1000 in patients with prosthetic valves.

IE is rare, with an overall annual incidence estimated at 1 per 1000 in patients with congenital heart disease, and between 3 and 12 per 1000 in patients with prosthetic valves.
and tetracyclines, and they should therefore only be used for vital indications.115

Given the inherent foetal risk, decision-making for valve surgery during pregnancy is particularly difficult.112 Urgent surgery is mandatory in cardiogenic shock or refractory HF due to acute regurgitation. When surgery is indicated for uncontrolled infection or prevention of embolism, an individual approach should weigh the foetal risk of surgery and the risk of maternal complications under medical therapy alone. A viable foetus should be delivered prior to surgery where possible. These patients should be managed in tertiary centres, and the endocarditis and pregnancy teams should interact closely.

3.10 Methods of contraception and termination of pregnancy, and in vitro fertilization

3.10.1 Methods of contraception

The risk of using a particular type of contraception needs to be balanced against the risk of pregnancy, estimated using the modified WHO classification (see above).116 which assesses the risk with each method for a given medical condition.117 Advice is best provided by cardiologists with appropriate training or obstetricians, and should be given from the time of menarche since an unplanned pregnancy has to be avoided. The average age of first intercourse in the UK is 17 years, with <30% before 15 years,118 regardless of the presence of heart disease.119 The key issues are reliability and the potential for complications, with thrombosis and infection being the most important. Hormonal contraception can have important non-contraceptive benefits, including the control of menstruation, prevention of anemia, reduction of dysmenorrhea, and of hyperandrogenism.120

Ethinyloestradiol-containing contraceptives have the greatest risk of thrombosis121,122 and are not advised in women with high-risk of thrombo-embolic disease; they also increase BP and are contraindicated in pre-existing hypertension.117 Progestin-only contraceptives are an alternative, since they have little (implant or depot injection) or no (levonorgestrel-loaded intrauterine device or oral desogestrel) effect on coagulation factors, BP, and lipid levels.123 Oral desogestrel inhibits ovulation, which could be an advantage for patients with polycystic ovary syndrome, endometriosis, or dysfunctional uterine bleeding.

Levonorgestrel-based long-acting reversible contraception implants or intrauterine devices are the safest and most effective contraceptives. However, intrauterine device insertion may cause a vasovagal response; consequently, this should be performed in a hospital setting, particularly for Fontan and Eisenmenger’s syndrome patients. The levonorgestrel-releasing intrauterine device reduces periods, causing amenorrhea in ≤60% of women, in contrast to copper intrauterine devices, which cause heavier periods. The newer, smaller levonorgestrel-based intrauterine devices are easier to insert, reducing the risk of pain and therefore vasovagal response.

Barrier methods are unreliable but reduce the risk of pelvic inflammatory disease. A good approach is the combination of barrier methods and long-acting reversible contraception (levonorgestrel-based long-acting reversible contraception, progestin-releasing implant, or progestin-releasing intrauterine device).

For emergency contraception, a copper intrauterine device is most effective and additionally provides ongoing contraception. Alternatively, a single dose of 1.5 mg levonorgestrel is effective if taken within 72 h after unprotected sex (1.1% failure rate),124 with no evidence of increased rates of thrombosis.125 The progesterone receptor modulator ulipristal acetate (UPA) has been shown to be more effective than levonorgestrel. UPA is not associated with an increased risk of thrombosis.126,127

3.10.2 Sterilization

Sterilization by tubal ligation is not unreasonable if pregnancy is contraindicated or the family is complete. Laparoscopy is not without risks in patients with PAH, cyanosis, and a Fontan circulation, and the risks are probably lower with the hysteroscopic method performed under regional anaesthesia.128 Vasectomy is an effective option.

3.10.3 Methods of termination of pregnancy

Pregnancy termination should be discussed if there is a high-risk of maternal morbidity or mortality, and/or of foetal abnormality. Both medical and surgical methods are effective with similar rates of major complications, but the greater need for unanticipated operative evacuation (2.1 vs. 0.6%) favours the surgical approach in this group of women.129 High-risk patients should be managed in an experienced centre with on-site cardiac surgery. Antibiotics are given to reduce the risk of endometritis and these should be modified to provide endocarditis prophylaxis. Medical terminations can be considered up to 9 weeks of gestation using a reduced misoprostol dose of 100 μg.

3.10.4 In vitro fertilization

The rates of subfertility in most women with heart disease are likely to those of the general population,130 but their management is more complex. Hysteroscopy and laparoscopy can be life-threatening procedures in women with some forms of heart disease (PH and Fontan), and should be undertaken in an experienced centre with appropriate support. Assisted reproduction has added risks above those of pregnancy alone; superovulation is pro-thrombotic and can be complicated by ovarian hyperstimulation syndrome (OHSS), with marked fluid shifts and an even greater risk of thrombosis. The risk of OHSS can be reduced by careful cycle monitoring, using low-dose follicle-stimulating hormone in combination with a gonadotropin-releasing hormone antagonist, freezing all embryos, or only transferring a single embryo.131 The last option is strongly advised in women with heart disease, since conceiving a multiple pregnancy is associated with greater cardiovascular changes132 and more maternal and foetal complications.133 Pregnancy, and consequently fertility treatment, is contraindicated in women with mWHO class IV. In women with mWHO class III or those who are anticoagulated, the risk of superovulation is very high and the alternative of natural cycle in vitro fertilization should be considered.
3.11 Recommendations

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-pregnancy risk assessment and counselling is indicated in all women with known or suspected congenital or acquired cardiovascular and aortic disease.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>It is recommended to perform risk assessment in all women with cardiac diseases of childbearing age before and after conception, using the mWHO classification of maternal risk.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>It is recommended that high-risk patients are treated in specialized centres by a multidisciplinary pregnancy heart team.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Foetal echocardiography by experienced specialists is recommended when there is an elevated risk of foetal abnormalities.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Echocardiography is recommended in any pregnant patient with unexplained or new cardiovascular signs or symptoms.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>If cardiac surgery is to be performed after 24 weeks and before 37 weeks of gestation, then corticosteroids are recommended for the mother.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Vaginal delivery is recommended as the first choice in most patients; for most important exceptions see below.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Induction of labour should be considered at 40 weeks of gestation in all women with cardiac disease.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Genetic counselling should be considered in women with congenital heart disease or congenital arrhythmia, cardiomyopathies, aortic disease, or genetic malformations associated with CVD.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>MRI (without gadolinium) should be considered if echocardiography is insufficient for a definite diagnosis.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>In patients with severe hypertension, vaginal delivery with epidural analgesia and elective instrumental delivery should be considered.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Delivery before necessary surgery should be considered when gestational age is ≥26 weeks.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Caesarean delivery should be considered for obstetrical indications or for patients with dilatation of the ascending aorta ≥45 mm, severe aortic stenosis, pre-term labour while on oral anticoagulants, Eisenmenger’s syndrome, or severe heart failure.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>A chest radiograph may be considered if other methods are not successful in clarifying the cause of dyspnoea.</td>
<td>IIb</td>
<td>C</td>
</tr>
<tr>
<td>Cardiac catheterization may be considered with very strict indications.</td>
<td>IIb</td>
<td>C</td>
</tr>
<tr>
<td>CT and electrophysiological studies may be considered in selected patients for vital indications.</td>
<td>IIb</td>
<td>C</td>
</tr>
<tr>
<td>Coronary bypass surgery or valvular surgery may be considered during pregnancy when conservative and medical therapy has failed, and in situations that threaten the mother’s life or that are not amenable to percutaneous treatment.</td>
<td>IIb</td>
<td>C</td>
</tr>
<tr>
<td>Prophylactic antibiotic therapy to prevent endocarditis during delivery is not recommended.</td>
<td>III</td>
<td>C</td>
</tr>
</tbody>
</table>

CT = computed tomography; CVD = cardiovascular disease; MRI = magnetic resonance imaging; mWHO = modified World Health Organization.

*Class of recommendation.

[1] Level of evidence.

4. Congenital heart disease and pulmonary hypertension

4.1 Introduction

Congenital heart disease is present in 0.8–0.9% of live births. Lesions vary in severity, but even patients with complex lesions now survive to childbearing years. In large international surveys of pregnancy and heart disease, two-thirds of cases have congenital heart disease and 5% have PH. However, congenital heart disease and PH are rare causes of maternal death. In most women with congenital heart disease, pregnancy is well tolerated. The risk of pregnancy depends on the underlying heart
defect as well as on additional factors such as ventricular function, functional class, and cyanosis. Maternal cardiac complications are present in ~10% of completed pregnancies and are more frequent in mothers with complex disease. Patients who experience complications during pregnancy may also be at higher risk of late cardiac events after pregnancy. Obstetric complications such as (pre-) eclampsia are more often encountered. Offspring complications, including miscarriage, prematurity, and neonatal death, are increased.

Diagnosis. In most cases, congenital heart disease is diagnosed well before pregnancy, giving the opportunity for a full pre-pregnancy risk assessment. The mWHO classes (Table 3) outline the broad risk categories.

4.2 Pulmonary hypertension and Eisenmenger’s syndrome

4.2.1 Pulmonary hypertension

4.2.1.1 Introduction

PH has many causes and is defined by an elevation in mean pulmonary arterial pressure (PAP) ≥ 25 mm Hg at right heart catheterization. The term PAH describes a subset of PH characterized by an LV filling pressure ≤ 15 mm Hg and a pulmonary vascular resistance > 3 Wood Units. Untreated, idiopathic PH results in death within a median of 2.8 years. PAH is frequently encountered in females and the first clinical manifestations may be seen in pregnancy.

4.2.1.2 Maternal risk

Maternal outcome, which varies according to the PH subset, has improved with the availability of new targeted therapies and the use of a team-based, multidisciplinary approach. While pregnancy appears safer today, mortality remains high in women with PAH (16–30% maternal mortality). Therefore, the recommendation to avoid pregnancy remains and, when pregnancy occurs, termination should be discussed. The greatest period of risk is the puerperium and early post-partum. These women should be managed by a multidisciplinary team, with a PH expert included, in an expert centre for pregnancy and cardiac disease. Pulmonary hypertensive crisis, pulmonary thrombosis, and right HF are the most common causes of death. This may occur even in patients with few symptoms prior to pregnancy. Risk factors for maternal death are: severity of PH, late hospitalization, and perhaps the use of general anaesthesia. Even moderate forms of pulmonary vascular disease can worsen during pregnancy. Although there is no safe cut-off for elevated PAP risk, it is thought to be less in those with only mildly increased pressure.

4.2.1.3 Obstetric and offspring risk

There is increased foetal and neonatal (0–30%) mortality, particularly if there is preterm delivery, reduced maternal CO, and/or hypoxaemia.

4.2.1.4 Management

The usual diagnostic algorithm of PH should be followed when a pregnant patient presents with new PH. Echocardiography is key and other diagnostic steps, in keeping with the PH guideline, are planned individually. Invasive right heart catheterization is recommended if there is diagnostic uncertainty and to assist important therapeutic decisions. If this is required, it should be performed in a specialist centre. Genetic counselling is appropriate in familial cases.

A multidisciplinary team is required to care for the pregnant PH patient. This should be tailored to the patient, but will require very regular follow-up (often weekly in the third trimester). A full assessment, including oxygen saturation and assessment of RV function, should occur at each visit. Bed rest may be required in symptomatic patients and additional risk factors (such as air travel) avoided.

Thromboembolism is a major risk and anticoagulation should be considered (see section 11). Diuretics may be needed in patients with HF and iron deficiency should be treated.

Pregnancy in PAH patients is a high-risk condition and a proactive approach should be taken to commencing advanced therapies. Risk stratification should be performed as in non-pregnant patients. There is no evidence of benefit comparing a stepwise approach vs. early combination therapy in pregnant patients, although the latter is often favoured, as per our Guidelines. Bosentan and other endothelin receptor antagonists are associated with embryopathy, and should be discontinued unless doing so would greatly increase maternal risk. An individualized approach is required and many units start therapy with oral sildenafil. The subset of patients with true vasodilator responsiveness who are well controlled on calcium channel blocker (CCB) therapy may be at lower risk and this therapy should be continued, as should all i.v. therapies. Section 12 discusses specific medications, including potential interactions with contraceptive drugs and anticoagulants.

4.2.1.5 Delivery

A detailed delivery plan, including the optimal mode and timing of delivery, should be decided by the pregnancy heart team. This should include the post-partum need for intensive care and mechanical support. Regional anaesthesia is usually favoured over general anaesthesia. Meticulous fluid balance and optimization of RV function are important determinants of a good outcome. Patients remain at high-risk for many months post-delivery, and individualized counselling is needed to discuss the need for ongoing therapies and the avoidance of future pregnancies. Therapies should not be discontinued in the early post-delivery period.

4.2.2 Eisenmenger’s syndrome

4.2.2.1 Maternal risk

Eisenmenger patients require special consideration because of the additional complications of cyanosis, right-to-left shunting, and paradoxical embolism. During pregnancy, systemic vasodilatation increases the right-to-left shunt and decreases pulmonary flow, leading to increased cyanosis and a low CO. Maternal mortality is high (20–50%) and termination of pregnancy should be discussed. However, termination also carries a risk.

4.2.2.2 Foetal risk

Foetal and neonatal risks are increased and relate to maternal CO and cyanosis. Miscarriage is common. Maternal hypoxaemia is the most important predictor of outcome.

4.2.2.3 Management

Many of the principles of caring for non-Eisenmenger PAH apply. However, patients with Eisenmenger’s syndrome are at increased risk of thrombocytopenia, deficiencies in vitamin K-dependent
clotting factors, and bleeding. Caution is therefore needed if prescribing antiplatelet therapy or LMWH. The evidence base for using advanced therapies is less developed. However, sildenafil (and other phosphodiestersase inhibitors such as tadalafil and vardenafil) is often prescribed, with the addition of prostanoids in patients who remain symptomatic. Care should be exercised if prescribing drugs that may lead to sudden systemic vasodilation or a risk of paradoxical air embolism (i.e. therapies). Advanced therapies for Eisenmenger patients should only be prescribed by experienced pregnancy heart teams including a PH expert. The principles guiding delivery are as per other forms of PH as above.

4.2.3 Cyanotic heart disease without pulmonary hypertension

4.2.3.1 Maternal risk

Cyanotic congenital heart disease is usually repaired before pregnancy, but some balanced, inoperable, or palliated cases do reach childbearing age. Maternal complications (HF, thrombosis, arrhythmias, and endocarditis) occur in >15% of cyanotic pregnant patients. Maternal outcome will be determined by the underlying condition and the ventricular function rather than the saturation level.

4.2.3.2 Foetal risk

If oxygen saturation is >90%, then there is usually a better foetal outcome (10% foetal loss). If oxygen saturation is <85%, foetal growth restriction, prematurity, and foetal death are common and pregnancy should be discouraged (live birth rate of only 12%).

4.2.3.3 Management

Patients should usually be reviewed once or twice during pregnancy with surveillance for PH.

4.3 Specific congenital heart defects

4.3.1 Left ventricular outflow tract obstruction

The principles for managing supravalvular or subvalvular LV outflow tract obstruction are the same as those for valvular aortic stenosis (AS) (section 5). However, balloon valvuloplasty is not a therapeutic option.

4.3.2 Atrial septal defect

4.3.2.1 Maternal risk

Pregnancy is well tolerated by most women with repaired atrial septal defect (ASD) (WHO risk class I). In unrepaired ASDs, thromboembolic complications have been described (5%). Atrial arrhythmias occur, especially when the ASD is un repaired or closed at an older age.

4.3.2.2 Obstetric and offspring risk

In women with unrepaired ASD, pre-eclampsia and growth restriction may occur more frequently.

4.3.2.3 Management

For a secundum defect, catheter device closure can be performed during pregnancy but is rarely indicated. If device closure is performed, antplatelet therapy will be required. Closure for the prevention of paradoxical emboli is not indicated. In women with a residual shunt, prevention of venous stasis (compression stockings and minimizing bed rest) is important and extra care should be taken to avoid air in i.v. lines.

4.3.3 Ventricular septal defect

4.3.3.1 Maternal risk

Small or repaired ventricular septal defects (VSDs) (without left heart dilatation or ventricular dysfunction) have a low-risk of complications during pregnancy (mWHO I and II).

4.3.3.2 Obstetric and offspring risk

There is no evidence of increased obstetric risks.

4.3.3.3 Management

Patients should usually be reviewed once or twice during pregnancy with surveillance for PH.

4.3.4 Atrioventricular septal defect

4.3.4.1 Maternal risk

After ASD repair, pregnancy is usually well tolerated (WHO risk class II–III). However, arrhythmias and worsening atrioventricular (AV) valve regurgitation have been described. The risk of HF is low, and only exists in women with severe regurgitation or impaired ventricular function.

4.3.4.2 Obstetric and offspring risk

Offspring mortality has been reported in 6% of cases, primarily due to the recurrence of congenital heart disease.

4.3.4.3 Management

Follow-up is advisable at least once each trimester. This should be increased to monthly or bimonthly in patients with significant valve regurgitation or impaired ventricular function.

4.3.5 Coarctation of the aorta

4.3.5.1 Maternal risk

Pregnancy is often well tolerated in women after repair of coarctation of the aorta (CoA) (WHO risk class II). In women with unrepaired CoA and those repaired who have systemic hypertension, residual CoA or aortic aneurysms have an increased risk of complications including dissection. Other risk factors include aortic dilatation and bicuspid aortic valve.

4.3.5.2 Obstetric and offspring risk

An excess of hypertensive disorders, including pre-eclampsia and miscarriages, has been reported.

4.3.5.3 Management

Close surveillance of BP is warranted and follow-up, at least every trimester, is indicated. Hypertension should be treated and care should be taken to avoid placental hypoperfusion in those with residual coarctation. Percutaneous intervention for re-CoA (using a covered stent) is possible during pregnancy, but should only be performed for refractory hypertension or maternal or foetal compromise.

4.3.6 Pulmonary valve and right ventricular outflow tract disease

4.3.6.1 Maternal risk

Pulmonary (valve) stenosis (PS) is generally well tolerated. However, severe stenosis may result in complications including RV failure and
arrhythmias. Severe pulmonary regurgitation has been identified as an independent predictor of maternal complications, especially in patients with impaired RV function.

4.3.6.2 Obstetric and offspring risk
There is no evidence of increased obstetric risks.

4.3.6.3 Management
Mild and moderate PS are low-risk lesions (WHO risk classes I and II) and two or three follow-up sessions are sufficient. In patients with severe PS, monthly or bimonthly cardiac evaluations are advised, focusing on RV function. In severely symptomatic PS, which is unresponsive to medical therapy and bed rest, percutaneous valvuloplasty can be appropriate.

4.3.7 Congenital aortic stenosis
AS, aortic dilatation, and bicuspid aortic disease are discussed in sections 5 and 6.

4.3.8 Tetralogy of Fallot
4.3.8.1 Maternal risk
Women with repaired tetralogy of Fallot usually tolerate pregnancy well (WHO risk class II). Cardiac complications have been reported in 8% of repaired patients, especially in those taking cardiac medication prior to pregnancy. Arrhythmias and HF are the most common complications. Thrombo-embolism and endocarditis are rarer. Dysfunction of the RV and/or moderate to severe pulmonary regurgitation are risk factors. Previous pregnancy may be associated with a persisting increase in RV size and long-term cardiac events.

4.3.8.2 Obstetric and offspring risk
The risk of offspring complications is increased, in particular foetal growth restriction. Maternal screening for 22q11 deletion should be undertaken prior to pregnancy.

4.3.8.3 Management
Follow-up every trimester is sufficient in most patients. In women with severe pulmonary regurgitation, monthly or bimonthly cardiac evaluation is indicated. If RV failure occurs during pregnancy, treatment with diuretics should be started and bed rest advised. Early delivery or, rarely, transcatheter valve implantation could be considered in those who do not respond to conservative treatment.

4.3.9 Ebstein’s anomaly
4.3.9.1 Maternal risk
In women with uncomplicated Ebstein’s anomaly, pregnancy is often tolerated well (WHO risk class II). Symptomatic patients with cyanosis and/or HF should be counselled against pregnancy. The haemodynamic problems seen largely depend on the severity of tricuspid regurgitation (TR) and on RV function. Cyanosis (due to ASD/patent foramen ovale) and arrhythmias due to accessory pathways are common. There is also an increased risk of HF and pre-term delivery.

4.3.9.2 Obstetric and offspring risk
Foetal and neonatal outcomes are related to maternal oxygen saturation and CO.

4.3.9.3 Management
Even severe TR with HF can usually be managed medically during pregnancy. Women with interatrial shunting can develop progressive cyanosis during pregnancy and be at increased risk of paradoxical emboli, and these should be assessed at each visit.

4.3.10 Transposition of the great arteries
4.3.10.1 Maternal risk
In patients with transposition of the great arteries (TGA), the risks associated with pregnancy are mainly attributable to women with a previous atrial (Senning and Mustard) switch, not an arterial switch. Though many women with an arterial switch operation tolerate pregnancy relatively well, there is an increased risk of developing arrhythmias (sometimes life-threatening) and HF (WHO risk class III). An irreversible decline in RV function and worsening TR are also described. Patients with more than moderate impairment of RV function or greater than moderate TR should be advised against pregnancy.

4.3.10.2 Obstetric and offspring risk
The risk of low birth weight and pre-term delivery is 38%.

4.3.10.3 Management
Monthly or bimonthly review focusing on systemic RV function and arrhythmia is required. Diuretics and other HF therapies may be required.

4.3.10.4 Arterial switch operation
The risk of pregnancy seems low in these patients with good clinical condition pre-pregnancy and preserved ventricular function. Women with a dilated neo-aorta will require closer surveillance. Although this is now the most common operation for TGA, few data are available on pregnancy outcomes.

4.3.11 Congenitally corrected transposition of the great arteries
4.3.11.1 Maternal risk
In patients with congenitally corrected TGA (also called AV and ventriculoarterial discordance) risk depends on functional status, ventricular function, and the presence of arrhythmias and associated lesions (such as a VSD and pulmonary valve stenosis). Complications include arrhythmias and HF (WHO risk class III). These patients are also predisposed to developing AV block. Some 10% of patients have an irreversible decline in RV function. Patients in New York Heart Association (NYHA) classes III or IV, with ventricular dysfunction (ejection fraction (EF) <40%), or severe TR should be counselled against pregnancy.

4.3.11.2 Obstetric and offspring risk
The rate of foetal loss is increased, especially if there is cyanosis.

4.3.11.3 Management
For follow-up, it is recommended that patients have frequent echo surveillance of systemic RV function (every 4–8 weeks) and assessment of symptoms and rhythm.
4.3.12 Fontan circulation

4.3.12.1 Maternal risk
Patients with a Fontan circulation have an increased risk of fertility issues, but successful pregnancy can occur. However, these are high-risk pregnancies (WHO risk class III or IV). Atrial arrhythmias and NYHA class deterioration are not uncommon. Patients with saturations <85%, depressed ventricular function, moderate to severe AV regurgitation, refractory arrhythmia, or protein-losing enteropathy should be counselled against pregnancy (mWHO IV).

4.3.12.2 Obstetric and offspring risk
Fontan patients have a high-risk of miscarriage (30%). Antenatal and peripartum bleeding is common. There is an increased risk of premature birth, small for gestational age, and neonatal death.

4.3.12.3 Management
It is recommended that Fontan patients have regular surveillance during pregnancy (monthly) and in the first weeks after delivery. Fontan patients are at risk of thrombo-embolic complications and therapeutic anticoagulation should be considered (balanced with the risk of bleeding). Atrial arrhythmias should be treated promptly and this often requires electrical cardioversion.

4.4 Recommendations

### Recommendations for congenital heart disease

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with a systemic right ventricle (Mustard/Senning or congenitally corrected TGA), in NYHA class III/IV, systemic ventricular dysfunction (EF &lt;40%), or severe TR should be advised against pregnancy.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Anticoagulation treatment should be considered during pregnancy in Fontan patients.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Symptomatic patients with Ebstein’s anomaly with saturations &lt;85% and/or heart failure should be advised against pregnancy.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>In patients with a Fontan circulation and saturations &lt;85%, depressed ventricular function, moderate–severe AV regurgitation, refractory arrhythmia, or protein-losing enteropathy, pregnancy is not recommended.</td>
<td>III</td>
<td>C</td>
</tr>
</tbody>
</table>

5. Aortic diseases

Several heritable disorders affect the thoracic aorta, predisposing patients to both aneurysm formation and aortic dissection. These include HTAD and either syndromic (Marfan syndrome, Loeys–Dietz syndrome, osteoaneurysm syndrome, and vascular Ehlers–Danlos syndrome) or non-syndromic HTAD (i.e. only aortic aneurysm). New genes are regularly discovered. Other forms of congenital heart disease (e.g. tetralogy of Fallot and CoA) may also be accompanied by aortic dilatation, and finally non-heritable aortic pathology may occur. Risk factors for aortic dilatation are hypertension and advanced maternal age. Pregnancy is a high-risk period for all patients with aortic pathology, which is rare during pregnancy but associated with very high mortality. Most deaths occur in women not previously known to have an aortopathy. Most of these women will have heritable disease, so autopsy tissue should be saved for DNA analysis and families offered referrals for screening. Guidelines for the diagnosis and management of patients with thoracic aortic disease have been published.
5.1 Maternal and offspring risk

Haemodynamic and hormonal changes during pregnancy increase the susceptibility to dissection. Dissection occurs most often in the last trimester of pregnancy (50%) or the early post-partum period (33%). All women with a genetically proven syndrome or familial aortic pathology should have counselling on the risk of dissection and the recurrence risk, and have a complete evaluation including imaging of the entire aorta before pregnancy (see section 3). When assessing aortic diameters, body surface area should be considered, especially in women of small stature. Parity seems associated with increased aortic diameter. The effect of pregnancy on aortic dilatation is not clear. The diagnosis of aortic dissection should be considered in all patients with chest pain during pregnancy.

5.2 Specific syndromes

Marfan syndrome is thought to affect 1 in 5000 individuals. Although bicuspid aortic valve is more common (1–2% of the population), associated aortic complications are uncommon, accounting for only 6% of type A dissections during pregnancy.

5.2.1 Marfan syndrome

The overall risk of a woman with Marfan syndrome having an aortic dissection associated with pregnancy is ~3%. Aortic size is a major determinant of risk, but even women with an aortic root <40 mm have a risk of dissection of 1%. Although there are limited data, pregnancy should be avoided in Marfan patients with an aortic root diameter >45 mm as there is an increased risk of dissection. When the aorta is 40–45 mm, other factors should be considered, such as family history of dissection and rate of aortic growth. Distal aortic dissection and dissection of other vessels are also a risk. For this reason, even after successful aortic root replacement, patients remain at risk of further events. Studies focusing on the potential growth during pregnancy in Marfan patients demonstrated contradicting results; some demonstrated no significant growth, while others demonstrated growth >3 mm with a partial diameter decrease post-partum.

Other important cardiac complications include progressive mitral regurgitation (MR) due to mitral valve prolapse, new arrhythmia, and HF due to ventricular dysfunction. Obstetric complications are also increased, including premature rupture of membranes.

5.2.2 Bicuspid aortic valve

Aortic dilatation occurs in ≤50% of patients with a bicuspid aortic valve and can occur even when valve function is normal. The dilatation can be in the distal ascending aorta, which cannot be adequately visualized by echocardiography. If not visible with echocardiography, MRI or CT should be performed pre-pregnancy. The risk of dissection is small. Risk factors are the type of bicuspid aortic valve morphology, aortic dilatation, and CoA. Pregnancy should be avoided when the aorta diameter is >50 mm.

5.2.3 Vascular Ehlers–Danlos syndrome

Serious vascular complications occur almost exclusively in type IV Ehlers–Danlos syndrome (vascular). Maternal mortality is significant, and relates to uterine rupture and dissection of major arteries and veins. Pregnancy is therefore considered as a very high-risk undertaking and not advised. These women should be engaged in a shared decision-making process when contemplating pregnancy.

5.2.4 Turner syndrome

Turner syndrome is associated with an increased risk of congenital heart disease, aortic dilatation, hypertension, diabetes, and atherosclerotic events. Aortic dissection occurs rarely in Turner syndrome, but it is six times more common at younger ages than in the general population. Risk factors for aortic dissection include aortic dilation, bicuspid aortic valve, and CoA. Pregnancy should be avoided when the aortic size index is >25 mm/m². Also, after aortic root surgery, the patient remains at risk of type B dissection.

Spontaneous pregnancy can occur in mosaic Turner patients (0.5–10%), but pregnancy is now most commonly secondary to assisted fertility techniques. Cardiovascular evaluation is recommended before starting fertility treatment. Good BP control and diabetes management is mandatory for all Turner patients, especially during pregnancy.

5.2.5 Other autosomal dominant aortopathies

With improved genotyping, a series of new aortopathies are being reported. These include syndromic and non-syndromic HTAD. These conditions are considered high-risk, especially when the aorta is dilated, and may also have multipath involvement with additional risks such as uterine rupture.

5.3 Management

5.3.1 Follow-up and medical therapy

Depending on the aortic diameter, patients with aortic pathology should be monitored by echocardiography at regular intervals throughout the pregnancy and 6 months post-partum. In women with a high-risk of dissection or an already severely dilated aorta, monitoring every month is warranted, while in low-risk women with only a mildly dilated aorta, monitoring every 12 weeks seems reasonable. When needed, cardiac MRI without contrast can be used. Pregnancy should be supervised by a cardiologist and obstetrician who are alert to the possible complications. Strict BP control is advised, and antihypertensive treatment that is safe for the foetus should be initiated if necessary. In women with HTAD, beta-blocker therapy throughout pregnancy should be considered. In patients with Ehlers–Danlos syndrome type IV, celiprolol is recommended (also in normotensive women) because of the very high-risk of dissections and the benefit demonstrated in

5.3.2 Surgery

5.3.2.1 Aortic root surgery

Aortic root surgery is indicated for women with Marfan syndrome, when the aorta diameter is >45 mm, or for other conditions such as dissection risk, or severe aortic regurgitation.
non-pregnant patients. Foetal growth should be monitored when the mother is taking beta-blockers.

5.3.2 Interventions
When progressive dilatation occurs during pregnancy, before the foetus is viable, surgical treatment with the foetus in utero should be considered. When the foetus is viable, caesarean delivery followed directly by aortic surgery is recommended (section 3). Caesarean section should be performed in a hospital in which cardiothoracic surgery and neonatal intensive care facilities are available.

In patients with acute aortic complications during pregnancy, management includes medical therapy where appropriate, and surgical or catheter-based interventions where needed.

Stanford type A aortic dissection occurring during pregnancy is a surgical emergency. Experienced cardiothoracic, cardiology, obstetric, and cardio-anaesthetic physicians must act rapidly to deliver the foetus (if viable) by caesarean section in a specialized cardiothoracic centre and proceed directly to repair of the dissection. If the baby is not viable, aortic surgery with the foetus in place should be performed. Although maternal outcome is good, foetal mortality is 20–30%.

In the case of uncomplicated type B aortic dissection, conservative treatment with strict BP control using medication allowed during pregnancy is recommended.

Thoracic endovascular aortic repair has recently been proposed as a new approach for complicated type B aortic dissection. Promising mid-term outcomes have been reported. However, the outcome of thoracic endovascular aortic repair during pregnancy is only described in a few cases, and it is not recommended in the case of genetic aortopathy.

5.3.3 Delivery
The primary aim of intrapartum management in patients with ascending aorta enlargement is to reduce the cardiovascular stress of labour and delivery. If the woman is taking beta-blockers during pregnancy, they should be continued in the peripartum period.

If the ascending aorta diameter is 40–45 mm, vaginal delivery with expedited second-stage and regional anaesthesia should be considered to prevent BP peaks, which may induce dissection. Caesarean delivery may also be considered in these patients, based on the individual situation. Caesarean delivery should be considered when the aortic diameter exceeds 45 mm, and is recommended in patients with vascular Ehlers–Danlos syndrome type IV or acute or chronic aortic dissection.

Table 5 provides an overview of the specific aortic disease syndromes.

<table>
<thead>
<tr>
<th>Location of aneurysm/dissection</th>
<th>Marfan</th>
<th>Bicuspid aortic valve</th>
<th>LoeysDietz</th>
<th>Turner</th>
<th>Vascular Ehlers–Danlos</th>
</tr>
</thead>
<tbody>
<tr>
<td>Everywhere (sinus of Valsalva)</td>
<td>Ascending aorta</td>
<td>Everywhere</td>
<td>Ascending aorta, arch and descending aorta</td>
<td>Everywhere</td>
<td></td>
</tr>
<tr>
<td>Risk of dissection</td>
<td>High: 1–10%</td>
<td>Low: &lt;1%</td>
<td>High:1–10%</td>
<td>High: 1–10%</td>
<td>High: 1–10%</td>
</tr>
<tr>
<td>Comorbidity</td>
<td>Dural abnormalities</td>
<td>Mitral regurgitation</td>
<td>Aortic stenosis or regurgitation</td>
<td>Dural abnormalities</td>
<td>Mitral regurgitation</td>
</tr>
<tr>
<td></td>
<td>Heart failure</td>
<td>Arrhythmias</td>
<td>Low height</td>
<td>Infertility</td>
<td>Hypertension</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Diabetes</td>
<td></td>
<td>Bicuspid aortic valve</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Coarctation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advise not to become pregnant</td>
<td>Ascending aorta &gt;45 mm (or &gt;40 mm in family history of dissection or sudden death)</td>
<td>Ascending aorta &gt;50 mm</td>
<td>Ascending aorta &gt;45 mm (or &gt;40 mm in family history of dissection or sudden death)</td>
<td>ASI &gt;25 mm/m²</td>
<td>All patients</td>
</tr>
</tbody>
</table>

ASI = aortic size index.
### 5.4 Recommendations

#### Recommendations for the management of aortic disease

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All aortic diseases</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>It is recommended that women with aortic disease have counselling about the risk of aortic dissection. [^19,178]\</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Imaging of the entire aorta (CT/MRI) is recommended before pregnancy in patients with a genetically proven aortic syndrome or known aortic disease. [^53]\</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>In bicuspid aortic valve patients, imaging of the ascending aorta is recommended before pregnancy.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>When a woman with known aortic dilatation (history of) dissection or genetic predisposition for dissection becomes pregnant, strict blood pressure control is recommended. [^185]\</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Repeated echocardiographic imaging every 4–12 weeks (depending on diagnosis and severity of dilatation) is recommended during pregnancy and 6 months post-partum in patients with ascending aorta dilatation. [^194]\</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>For imaging of pregnant women with dilatation of the distal ascending aorta, aortic arch, or descending aorta, MRI (without gadolinium) is recommended. [^53]\</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>It is recommended to deliver all women with aortic dilatation or (history of) aortic dissection in an experienced centre with a pregnancy heart team, where cardiothoracic surgery is available.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>In patients with an ascending aorta &lt;40 mm, vaginal delivery is recommended. [^96]\</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>In patients with an ascending aorta ≥45 mm, caesarean delivery should be considered.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>In patients with (history of) aortic dissection, caesarean delivery should be considered.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Prophylactic surgery should be considered during pregnancy if the aorta diameter is ≥45 mm and increasing rapidly.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>When the foetus is viable, delivery before necessary surgery should be considered. [^96]\</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>In patients with an aorta 40–45 mm, vaginal delivery with epidural anaesthesia and an expedited second stage should be considered.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>In patients with an aorta 40–45 mm, caesarean section may be considered.</td>
<td>IIb</td>
<td>C</td>
</tr>
<tr>
<td>Pregnancy is not recommended in patients with (or history of) aortic dissection.</td>
<td>III</td>
<td>C</td>
</tr>
<tr>
<td>When possible, the use of ergometrine is not recommended in women with aortic disease.</td>
<td>III</td>
<td>C</td>
</tr>
<tr>
<td><strong>Specific syndromes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In patients with vascular Ehlers–Danlos syndrome, celiprolol is recommended. [^186]\</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Beta-blocker therapy throughout pregnancy should be considered in women with Marfan syndrome and other heritable thoracic aortic diseases.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Pregnancy is not recommended in patients with severe dilatation of the aorta (heritable thoracic aortic disease such as Marfan syndrome ≥45 mm, bicuspid aortic valve ≥50 mm or ≥27 mm/m² BSA, or Turner syndrome ASI ≥25 mm/m² BSA). [^19,20]\</td>
<td>III</td>
<td>C</td>
</tr>
<tr>
<td>Pregnancy is not recommended in patients with vascular Ehlers–Danlos syndrome. [^76]\</td>
<td>III</td>
<td>C</td>
</tr>
</tbody>
</table>

ASI = aortic size index; BSA = body surface area; CT = computed tomography; MRI = magnetic resonance imaging.

[^1]: Class of recommendation.
[^2]: Level of evidence.
6. Valvular heart disease

At childbearing age, valvular heart disease is often due to rheumatic heart disease, particularly in low–middle-income countries. Mechanical valve prostheses raise specific problems during pregnancy.192,195,196 Risk assessment and management need to consider the resources available in high- and low–middle-income countries.

6.1 Stenotic valve lesions

In stenotic valve diseases, increased CO causes an increase in transvalvular gradient of ∼50%, mainly between the first and second trimesters,197 which increases the risk of maternal and foetal complications.

6.1.1 Mitral stenosis

6.1.1.1 Maternal risk

Mild mitral stenosis (MS) is generally well tolerated.198,199 HF occurs in one-third of pregnant women with a valve area <1.0 cm² and in one-half of those with a valve area <1.5 cm²,199 most often during the second trimester, even in the absence of symptoms before pregnancy.199 Sustained AF, although rare (<10%), may precipitate HF and thrombo-embolic events.199,200 Mortality is between 0–3% in western countries198–200 and higher in low–middle-income countries.201,202 NYHA class ≥ II, systolic PAP >30 mmHg, severe stenosis, and older age are associated with maternal complications.199

6.1.1.2 Obstetric and offspring risk

The risk of acute HF peripartum depends on symptoms and PAP.194 Prematurity rates are 20–30%, intrauterine growth retardation 5–20%, and foetal death 1–5%.198–200,203 Offspring risk is higher in women in NYHA class III/IV during pregnancy.29,194

6.1.1.3 Management

Diagnosis. MS is considered clinically significant if valve area is <1.5 cm².204,205 The reference measurement of MS severity is planimetry; Doppler-derived pressure half-time is less reliable but can be used during pregnancy.204,205 Mean gradient and PAP assess haemodynamic consequences and prognosis.204,205 The assessment of mitral anatomy and associated regurgitation is important when percutaneous mitral commissurotomy is considered.204,205 Before pregnancy, exercise testing is useful to assess objective exercise tolerance and exercise echocardiography may provide additional information.

Medical therapy. When symptoms or clinically significant PH (echocardiographically estimated systolic PAP ≥50 mmHg) develop, activity should be restricted and beta-1-selective blockers (preferably metoprolol or bisoprolol) commenced.5 Diuretics may be used if symptoms persist, avoiding high doses (see table ‘Recommendations for drug use in pregnancy’).5 Anticoagulation using UFH, LMWH, or vitamin K antagonist (VKA), according to the context and term, is recommended in the case of paroxysmal or permanent AF, left atrial thrombosis, or prior embolism.5 Anticoagulation should be considered in women in sinus rhythm with significant MS and spontaneous echocardiographic contrast in the left atrium, large left atrium (≥ 60 mL/m²), or congestive HF.

Interventions. All patients with significant MS should be counselled against pregnancy and intervention should be considered pre-pregnancy, favouring percutaneous intervention, even if asymptomatic, and even more so if the valve area is <1.0 cm².198,204

During pregnancy, percutaneous mitral commissurotomy is preferably performed after 20 weeks of gestation. It should only be considered in women with NYHA class III/IV and/or systolic PAP ≥50 mmHg, despite optimal medical treatment in the absence of contraindications (see table ‘General Recommendations’).204 Closed commissurotomy remains an alternative in low–middle-income countries. Due to foetal risk, open-heart surgery should be reserved for cases in which all other measures have failed and the mother’s life is threatened.206

Follow-up during pregnancy. Clinical and echocardiographic follow-up is indicated monthly or bimonthly depending on haemodynamic tolerance. In mild MS, evaluation is recommended every trimester and prior to delivery.

Labour and delivery. Vaginal delivery should be favoured in patients with mild MS, and in patients with significant MS in NYHA class III without PH. Caesarean section is generally considered in patients who are in NYHA class III/IV or have PH, or in whom percutaneous mitral commissurotomy cannot be performed or has failed.

Follow-up and prognosis after delivery. Close monitoring is needed in the days following delivery. Late prognosis depends mainly on the risk of stenosis progression or re-stenosis after commissurotomy, and justifies regular follow-up.204

6.1.2 Valvular aortic stenosis

The main cause of AS is bicuspid aortic valve followed by rheumatic heart disease.

6.1.2.1 Maternal risk

Cardiac morbidity is related to the baseline severity of AS and symptoms.207 HF is rare (<10%) in women with moderate AS and in those who were asymptomatic before pregnancy, while it occurs in one out of four symptomatic patients.207 Even in patients with severe AS, pregnancy is often well tolerated if prior exercise tolerance was normal. Mortality is now rare if careful management is provided.194,198,207–209 Arrhythmias are rare.206 Women with bicuspid aortic valve have a low-risk of aortic dissection if the aortic diameter is <50 mm (section 5.2).

6.1.2.2 Obstetric and offspring risk

Obstetric complications may be increased in patients with severe AS.207,209 Pre-term birth, intrauterine growth retardation, and low birth weight occur in 20–25% of the offspring of mothers with moderate and severe AS, and are increased in severe AS.207 Miscarriages and foetal death rates are <5%. The risk of genetic transmission of LV outflow tract malformations justifies the performance of foetal echocardiography in AS due to bicuspid aortic valve.5

6.1.2.3 Management

Diagnosis. The severity of AS is assessed by combining flow-dependent indices and valve area.204,205 Exercise testing is recommended in asymptomatic patients before pregnancy to evaluate
exercise tolerance, BP response, and arrhythmias, and exercise echocardiography may provide additional information. In women with bicuspid aortic valve, aortic diameters should be assessed before and during pregnancy.

Medical therapy. Medical treatment and restricted activities are indicated if HF occurs during pregnancy. Diuretics can be administered for congestive symptoms.

Interventions. All symptomatic patients with severe AS or asymptomatic patients with impaired LV function or a pathological exercise test should be counselled against pregnancy, and surgery should be performed pre-pregnancy. Pregnancy should not be discouraged in asymptomatic patients, even with severe AS, when LV size and function and the exercise test are normal (see table ‘General Recommendations’). There should also be no recent progression of AS.

During pregnancy in patients who are severely symptomatic despite medical therapy, percutaneous valvuloplasty can be undertaken by an experienced operator. If this is not possible and patients have life-threatening symptoms, valve replacement should be considered after early delivery by caesarean section if this is an option (see table ‘General Recommendations’). Given the foetal risk of surgery, transcatheter aortic valve implantation is a promising alternative, but experience during pregnancy is very limited.

Follow-up during pregnancy. Regular follow-up is required by an experienced team. In severe AS, monthly or bimonthly cardiac evaluations including echocardiography are advised.

Labour and delivery. In severe symptomatic AS, caesarean delivery should be preferred. An individual approach is recommended for asymptomatic severe AS. In non-severe AS, vaginal delivery is favoured.

Follow-up and prognosis after delivery. Disease progression is frequent after delivery and requires close follow-up.

6.2 Regurgitant lesions

6.2.1 Mitral and aortic regurgitation

Mitral and aortic regurgitation can be of rheumatic, congenital, or degenerative origin.

6.2.1.1 Maternal risk

Women with severe regurgitation and symptoms or compromised LV function are at high-risk of HF. HF occurs in 20–25% of women with moderate or severe rheumatic MR. Acute severe regurgitation is poorly tolerated. In women with congenital heart disease, significant left AV valve regurgitation is associated with cardiac complications during pregnancy. A persistent worsening of regurgitation may occur.

6.2.1.2 Obstetric and offspring risk

No increased risk of obstetric complications has been reported. Intrauterine growth retardation occurs in 5–10%, and other offspring complications in <5%, of women with moderate or severe MR.

6.2.1.3 Management

Diagnosis. Evaluation, preferably pre-conception, should include the assessment of symptoms and comprehensive echocardiographic evaluation of regurgitation severity, LV dimensions, and function.

Ascending aortic diameters should be measured in women with aortic regurgitation, especially in those with bicuspid valves.

Medical therapy. Symptoms of fluid overload can usually be managed medically.

Interventions. Pre-pregnancy surgery favouring valve repair should be performed according to guidelines. In acute severe regurgitation with therapy-refractory HF, surgery is sometimes unavoidable during pregnancy. If the foetus is sufficiently mature, delivery should be undertaken prior to cardiac surgery (see table ‘General Recommendations’).

Follow-up during pregnancy. Follow-up is required every trimester in mild/moderate regurgitation, and more often in severe regurgitation.

Labour and delivery. Vaginal delivery with epidural anaesthesia and shortened second stage is advisable.

Follow-up and prognosis after delivery. The prognosis depends on the regurgitation severity and its consequences on symptoms, LV size, and function.

6.2.2 Tricuspid regurgitation

Secondary TR is more frequent than primary TR, which may be due to endocarditis or Ebstein’s anomaly.

Maternal risk is usually determined by left-sided valve disease or PH. However, maternal risk can be increased in severe symptomatic TR or in women with RV dysfunction. In women with congenital heart disease, moderate/severe AV valve regurgitation may be associated with maternal cardiac complications, which are mainly arrhythmias.

Even severe TR with HF can usually be managed conservatively during pregnancy (see table ‘General Recommendations’). When surgery is necessary for left-sided valve lesions, additional tricuspid repair is indicated in severe TR and should be considered in moderate TR with annular dilatation (≥ 40 mm). In severe symptomatic TR, repair should be considered pre-pregnancy.

6.3 Atrial fibrillation in native heart valve disease

A high thrombo-embolic risk is associated with AF, particularly in clinically significant MS. Immediate anticoagulation is required, using LMWH at therapeutic doses in the first and last trimesters, and VKAs with the usual target INRs or LMWH for the second trimester. Non-VKA OACs are contraindicated throughout pregnancy. The choice between cardioversion and rate control using digoxin or beta-blockers depends on the severity of the underlying valve disease and the tolerance (see section 12).

6.4 Prosthetic valves

6.4.1 Choice of valve prosthesis

When implantation of a prosthetic valve is unavoidable in a woman who wants to become pregnant in the future, valve selection is
challenging. Mechanical valves offer excellent haemodynamic performance and long-term durability, but the need for anticoagulation increases maternal and foetal mortality and morbidity, and the risk of major cardiac events during pregnancy is much higher than with bioprosthetic valves. However, bioprosthetic valves in young women are associated with a high-risk of structural valve deterioration resulting in the risk of going through pregnancy with a dysfunctional valve, and eventually in the inevitable need for re-operation. Transcatheter valve implantation (currently especially in pulmonary valves) and the Ross procedure in aortic valve disease (pulmonary autograft in the aortic position and pulmonary homograft) are alternative options to be considered.

In conclusion, Suboptimal target anti-Xa levels or poor compliance often contribute to valve thrombosis, but several valve thromboses occurred with peak anti-Xa levels within the target range of 1.0–1.2 IU/mL. Valvular thrombosis occurs in 5.8–7.4% when LMWH is used in the first trimester only, which is similar to using LMWH throughout pregnancy. However, the high-risk of valve thrombosis in the UK study was mainly related to the use of LMWH throughout pregnancy. The occurrence of valve thrombosis with adequate peak anti-Xa levels has raised concerns about the safety of this approach. Fast renal clearance can result in subtherapeutic trough (pre-dose) anti-Xa levels despite adequate peak levels, but data on pregnancies with LMWH dosing according to trough and peak anti-Xa levels are limited to case reports.

In conclusion, there are unresolved questions concerning LMWH in pregnant women with mechanical valves, including optimal anti-Xa levels, the importance of peak vs. trough levels, the best time intervals for anti-Xa monitoring, and the duration of use.

Current evidence (lacking adequate randomized studies) indicates that the use of VKAs throughout pregnancy, under strict INR control, is the safest regimen to prevent valve thrombosis. LMWH is possibly superior to UFH for preventing valve thrombosis.

### 6.5 Mechanical prostheses and anticoagulation

In women with mechanical valves, pregnancy is associated with a very high-risk of complications (WHO risk classification III). In the ROPAC registry, the chances of an event-free pregnancy with a live birth were 58% for women with a mechanical valve, compared with 79% for women with a bioprosthesis and 78% for women with heart disease but no valve prosthesis. A recent study from the UK reported a favourable outcome for mother and baby in only 28% of cases.

The main risks are related to the need for anticoagulation therapy (valve thrombosis and haemorrhagic complications). Additional risks are related to ventilricular and valvular dysfunction.

#### 6.5.1 Maternal risk

The risk of valve thrombosis is markedly increased during pregnancy. The risk is lower with adequate dosing of anticoagulant therapy, and depends on the type and position of the mechanical valve, and on additional patient-related risk factors. In the ROPAC registry, valve thrombosis occurred in 4.7% of 202 pregnancies and mortality was 20%. In the UK study, maternal mortality related to thrombotic complications or valve dysfunction occurred in 9% and severe morbidity in 41% (16% thrombo-embolic complications). The risk of valve thrombosis is relatively low with VKAs throughout pregnancy (0–4%). Scarce evidence concerning UFH in the first trimester or throughout pregnancy indicates a high-risk of valve thrombosis (9–33%); additional risks are thrombocytopenia and osteoporosis. LMWH is also associated with the risk of valve thrombosis. Because the dose requirement markedly increases due to increased renal clearance, monitoring of anti-Xa levels with dose adjustment decreases the risk. LMWH throughout pregnancy with anti-Xa monitoring and dose adjustment according to peak levels carries a valve thrombosis risk of 4.4–8.7%. Suboptimal target anti-Xa levels or poor compliance often contribute to valve thrombosis, but several valve thromboses occurred with peak anti-Xa levels within the target range of 1.0–1.2 IU/mL. Valvular thrombosis occurs in 5.8–7.4% when LMWH is used in the first trimester only, which is similar to using LMWH throughout pregnancy. However, the high-risk of valve thrombosis in the UK study was mainly related to the use of LMWH throughout pregnancy. The occurrence of valve thrombosis with adequate peak anti-Xa levels has raised concerns about the safety of this approach. Fast renal clearance can result in subtherapeutic trough (pre-dose) anti-Xa levels despite adequate peak levels, but data on pregnancies with LMWH dosing according to trough and peak anti-Xa levels are limited to case reports.

In conclusion, there are unresolved questions concerning LMWH in pregnant women with mechanical valves, including optimal anti-Xa levels, the importance of peak vs. trough levels, the best time intervals for anti-Xa monitoring, and the duration of use.

Current evidence (lacking adequate randomized studies) indicates that the use of VKAs throughout pregnancy, under strict INR control, is the safest regimen to prevent valve thrombosis. LMWH is possibly superior to UFH for preventing valve thrombosis.

#### 6.5.2 Obstetric and offspring risk

All anticoagulation regimens carry an increased risk of miscarriage and haemorrhagic complications, including post-partum haemorrhage and retroplacental bleeding leading to premature birth and foetal death. ROPAC shows that VKAs during the first trimester are associated with an increased risk of miscarriage compared with LMWH or UFH (28.6% vs. 9.2%), and the live birth rate is lower, in line with other literature. Two systematic reviews concluded that the risk of foetal loss is dose-related (foetal loss rate with low-dose VKA is 13.4–19.2%, total foetal loss rate with VKA is 32.5%). Foetal loss rate with a combined heparin/VKA regimen is 22.7%, and with LMWH throughout pregnancy is 12.2%. Comparison between studies is hampered by reporting differences, and conclusions concerning the safety of low-dose VKA are controversial.

VKA use in the first trimester results in embryopathy (limb defects, nasal hypoplasia) in 0.6–10% of cases. UFH and LMWH do not cross the placenta, therefore substitution of VKA with UFH or LMWH in weeks 6–12 almost eliminates the risk of embryopathy. The embryopathy risk is also dose-dependent (0.45–0.9% with low-dose warfarin). Additionally, there is 0.7–2% risk of foetoopathy (e.g. ocular and central nervous system abnormalities, intracranial haemorrhage) with VKAs in the second and third trimester. Foetoopathy has been described with UFH but not with LMWH throughout pregnancy. Vaginal delivery while the mother is on VKAs is contra-indicated because of the risk of foetal intracranial bleeding. Haemorrhagic complications in the mother occur with all regimens, but the incidence is lower with VKA throughout pregnancy than with LMWH/UFH throughout pregnancy. Addition of low-dose aspirin to VKA or heparin has no proven advantage in preventing valve
thrombosis but is associated with significantly more maternal bleed-
ing complications, including fatal events.\textsuperscript{196,219,222}

6.5.3 Management
Pre-pregnancy evaluation should include the assessment of symptoms and echocardiographic evaluation of ventricular function, as well as prosthetic and native valve function. The type and position of valve(s), as well as the history of valve thrombosis, should be taken into account. The option to avoid pregnancy should be discussed with the mother.

6.5.3.1 Medical therapy
The advantages and disadvantages of different anticoagulation regimens should be discussed extensively before pregnancy. The mother must understand that the use of VKAs is the most effective regimen to prevent valve thrombosis, and therefore the safest regimen for her, and that risks to the mother also jeopardize the baby. However, the increased risks of embryopathy, foetopathy, foetal loss, and foetal haemorrhage associated with the use of VKAs need to be discussed while considering the VKA dose. The higher risk of valve thrombosis and lower foetal risks associated with LMWH should be discussed. Compliance with prior anticoagulant therapy should be considered. The mother should understand that whatever anticoagulation regime is chosen, her strict compliance is crucial for a successful outcome of the pregnancy.

VKAs should be continued until pregnancy is achieved. Continuation of VKAs throughout pregnancy should be considered when the VKA dose is low (see Table 7). Because of the low risks of embryopathy, foetopathy (<2%), and foetal loss (<20%), VKAs are the most effective regi-
men to prevent valve thrombosis.\textsuperscript{215,218,219} The target INR should be chosen according to current guidelines,\textsuperscript{204} with INR monitoring weekly or every 2 weeks. Self-monitoring of INR in suitable patients is recom-

recommended. Alternatively, a switch to LMWH from weeks 6–12 under strict monitoring may be considered in patients with a low dose requirement, after full information has been given to the mother. When a higher dose of VKAs is required, discontinuation of VKAs between weeks 6 and 12, and replacement with adjusted-dose i.v. UFH or LMWH twice daily with dose adjustment according to peak anti-Xa lev-
els, should be considered. See Table ‘Recommendations for the manage-
ment of prosthetic heart valves’ and Figures 2–4 for details of dosing and monitoring. Alternatively, continuation of VKAs may be considered in these patients after fully informed consent. In addition to monitoring the

Figure 2 Flowchart on anticoagulation in mechanical valves and high-dose VKA *weeks 6–12.\textsuperscript{4}monitoring LMWH: - starting dose for LMWH is 1 mg/kg body weight for enoxaparin and 100 IU/kg for dalteparin, twice daily subcutaneously; -in-hospital daily anti-Xa levels until target, then weekly (); -target anti-

Xa levels: 1.0–12 U/ml (mitral and right sided valves) or 0.8–12 U/ml (aortic valves) 46 hours post-dose (); -pre-dose anti-Xa levels >0.6 U/ml (lb); -aPTT = activated partial thromboplastin time; INR = international normalized ratio; i.v. = intravenous; LMWH = low molecular weight heparin; LVEF = left ventricular ejection fraction; UFH = unfractionated heparin; VKA = vitamin K antagonist.

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/34/3165/5078465 by guest on 17 June 2019
peak anti-Xa levels, monitoring of the trough (pre-dose) anti-Xa level and dose-adjustment to maintain this trough level at >0.6 IU/mL may be considered based on theoretical grounds, despite limited evidence.\textsuperscript{5,224,225} The starting dose for LMWH is 1 mg/kg body weight for enoxaparin and 100 IU/kg for dalteparin, twice daily subcutaneously; in-hospital daily anti-Xa levels until target, then weekly (I); -target anti-Xa levels: 1.0–1.2 U/ml (mitral and right sided valves) or 0.8–1.2 U/ml (aortic valves) 4–6 hours post-dose (I); -pre-dose anti-Xa levels >0.6 U/ml (IIb). aPTT = activated partial thromboplastin time; INR = international normalized ratio; i.v. = intravenous; LMWH = low molecular weight heparin; LVEF = left ventricular ejection fraction; UFH = unfractionated heparin; VKA = vitamin K antagonist.

\textbf{Figure 3} Flowchart on anticoagulation in mechanical valves and low-dose VKA: \textsuperscript{6}weeks 6–12 \textsuperscript{7}monitoring LMWH: - starting dose for LMWH is 1 mg/kg body weight for enoxaparin and 100 IU/kg for dalteparin, twice daily subcutaneously; -in-hospital daily anti-Xa levels until target, then weekly (I); -target anti-Xa levels: 1.0–1.2 U/ml (mitral and right sided valves) or 0.8–1.2 U/ml (aortic valves) 4–6 hours post-dose (I); -pre-dose anti-Xa levels >0.6 U/ml (IIb). aPTT = activated partial thromboplastin time; INR = international normalized ratio; i.v. = intravenous; LMWH = low molecular weight heparin; LVEF = left ventricular ejection fraction; UFH = unfractionated heparin; VKA = vitamin K antagonist.

\textbf{Figure 4} Flowchart on anticoagulation in mechanical valves and target international normalized ratio for mechanical prostheses (modified from Baumgartner et al.\textsuperscript{204}). INR = international normalized ratio; LVEF = left ventricular ejection fraction. \textsuperscript{a}Mitrail or tricuspid valve replacement, previous thrombo-embolism, atrial fibrillation, mitral stenosis of any degree, or LVEF <35%. \textsuperscript{b}Carbomedics, Medtronic Hall, ATS, or Medtronic Open-Pivot, St Jude Medical, On-X, or Sorin Bicarbon. \textsuperscript{c}Other bileaflet valves with insufficient data. \textsuperscript{d}Lillehei-Kaster, Omnicience, Starr-Edwards (ball-cage), Björk-Shiley and other tilting-disc valves; any pulmonary valve prosthesis.

\textbf{6.5.3.2 Surveillance during pregnancy}
These high-risk pregnancies should be managed by a pregnancy heart team in an expert centre. The effectiveness of the anticoagulation regimen should be monitored weekly or every 2 weeks depending on the anticoagulation regimen (see Table 7), and clinical follow-up including echocardiography should be performed monthly.
6.5.3.3 Diagnosis and management of valve thrombosis

Dyspnoea and/or an embolic event are reasons for immediate trans-thoracic echocardiography to search for valve thrombosis, usually followed by transeosophageal echocardiography. Additionally, fluoroscopy can be performed with limited foetal risk. Management of valve thrombosis is comparable with management in non-pregnant patients. This includes optimizing anticoagulation with i.v. UFH and the resumption of oral anticoagulation in non-critically ill patients with recent subtherapeutic anticoagulation, and surgery when anticoagulation fails and for critically ill patients with obstructive thrombosis. A molecular weight >1000 Da prevents most fibrinolytic items from easily crossing the placenta, though small amounts of streptokinase and fragments of urokinase may pass into the foetal circulation. Alteplase (a recombinant tissue plasminogen activator) has the highest molecular weight and does not cross the placenta. However, the risk of embolization (10%) and subplacental bleeding is a concern, and experience in pregnancy is limited. Fibrinolysis should be applied in critically ill patients when surgery is not immediately available, and it should be considered when the risk of surgery is high. Because foetal loss is high (30%) with surgery, fibrinolysis may be considered instead of surgery in non-critically ill patients when anticoagulation fails. Fibrinolysis is the therapy of choice in right-sided prosthetic valve thrombosis. The mother should be informed about the risks.

6.5.3.4 Delivery

Planned delivery is necessary. Vaginal delivery requires a prior switch to i.v. heparin. The use of epidural anaesthesia requires a prolonged interruption of anticoagulant therapy, which may contraindicate its use in women with a mechanical prosthesis. A planned caesarean section may therefore be considered as an alternative, especially in patients with a high-risk of valve thrombosis, to keep the time without VKAs as short as possible. Caesarean section should be performed if labour onset occurs while the patient is still on VKAs.

6.6 Recommendations

### Recommendations for the management of native valvular heart disease

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-pregnancy evaluation, including echocardiography, and counselling is recommended for any woman with known or suspected valvular disease.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td><strong>Mitrval stenosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In patients with symptoms or pulmonary hypertension, restricted activities and beta-1-selective blockers are recommended.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>Diuretics are recommended when congestive symptoms persist despite beta-blockers.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>Intervention is recommended before pregnancy in patients with MS and valve area &lt;1.0 cm².</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Therapeutic anticoagulation using heparins or VKA is recommended in case of atrial fibrillation, left atrial thrombosis, or prior embolism.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Intervention should be considered before pregnancy in patients with MS and valve area &lt;1.5 cm².</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Percutaneous mitral commissurotomy should be considered in pregnant patients with severe symptoms or systolic pulmonary artery pressure &gt;50 mmHg despite medical therapy.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td><strong>Aortic stenosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intervention is recommended before pregnancy in patients with severe aortic stenosis if:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- they are symptomatic</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>- OR LV dysfunction (LVEF &lt;50%) is present</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>- OR when they develop symptoms during exercise testing.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Intervention should be considered before pregnancy in asymptomatic patients with severe AS when a fall in blood pressure below baseline during exercise testing occurs.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Balloon aortic valvuloplasty should be considered during pregnancy in patients with severe aortic stenosis and severe symptoms.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td><strong>Chronic regurgitant lesions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical treatment is recommended before pregnancy in patients with severe aortic or mitral regurgitation with symptoms of impaired ventricular function or ventricular dilatation.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Medical therapy is recommended in pregnant women with regurgitant lesions when symptoms occur.</td>
<td>I</td>
<td>C</td>
</tr>
</tbody>
</table>

LV = left ventricular; LVEF = left ventricular ejection fraction; MS = mitral stenosis; VKA = vitamin K antagonist.

*Class of recommendation.

*Level of evidence.
### Recommendations for the management of prosthetic heart valves

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is recommended that the valve prosthesis for a woman contemplating pregnancy is chosen in consultation with a pregnancy heart team.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>It is recommended to manage pregnancy in women with mechanical valves in a centre with a pregnancy heart team.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>If delivery starts while on a VKA or in less than 2 weeks after discontinuation of a VKA, caesarean section is recommended.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>It is recommended to discontinue VKAs and start adjusted-dose intravenous UFH ([aPTT &gt; 2x control]) or adjusted-dose LMWH (see separate recommendations) at the 36th week of gestation.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>In pregnant women on LMWH or UFH, it is recommended to perform weekly anti-Xa level monitoring or aPTT monitoring with dose adjustment (within 36 h).</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>In pregnant women on a VKA, it is recommended to perform INR monitoring weekly or every 2 weeks.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>In pregnant women with LMWH, it is recommended to target anti-Xa levels 4–6 h post-dose at 0.8–1.2 U/l (aortic valve prosthesis) or 1.0–1.2 IU/mL (mitral and right-sided valve prostheses).</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>It is recommended to replace LMWH with intravenous UFH ([aPTT &gt; 2x control]) at least 36 h before planned delivery. UFH should be continued until 4–6 h before planned delivery and restarted 4–6 h after delivery if there are no bleeding complications.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>It is recommended to anticipate the timing of delivery to ensure safe and effective peripartum anticoagulation.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Immediate echocardiography is recommended in women with mechanical valves presenting with dyspnoea and/or an embolic event.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>It is recommended to implement changes in the anticoagulation regimen during pregnancy in hospital.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>During the second and third trimesters until the 36th week, VKAs are recommended in women needing a low dose.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>A bioprostheses should be considered in young women contemplating pregnancy.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>During the second and third trimesters until the 36th week, VKAs should be considered in women needing a high dose.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Continuation of VKAs should be considered during the first trimester if the warfarin dose required for therapeutic anticoagulation is &lt; 5 mg/day (or phenprocoumon &lt; 3 mg/day or acenocoumarol &lt; 2 mg/day) after patient information and consent.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Discontinuation of VKAs between weeks 6 and 12, and replacement with adjusted-dose intravenous UFH ([aPTT &gt; 2x control]) or adjusted-dose LMWH twice daily (see separate recommendations), should be considered in patients with a warfarin dose &gt; 5 mg/day (or phenprocoumon &gt; 3 mg/day or acenocoumarol &gt; 2 mg/day).</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>During the second and third trimesters, LMWH with anti-Xa level monitoring and dose adjustment (see separate recommendations) may be considered in women who need a high dose of VKA after patient information and consent.</td>
<td>IIb</td>
<td>C</td>
</tr>
<tr>
<td>In pregnant women with LMWH, in addition to monitoring peak anti-Xa levels, monitoring pre-dose levels targeted at ≥0.6 IU/mL may be considered.</td>
<td>IIb</td>
<td>C</td>
</tr>
<tr>
<td>LMWH is not recommended when weekly anti-Xa level monitoring and dose-adjustment is not available.</td>
<td>III</td>
<td>C</td>
</tr>
</tbody>
</table>

aPTT = activated partial thromboplastin time; INR = international normalized ratio; LMWH = low molecular weight heparin; UFH = unfractionated heparin; VKA = vitamin K antagonist.

*Class of recommendation.

*Level of evidence.

The starting dose for LMWH is 1 mg/kg body weight for enoxaparin and 100 IU/kg for dalteparin, twice daily subcutaneously.

Low-dose VKA: warfarin < 5 mg/day (or phenprocoumon < 3 mg/day or acenocoumarol < 2 mg/day).

High-dose VKA: warfarin ≥ 5 mg/day (or phenprocoumon > 3 mg/day or acenocoumarol > 2 mg/day).
7. Coronary artery disease

The incidence of CAD in women of childbearing age is unclear and varies between countries. Although acute MI (AMI)/acute coronary syndromes (ACS) complicating pregnancy is relatively uncommon (1.7–6.2/100 000 deliveries), CAD accounts for >20% of all maternal cardiac deaths.

7.1 Aetiopathology

Pregnancy is associated with a three- to four-fold increase in AMI risk compared with age-matched non-pregnant women. Risk factors include smoking, maternal age, hypertension, diabetes, obesity, and dyslipidaemia. Additional risk factors include (pre-)eclampsia, thrombophilia, transfusion, post-partum infection, cocaine use, multiparity, and post-partum haemorrhage. As the birth rate in women >40 years increases, ACS complicating pregnancy will become more common, as for every year increase in maternal age there is a 20% increase in MI risk.

The aetiology of CAD in pregnancy differs from the general population; the majority of CAD has non-atherosclerotic mechanisms, including pregnancy-related spontaneous coronary artery dissection (P-SCAD) (43%), angiographically normal coronary arteries (18%), and coronary thrombosis (17%).

P-SCAD-related AMI occurs most commonly in late pregnancy/early post-partum, and predominantly involves the left-sided coronary arteries, frequently with multivessel involvement. Potential pregnancy-related precipitating factors include fluctuating oestrogen/progesterone levels resulting in structural changes in coronary vasculature, in background of fibromuscular dysplasia or connective tissue disease, and increased coronary shear stresses associated with labour.

The mechanisms of AMI with angiographically normal coronary arteries remains unclear and include transient coronary spasm (increased vascular reactivity and/or use of ergot derivatives), rather reflecting the limitations of this diagnostic technique. Coronary thrombosis in the absence of atherosclerosis is most likely due to the hypercoagulability of pregnancy and can result from paradoxical embolization.

Increasing survival in Kawasaki disease (in the USA it is predicted that by 2030, one in every 1600 adults will have suffered from Kawasaki disease) presents an additional challenge. Relevant Kawasaki disease manifestations include aneurysms, coronary blood flow alteration, coronary stenoses, myocardial ischaemia/fibrosis, congestive cardiac failure, and valvular abnormalities.

Coronary thrombosis in the absence of atherosclerosis is the most likely due to the hypercoagulability of pregnancy and can result from paradoxical embolization.

7.2 Presentation and diagnosis

Development of pregnancy-related ACS/AMI is most common during the third trimester [STEMI 25% and non-STEMI (NSTEMI) 32%] or post-partum (STEMI 45% and NSTEMI 55%). Clinical presentation is the same as in the non-pregnant population. ECG interpretation can be challenging, with inverted T waves in the absence of coronary ischaemia, and anaesthesia induction for caesarean section associated with ST-segment depression. A serum troponin rise should suggest myocardial ischaemia, even in pre-eclampsia. Where the ECG is non-diagnostic, echocardiography may be helpful. The main differential diagnoses include PE, aortic dissection, and pre-eclampsia. Potential complications include HF/cardiogenic shock (38%), arrhythmias (12%), recurrent angina/AMI (20%), maternal mortality (7%), and foetal death (7).

7.3 Management

AMI management in pregnancy is similar to that in the general population, including revascularization techniques. In P-SCAD, enhanced vascular vulnerability should be considered when applying revascularization strategies. Management should be multidisciplinary, including emergency, obstetric, and cardiovascular teams, and any revascularization should be undertaken by the most experienced operator due to the attendant risks associated with coronary intervention in this patient population. In cardiogenic shock, there should be facilities for emergency mechanical circulatory support. Close monitoring of the mother and foetus is required, with a delivery strategy in place if there is sudden maternal or foetal deterioration. In the event of maternal cardiac arrest, resuscitation (and delivery) should be performed according to existing guidelines.

7.4 Pharmacotherapy

There is little information regarding the foetal safety of guideline-recommended drug therapy in AMI. Low-dose aspirin appears to be safe, but there is little information regarding P2Y12 inhibitors. Clopidogrel should be used only when strictly necessary and for the shortest duration. In the absence of data regarding glycoprotein IIb/IIIa inhibitors-bivalirudin, prasugrel, and ticagrelor, their use is not recommended. Beta-blockade may be beneficial in reducing shear stress in P-SCAD. Recombinant tissue plasminogen activator does not cross the placenta but may induce bleeding complications (subplacental bleeding). The benefits of short-term heparinization during PCI probably outweigh the risk of bleeding complications.

7.5 Intervention

The effects of ionizing radiation should not prevent primary PCI in pregnant patients with standard indications for revascularization in AMI. However, the radiation dose must be minimized. In stable, low-risk NSTEMI, a non-invasive approach should be considered. Although CT coronary angiography provides an alternative diagnostic method, it requires radiation, potentially high-dose beta-blockade, and may fail to demonstrate limited P-SCAD.

7.5.1 Stent choice and antiplatelet therapy

The majority of reports regarding STEMI in pregnancy relate to bare-metal stents. However, new-generation drug-eluting stents (DES) are recommended according to the 2017 AMI STEMI Guidelines. Because no complications have been reported in stented pregnant patients treated with clopidogrel and aspirin, and because pregnancy is a high bleeding risk situation, use of a more potent P2Y12 inhibitor should be considered with caution. The duration of dual antiplatelet therapy with a second/third-generation DES can be shortened, particularly in the absence of great thrombotic burden. Bioabsorbable stent usage has been reported in spontaneous coronary artery dissection; however, there is currently no evidence to recommend them in pregnancy.
7.6 Pre-existing CAD

Women with pre-established CAD or ACS/MI are at risk of serious adverse cardiac events during pregnancy, the highest risk of which is seen in atherosclerotic coronary disease with reported maternal mortality between 0–23%. Adverse obstetric outcomes occur in <16%, with 30% of pregnancies complicated by an adverse foetal/neonatal event, most commonly in coronary atherosclerosis (50%).

Pregnancy may be considered in patients with known CAD in the absence of residual ischaemia and clinical signs of LV dysfunction. There are no high-quality data defining how long pregnancy should be delayed post-AMI/ACS. However, recommending 12 months seems reasonable, individualized according to comorbidities, cardiovascular status, and the requirement for medical therapy. There is no definitive evidence that previous P-SCAD increases recurrence risk. However, avoidance of further pregnancy is advised and, if the patient chooses to proceed, close monitoring is recommended.

7.7 Labour and delivery

Timing of delivery must be individualized. However, treatment of STEMI/NSTEMI should not be delayed for delivery. Delivery should be postponed (if possible) for at least 2 weeks post-AMI to facilitate maternal management. Vaginal delivery is preferable (see section 3).

8. Cardiomyopathies and heart failure

The aetiology of pregnancy-associated cardiomyopathy includes acquired and inherited diseases, such as PPCM, toxic cardiomyopathies, HCM, dilated cardiomyopathy (DCM), Takotsubo cardiomyopathy, and storage diseases. Although rare, they may cause severe complications in pregnancy: HF with preserved EF, an important cause of HF in older patients, does not appear to be a major clinical problem in pregnancy; however, it may be underdiagnosed.

8.1 Peripartum cardiomyopathy

PPCM has recently been reviewed and the EURObservational Research Programme international PPCM registry will provide fundamental data on this condition. Important predisposing factors include multiparity, African ethnicity, smoking, diabetes, pre-eclampsia, malnutrition, advanced age, and teenage pregnancy. The cause is uncertain, but potential aetiologies include inflammation and angiogenic imbalance, inducing vascular damage. The biologically active 16 kDa prolactin and other factors, such as soluble fms-like tyrosine kinase 1 (sFlt1), may initiate and drive PPCM.

8.1.1 Diagnosis

PPCM presents with HF secondary to LV systolic dysfunction towards the end of pregnancy and in the months following delivery, with the majority diagnosed post-partum. Careful history taking is necessary to identify and exclude other causes of HF. The LV may be non-dilated, but the EF is usually <45%. Symptoms and signs are often typical for HF with numerous phenotypes reported. Patients frequently present with acute HF, but also with ventricular arrhythmias and/or cardiac arrest. Echocardiography is the imaging modality of choice. Initial LVEF <30%, marked LV dilatation (LV end-diastolic diameter >6.0 cm), and RV involvement are associated with adverse outcomes.

8.1.2 Prognosis and counselling

Prospective larger cohort studies have mainly focused on 6 month outcomes, reporting a mortality ranging from 2.0% in Germany to 12.6% in a large cohort of 206 patients with PPCM from South Africa. A prospective study over 24 months from Turkey reported a 24% mortality. When the EF has not recovered to >50–55%, subsequent pregnancy should be discouraged. Even with normalized EF, counselling is required due to potential recurrence. With expert interdisciplinary management and immediate bromocriptine treatment post-delivery, successful subsequent pregnancies, especially in patients with recovered EF, have been reported.

8.2 Dilated cardiomyopathy

DCM encompasses a number of conditions resulting in LV dilatation and dysfunction including prior viral infection, drugs, and ischaemia. Some 50% of cases are idiopathic, of which 20–35% are hereditary. Around 40% of the genetic causes of DCM have been identified, with >50 gene mutations described. The prevalence of idiopathic DCM is 1:2500; however, this is likely an underestimate.
Patients may already be known to have DCM, or may present de novo during pregnancy. Distinguishing symptoms and signs of normal pregnancy from HF demands careful attention. Although PPCM and DCM are distinct disease entities, patients may share a genetic predisposition, and differentiation during pregnancy may be impossible.\textsuperscript{273–276,287}

### 8.2.1 Prognosis and counselling

Pregnancy is poorly tolerated in some women with pre-existing DCM, with the potential for significant deterioration in LV function.\textsuperscript{29} Predictors of maternal mortality are NYHA class III/IV and EF <40%.\textsuperscript{288} Highly adverse risk factors include EF <20%, MR, RV failure, AF, and/or hypotension. All patients with DCM planning pregnancy require appropriate counselling and joint multidisciplinary care, as there is a high-risk of irreversible deterioration in ventricular function, maternal mortality, and foetal loss.

Pre-pregnancy management includes the modification of existing HF medications to avoid foetal harm. Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), angiotensin receptor neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs), and ivabradine are contraindicated and should be stopped prior to conception, with close clinical and echocardiographic monitoring. However, beta-blockers should be continued and switched to beta-1-selective blockers (see section 12). If EF falls, then further discussion should occur, reconsidering the safety of pregnancy.

If contraindicated drugs have been inadvertently taken during the first trimester, they should be stopped, and the patient monitored closely with maternal echocardiography and foetal ultrasound.

### 8.3 Management of heart failure during and after pregnancy

Assessment and management of pregnant patients with DCM or PPCM depends upon the clinical setting. However, all require joint cardiac and obstetric care, serial echocardiograms, serum B-type natriuretic peptide, and foetal ultrasound.\textsuperscript{46}

#### 8.3.1 Acute/subacute heart failure and cardiogenic shock during or after pregnancy

HF in DCM or PPCM can develop rapidly and Guidelines for the management of acute HF and cardiogenic shock apply.\textsuperscript{286,289} For rapid diagnosis and decision-making, a pre-specified management algorithm and expert interdisciplinary team are crucial (Figures 5 and 6).\textsuperscript{279,290}

#### 8.3.1.1 Haemodynamic instability and cardiogenic shock

If a patient is in cardiogenic shock or dependent on inotropes or vasopressors, she should be transferred early to a facility where mechanical circulatory support teams are available.\textsuperscript{279,280} Urgent delivery by caesarean section (irrespective of gestation) should be considered with mechanical circulatory support immediately available. PPCM patients...
are sensitive to the toxic effects of beta-adrenergic agonists, which should be avoided whenever possible. Levosimendan may be the preferred inotrope.

8.3.1.2 Acute/subacute heart failure
Patients with symptoms and signs of acute HF should be evaluated according to acute HF Guidelines. Differential diagnoses include uncomplicated pregnancy, pulmonary oedema (pre-eclampsia/eclampsia), PE, pneumonia, and MI, all of which should be diagnosed or excluded using standard algorithms.

Management goals are similar to non-pregnant acute HF, while avoiding foetotoxic agents (ACE inhibitors, ARB, ARNI, MRA, and atenolol). HF with pulmonary congestion is treated with loop diuretics and thiazides if required; however, diuretics should be avoided in the absence of pulmonary congestion, due to the potential reduction in placental blood flow. Hydralazine and nitrates appear safe in pregnancy, although with less evidence for benefit than ACE inhibitors, and should only be used in the presence of hypertension, severe LV dysfunction, and/or evidence of congestion in decompensated HF. Beta-blockers should be initiated cautiously and gradually uptitrated to the maximum tolerated dose (details in section 12). High resting heart rate is a predictor of adverse outcome in PPCM, and treatment with ivabradine may be useful if the patient is not pregnant or breastfeeding.

Relapse of PPCM has been observed after rapid tapering of HF therapies, and therefore treatment should continue for at least 6 months after full recovery of LV function followed by gradual tapering.
8.3.2 Bromocriptine and peripartum cardiomyopathy

Addition of bromocriptine to standard HF therapy may improve LV recovery and clinical outcome in women with acute severe PPCM.\textsuperscript{24,25,277,278,294} Bromocriptine (2.5 mg once daily) for at least 1 week may be considered in uncomplicated cases, whereas prolonged treatment (2.5 mg twice daily for 2 weeks, then 2.5 mg once daily for 6 weeks) may be considered in patients with EF <25% and/or cardiogenic shock. Bromocriptine treatment must always be accompanied by anticoagulation with heparin (LMWH or UFH), at least in prophylactic dosages.\textsuperscript{24,25,294,295} The essential therapies for patients with acute PPCM have been summarized under the BOARD label: Bromocriptine, Oral heart failure therapies, Anticoagulants, vasoRelaxing agents, and Diuretics.\textsuperscript{296}

8.3.3 Devices and transplantation

Given the high rate of improvement of LV function during optimal HF drug therapy, early implantation of an implantable cardioverter-defibrillator (ICD) in patients with newly diagnosed PPCM or DCM is not appropriate. A wearable cardioverter-defibrillator (WCD) may prevent sudden cardiac death (SCD) during the first 3–6 months after diagnosis, especially in patients with EF <35%, allowing protected recovery from severe LV impairment.\textsuperscript{279,279} In severe LV dysfunction during the 6–12 months following first presentation despite optimal medical therapy, implantation of an ICD and cardiac resynchronization therapy (for patients with left bundle branch block and QRS >130ms) are recommended.\textsuperscript{286,298} However, mortality reduction in those with non-ischaemic cardiomyopathy is uncertain.\textsuperscript{299}

Cardiac transplantation is reserved for patients where mechanical circulatory support is not possible or desirable, or for patients who do not recover after 6–12 months. Patients with PPCM have higher rates of graft failure and death after heart transplantation.\textsuperscript{300}

8.3.3.1 Pregnancy post-cardiac transplantation

Despite successful pregnancies post-cardiac transplantation, data are limited. Multidisciplinary team management is required relating to the timing and management of pregnancy.\textsuperscript{301} Pre-conception counselling includes the risks of graft rejection and dysfunction, infection, and the teratogenicity of immunosuppressive agents. Some centres recommend human leucocyte antigen testing prior to conception. If the donated heart and father have the same human leucocyte antigen, and the recipient has donor-specific antigens, the risk of autograft rejection is high.\textsuperscript{302} PPCM recurrence rates in transplanted patients are unknown. However, as rejection risk in these patients is higher in the first year post-transplant and graft survival is shorter, many advise against pregnancy in such patients.\textsuperscript{303}

Pregnancy should be avoided for at least 1 year post-transplantation, and discouraged in patients at high-risk of rejection and/or with poor baseline graft function before pregnancy.\textsuperscript{303–305} Besides graft rejection or dysfunction and infection, hypertension is the most common maternal complication. Additional increased risks include hyperemesis and thrombo-embolic disease.\textsuperscript{301} All immunosuppressive medications enter the foetal circulation, thus the management of immunosuppression in the pregnant post-transplant recipient is highly specialized.\textsuperscript{303} As all immunosuppressive agents are excreted into breast milk with unknown long-term effects, the International Society for Heart and Lung Transplantation currently recommends against breastfeeding.\textsuperscript{303}

8.3.4 Anticoagulation

Standard indications for anticoagulation in PPCM and DCM apply during and after pregnancy. The choice of anticoagulant agent depends upon the stage of pregnancy and patient preference (see section 12 and Table 7).\textsuperscript{306} In PPCM patients with very low EF, prophylactic anticoagulation should be considered.\textsuperscript{263}

8.3.5 Delivery and breastfeeding

Urgent delivery irrespective of gestation duration should be considered in women with advanced HF and haemodynamic instability despite treatment.\textsuperscript{279} Caesarean section is recommended with central neuraxial anaesthesia. To prevent abrupt pressure or volume changes, epidural anaesthesia might be the method of choice but should be carefully titrated, guided by an expert anaesthetic team.\textsuperscript{279,290} In stable congestive HF, vaginal delivery is preferred with spinal/epidural analgesia.

In HF with reduced EF (HFrEF), breastfeeding is discouraged in more severe cases (e.g. NYHA III/IV). Stopping lactation reduces the high metabolic demand and enables early optimal HF treatment.\textsuperscript{24} For drug treatment during breastfeeding see section 12.

8.4 Hypertrophic cardiomyopathy

The true prevalence of HCM in different populations is a topic of debate, but a number of methodologically diverse studies in North America, Europe, Asia, and Africa have reported a prevalence of unexplained increase in LV thickness in the range of 0.02–0.23% in adults.\textsuperscript{65} The observed incidence of HCM in pregnancy is <1:1000.\textsuperscript{65,307}

Women with HCM usually tolerate pregnancy well. In a recent meta-analysis, maternal mortality was 0.5%, and complication or worsening of symptoms occurred in 29% of cases. Foetal mortality by spontaneous abortion (15%), therapeutic abortion (5%), or stillbirth (2%) is comparable to the general population; however, the risk of premature birth is increased (26%).\textsuperscript{308,309} Risk is increased where women are symptomatic pre-pregnancy or exhibit a high-risk profile, including diastolic dysfunction, severe LV outflow tract obstruction, and arrhythmia.\textsuperscript{310,311} Medication in the pre-pregnancy period, and a CARPREG or ZAHARA score ≥1, are risk factors for pregnancy/post-partum cardiac events.\textsuperscript{312} Symptoms are typical for HF with pulmonary congestion and echocardiography is usually diagnostic.

8.4.1 Management

Women in WHO class II should be assessed each trimester, and those in class III assessed monthly or bimonthly.\textsuperscript{9} Beta-blockers should be continued if they are already being taken (see section 12). They should be started when new symptoms occur, for rate control in AF, and to suppress ventricular arrhythmias, with verapamil as second choices when beta-blockers are not tolerated (with foetal monitoring for AV block).\textsuperscript{65,313}

Cardioversion should be considered for poorly tolerated persistent AF.\textsuperscript{314} Therapeutic anticoagulation is recommended for those with paroxysmal or persistent arrhythmias. Hypoventilation is poorly tolerated. Patients with a past history or family history of sudden death need close surveillance with prompt investigation if they develop symptoms of palpitations or presyncope. When indicated, a device should be implanted.\textsuperscript{315,316}
8.4.2 Delivery
Low-risk cases may have a spontaneous labour and vaginal delivery. Caesarean section should be considered in patients with severe LV outflow tract obstruction, pre-term labour while on OACs, or severe HF. Epidural and spinal anaesthesia must be applied cautiously, especially with severe LV outflow tract obstruction, because of potential hypovolaemia, and single-shot spinal anaesthesia avoided.

During delivery, monitoring of heart rate and rhythm should be considered in patients with a high-risk of developing arrhythmias. Oxytocin should be given as a slow infusion and any i.v. fluids given judiciously.

8.5 Recommendations

### Recommendations for the management of cardiomyopathies and heart failure

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticoagulation is recommended in patients with intracardiac thrombus detected by imaging or with evidence of systemic embolism.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>It is recommended to treat women with HF during pregnancy according to current guidelines for non-pregnant patients, respecting contraindications for some drugs in pregnancy (see Table 7).</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>It is recommended to inform women with HFrEF about the risk of deterioration of the condition during gestation and peripartum.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Therapeutic anticoagulation with LMWH or vitamin K antagonists according to the stage of pregnancy is recommended for patients with atrial fibrillation.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>In HFrEF, it is recommended that beta-blockers are continued in women who used them before pregnancy or are installed with caution, if clinically indicated.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>In patients with PPCM and DCM, counselling for recurrence risk during subsequent pregnancy is recommended in all cases, even after recovery of LV function.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>As rapid diagnosis and decision-making is crucial for all pregnant women with acute HF, a pre-specified management algorithm and an interdisciplinary team should be established.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Patients in cardiogenic shock/dependent on inotropes should be transferred early to a facility where mechanical circulatory support is available.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Bromocriptine treatment should be accompanied by prophylactic (or therapeutic) anticoagulation.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Due to the high metabolic demands of lactation and breastfeeding, preventing lactation may be considered in patients with severe HF.</td>
<td>IIb</td>
<td>B</td>
</tr>
<tr>
<td>In patients with PPCM, bromocriptine treatment may be considered to stop lactation and enhance recovery (LV function).</td>
<td>IIb</td>
<td>B</td>
</tr>
<tr>
<td>In women with PPCM and DCM, subsequent pregnancy is not recommended if LVEF does not normalize.</td>
<td>III</td>
<td>C</td>
</tr>
</tbody>
</table>

**HCM**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>In patients with HCM, the same risk stratifications as for non-pregnant women are recommended.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>In patients with HCM, it is recommended that beta-blockers are continued in women who used them before pregnancy.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>In patients with HCM, beta-blockers should be started in women who develop symptoms due to outflow tract obstruction or arrhythmia during pregnancy.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>In HCM, cardioversion should be considered for persistent atrial fibrillation.</td>
<td>IIa</td>
<td>C</td>
</tr>
</tbody>
</table>

DCM = dilated cardiomyopathy; HCM = hypertrophic cardiomyopathy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; LMWH = low molecular weight heparin; LV = left ventricular; LVEF = left ventricular ejection fraction; PPCM = peripartum cardiomyopathy.

*Class of recommendation.

*Level of evidence.
9. Arrhythmias

9.1 Introduction
Tachyarrhythmias, particularly AF, may manifest for the first time and become more frequent during pregnancy, especially in older women and in women with congenital heart disease. AF (27/100 000) and paroxysmal supraventricular tachycardia (PSVT) (22-24/100 000) are, apart from premature beats, the most frequent arrhythmias. Symptomatic exacerbations of PSVT are outlined in ‘Recommendations for the management of arrhythmias’ below. The i.v. administration of adenosine is recommended as the first drug of choice for acute conversion of PSVT (see table ‘Recommendations for the management of arrhythmias’).

For the prevention of PSVT, beta-blockers (except atenolol) or verapamil are first-line agents, except for patients with Wolff–Parkinson–White syndrome (see section 12). The use of preventive drug therapy should be related to the severity of symptoms and haemodynamic compromise during tachycardia.

Focal atrial tachycardia (AT) can be associated with drug resistance and tachycardia-induced cardiomyopathy. Adenosine may aid in diagnosis and terminates focal AT in 30% of cases. AV nodal blocking drugs are recommended for long-term rate control. Flecainide, propafenone (in the absence of ischaemic heart disease), or sotalol should be considered for rhythm control if these agents fail (see Table 7).

9.2 Maternal risk
AF is associated with an increased mortality risk [odds ratio (OR) 13.13, 95% CI 7.77–22.21; P <0.0001]. and a rapid ventricular response can lead to serious haemodynamic consequences for both the mother and the foetus. Diagnosis and treatment of underlying conditions are the first priorities. Patients with a known history of any symptomatic supraventricular tachycardia (SVT) or VT should be considered for catheter ablation prior to pregnancy.

SCD is recognized as an increasing risk factor in pregnancy and therefore cascade screening for channelopathies with genetic counselling is important. Women with congenital LQTS are at substantial risk of cardiac events during the post-partum period. New-onset VT warrants the exclusion of underlying structural heart disease, as it is associated with increased risk of SCD for the mother (OR 40.89, 95% CI 26.08–64.1; P <0.0001).

Bradyarrhythmias and conduction disturbances usually have a favourable outcome in the absence of underlying heart disease.

9.3 Obstetric and offspring risk
Pregnant PSVT subjects have worse obstetric and foetal outcomes, with higher adjusted ORs (1.54–3.52) for severe maternal morbidity, caesarean delivery, low birth weight, pre-term labour, foetal stress, and foetal abnormalities than those without PSVT. Women with congenital heart disease are more likely to die during admission for delivery than those without (OR 6.7), arrhythmia being the most frequent cardiovascular event. Recommendations for optimal surveillance levels during delivery for women with arrhythmias are outlined in ‘Recommendations for the management of arrhythmias’.

9.4 Supraventricular tachycardia
Recommendations for acute termination of PSVT (AV nodal re-entry tachycardia and AV re-entry tachycardia) are outlined in ‘Recommendations for the management of arrhythmias’ below. The choice of prophylactic antiarrhythmic drug therapy relates to the presence of underlying structural heart disease and LV function.
Implantation of an ICD in PPCM patients with in patients with congenital LQTS 12

The use of WDCs in Temporary ventricular pacing dur-
but recommended in selected women with symptoms due continued throughout pregnancy
Exceptions may be LQTS patients considering the rela-

Safety considerations regarding radia-
15
and the risk of inducing
and deserves further study as it has

9.8.2 Catheter ablation
Catheter ablation should be postponed to the second trimester if possible, and performed at an experienced centre using non-fluoroscopic electroanatomical mapping and catheter navigation systems.15,16 Catheter ablation of recurrent drug-refractory AV nodal re-entry tachycardia, AV re-entrant tachycardia, focal ATs, cavotricuspid isthmus-dependent atrial flutter, and certain benign right-sided VTs may be considered for ablation to avoid potentially harmful medications during pregnancy (see table ‘Recommendations for the management of arrhythmias’),12,15,17 but has no role for other macroreentry tachyarrhythmias or AF.15,17

9.8.3 Implantable cardioverter-defibrillator and pacing
The implantation of an ICD should be considered prior to pregnancy in patients with high-risk factors for SCD.72,340 Treatment with an ICD during pregnancy does not cause an increased risk of major ICD-related complications and is recommended if an indication emerges (see table ‘Recommendations for the management of arrhythmias’),330,340 Safety considerations regarding radiation during ICD implantation are similar to those discussed for catheter ablation. Subcutaneous ICD is limited by a lack of pacing capability and a higher risk of inappropriate shock, which may warrant ICD inactivation during delivery.341,342 The use of WDCs in PPCM patients is limited14 and deserves further study as it has not undergone clinical testing in pregnant patients. Routine ICD interrogation and advice is recommended prior to delivery.

Implantations, for ICD preferably one chamber, can be performed safely, especially if the foetus is beyond 8 weeks of gestation. Echocardiographic guidance or electroanatomical mapping may be helpful.344

9.7 Bradyarrhythmias
9.7.1 Sinus node dysfunction
Rare cases of sinus bradycardia may be related to the supine hypotensive syndrome of pregnancy. Symptomatic bradycardia should be managed by changing the position of the mother to a left lateral decubitus position. For persistent symptoms, a temporary pacemaker may be necessary.

9.7.2 Atrioventricular block
Isolated congenital complete heart block in the mother has a favourable outcome during pregnancy, especially when the escape rhythm has a narrow QRS complex.334,335 Temporary ventricular pacing during delivery is unnecessary in stable patients with complete heart block,334 but recommended in selected women with symptoms due to the risk of bradycardia and syncope.

9.8 Interventions
9.8.1 Electrical cardioversion
Cardioversion seems safe in all phases of pregnancy as it does not compromise foetal blood flow,336 and the risk of inducing foetal arrhythmias or initiating pre-term labour seems small.337,338 The foetal heart rate should routinely be controlled after cardioversion.219
<table>
<thead>
<tr>
<th>Risk for arrhythmia with hemodynamic compromise at delivery</th>
<th>Level of surveillance</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low-risk PSVT, AF, idiopathic VT, low-risk LQTS, WPW syndrome</td>
<td>1</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Medium-risk Unstable VT, VT, those with an implanted ICD, VT and structural heart disease, Brugada syndrome; moderate risk: LQTS, catecholaminergic polymorphic VT</td>
<td>2</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>High-risk for life threatening arrhythmia Unstable VT in structural heart disease/congenital heart disease, unstable VT/TdP in high-risk LQTS patients, short QT syndrome, high-risk catecholaminergic polymorphic VT</td>
<td>3</td>
<td>I</td>
<td>C</td>
</tr>
</tbody>
</table>

**Descriptions of actions to be planned**

<table>
<thead>
<tr>
<th>Surveillance level</th>
<th>Low 1</th>
<th>Medium 2</th>
<th>High 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consult cardiologist</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consultation with multidisciplinary team including arrhythmologists at specialized centre</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Mode and location of delivery as advised by obstetricians</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Caesarean delivery recommended</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monitor cardiac rhythm (telemetry, external rhythm monitor)</td>
<td>(x)</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Intravenous line</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Arterial line</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepare for intravenous administration of adenosine</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepare for intravenous administration of a beta-blocker</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Prepare for intravenous administration of selected antiarrhythmic drugs</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>External cardioverter defibrillator at site</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Delivery at thoracic operating theatre</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepare for transfer to cardiac intensive care unit post-partum if needed</td>
<td>x</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This table has been developed by expert consensus. AF = atrial fibrillation; ICD = implantable cardioverter-defibrillator; LQTS = long QT syndrome; PSVT = paroxysmal supraventricular tachycardia; SVT = supraventricular tachycardia; TdP = torsade de pointes; VT = ventricular tachycardia; WPW = Wolfe-Parkinson-White.

* The risk stratification should follow published Guidelines for the particular disease.

* Class of recommendation.

* Level of evidence.
## 9.9 Recommendations

### Recommendations for the management of arrhythmias

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute management (intravenous administration of drugs) of SVT and AF</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vagal manoeuvres and if these fail, adenosine are recommended for acute conversion of PSVT.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Immediate electrical cardioversion is recommended for any tachycardia with haemodynamic instability and for pre-excited AF.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Beta-1-selective blockers should be considered for acute conversion of PSVT.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Ibutilide or flecainide may be considered for termination of atrial flutter and AF in stable patients with structurally normal hearts.</td>
<td>IIb</td>
<td>C</td>
</tr>
<tr>
<td><strong>Long-term management (oral administration of drugs) of SVT and AF</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-1-selective blockers or verapamil is recommended for the prevention of SVT in patients without pre-excitation on resting ECG.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Flecainide or propafenone are recommended for the prevention of SVT in patients with WPW syndrome.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Beta-selective blockers are recommended for rate control of AT or AF.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Flecainide, propafenone, or sotalol should be considered to prevent SVT, AT, and AF if AV nodal blocking agents fail.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Digoxin and verapamil should be considered for rate control of AT or AF if beta-blockers fail.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Catheter ablation with electroanatomical systems should be considered in experienced centres in cases of drug-refractory and poorly tolerated SVT.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td><strong>Acute management (intravenous administration of drugs) of ventricular tachyarrhythmias</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immediate electrical cardioversion is recommended for sustained both unstable and stable VT.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>For acute conversion of sustained, haemodynamically stable, monomorphic VT (e.g. idiopathic VT), a beta-blocker, sotalol, flecainide, procainamide, or overdrive ventricular pacing should be considered.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td><strong>Long-term management (oral administration of drugs) of ventricular tachyarrhythmias</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICD (preferably one chamber) is recommended prior to pregnancy if clinically indicated. If indication emerges during pregnancy, ICD implantation is recommended using echocardiographic guidance or mapping, especially if the foetus is beyond 8 weeks of gestation.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Beta-blocking agents are recommended during pregnancy and post-partum in patients with long QT syndrome or catecholaminergic polymorphic VT.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Beta-blocking agents or verapamil are recommended for the prevention of idiopathic sustained VT if associated with severe symptoms or haemodynamic compromise.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>In idiopathic sustained VT, sotalol or flecainide should be considered for prevention if other drugs fail.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Catheter ablation with electroanatomical mapping systems may be considered in experienced centres in sustained drug-refractory and poorly tolerated VT if there are no other alternatives.</td>
<td>IIb</td>
<td>C</td>
</tr>
</tbody>
</table>

AF = atrial fibrillation; AT = atrial tachycardia; AV = atrioventricular; ECG = electrocardiogram; ICD = implantable cardioverter-defibrillator; PSVT = paroxysmal supraventricular tachycardia; SVT = supraventricular tachycardia; TdP = torsade de pointes; VT = ventricular tachycardia; WPW = Wolff–Parkinson–White.

*Class of recommendation.

Level of evidence.

Cardioversion of AF and atrial flutter should generally be preceded by anticoagulation (see below).

AV nodal blocking agents should not be used in patients with pre-excitation on resting ECG or pre-excited AF.

Flecainide and propafenone should be combined with AV nodal blocking agents for certain ATs, but structural heart disease, reduced left ventricular function, and bundle branch block should be excluded.

Vaughan Williams class III antiarrhythmic drugs should not be used in patients with prolonged QTc.
10. Hypertensive disorders

Hypertensive disorders in pregnancy are the most common medical complications, affecting 5–10% of pregnancies worldwide. They remain a major cause of maternal, foetal, and neonatal morbidity and mortality. Maternal risks include placental abruption, stroke, multiple organ failure, and disseminated intravascular coagulation. The foetus is at high-risk of intrauterine growth retardation (25% of cases of pre-eclampsia), pre-maturity (27% of cases of pre-eclampsia), and intraterine death (4% of cases of pre-eclampsia). 345

10.1 Diagnosis and risk assessment

Repeated BP readings should be performed, preferably on two occasions, 346 ≥15 min apart in severe hypertension (i.e. ≥160/110 mmHg in the obstetric literature). 347,348

10.1.1 Blood pressure measurement

BP should be measured in the sitting position (or the left lateral recumbent during labour) with an appropriately-sized arm cuff at heart level and using Korotkoff V for diastolic BP (DBP). Mercury sphygmomanometers are still the gold standard for BP measurement in pregnancy. Automatic devices tend to under-record the true BP and are unreliable in severe pre-eclampsia. Therefore, only devices validated according to recognized protocols should be used in pregnancy. 349,350

The diagnosis of hypertension in pregnancy by ambulatory BP monitoring (ABPM) is superior to routine BP measurement for the prediction of pregnancy outcome. 351,352 The devices used for ABPM are technically more accurate than those used for office or home BP measurement. ABPM avoids unnecessary treatment of white-coat hypertension, and is useful in the management of high-risk pregnant women with hypertension and those with diabetics or hypertensive nephropathy.

10.1.2 Laboratory tests

Basic laboratory investigations recommended for monitoring pregnant hypertensive patients include urinalysis, blood count, haematocrit, liver enzymes, serum creatinine, and serum uric acid (increased in clinically evident pre-eclampsia, hyperuricaemia in hypertensive pregnancies identifies women at increased risk of adverse maternal and foetal outcomes). 353

All pregnant women should be assessed for proteinuria in early pregnancy to detect pre-existing renal disease and, in the second half of pregnancy, to screen for pre-eclampsia. A dipstick test of ≥1+ should prompt further investigations, including an albumin/creatinine ratio (ACR), 354 which can be quickly determined in a single spot urine sample. A value <30 mg/mmol can reliably rule out proteinuria in pregnancy, 355 but a positive test should possibly be followed by a 24 h urine collection. In cases of proteinuria >2 g/day, close monitoring is warranted. However, the result of a 24 h urine collection is often inaccurate 356 and delays the diagnosis of pre-eclampsia. Consequently, an ACR cut-off of 30 mg/mmol can be used to identify significant proteinuria.

In addition to basic laboratory tests, the following investigations may be considered:

- Ultrasound investigation of the adrenals, and plasma and urinary fractionated metanephrine assays in hypertensive pregnant women with a suggestive clinical presentation of pheochromocytoma in particular.
- Doppler ultrasound of uterine arteries (performed after 20 weeks of gestation) is useful to detect those at higher risk of gestational hypertension, pre-eclampsia, and intraterine growth retardation. 357
- An sFlt1 to placental growth factor (sFlt1:PIGF) ratio ≤38 can be used to exclude the development of pre-eclampsia in the next week when suspected clinically. 358,359

10.2 Definition and classification of hypertension in pregnancy

The definition of hypertension in pregnancy is based on office (or in-hospital) BP values [systolic BP (SBP) ≥140 mmHg and/or DBP ≥90 mmHg] 360–362 and distinguishes mildly (140–159/ 90–109 mmHg) or severely (≥160/110 mmHg) elevated BP, in contrast to the grades used by the joint ESC/ESH Hypertension Guidelines. 348

Hypertension in pregnancy is not a single entity but comprises: 9

- Pre-existing hypertension: precedes pregnancy or develops before 20 weeks of gestation. It usually persists for more than 42 days post-partum and may be associated with proteinuria.
- Gestational hypertension: develops after 20 weeks of gestation and usually resolves within 42 days post-partum.
- Pre-eclampsia: gestational hypertension with significant proteinuria (>0.3 g/24 h or ACR >30 mg/mmol). It occurs more frequently during the first pregnancy, in multiple pregnancy, in hydatidiform mole, in antiphospholipid syndrome, or with pre-existing hypertension, renal disease, or diabetes. It is often associated with foetal growth restriction due to placental insufficiency and is a common cause of prematurity. The only cure is delivery. 63 As proteinuria may be a late manifestation of pre-eclampsia, it should be suspected when de novo hypertension is accompanied by headache, visual disturbances, abdominal pain, or abnormal laboratory tests, specifically low platelets and/or abnormal liver function.
- Pre-existing hypertension plus superimposed gestational hypertension with proteinuria.
- Antenatally unclassifiable hypertension: this term is used when BP is first recorded after 20 weeks of gestation and hypertension is diagnosed; re-assessment is necessary after 42 days post-partum.

10.3 Prevention of hypertension and pre-eclampsia

Women at high or moderate risk of pre-eclampsia should be advised to take 100–150 mg of aspirin daily from week 12 to weeks 36–37. 346,345

Downloaded from https://academic.oup.com/eurheartj/article-abstract/39/34/3165/5078465 by guest on 17 June 2019
High risk of pre-eclampsia includes any of the following:

- hypertensive disease during a previous pregnancy
- chronic kidney disease
- autoimmune disease such as systemic lupus erythematosus or antiphospholipid syndrome
- type 1 or type 2 diabetes
- chronic hypertension.

Moderate risk of pre-eclampsia includes more than one of the following risk factors:

- first pregnancy
- age 40 years or older
- pregnancy interval of more than 10 years
- BMI of $>35$ kg/m$^2$ at first visit
- family history of pre-eclampsia
- multiple pregnancy.

Calcium supplementation (1.5–2 g/day, orally) is recommended for the prevention of pre-eclampsia in women with low dietary intake of calcium ($<600$ mg/day).$^{366}$ to be commenced at the first antenatal visit.

Vitamins C and E do not decrease pre-eclampsia risk; on the contrary, they are more frequently associated with a birth weight $<2.5$ kg and adverse perinatal outcomes. $^{367–370}$

### 10.4 Management of hypertension in pregnancy

#### 10.4.1 Background

Management of hypertension in pregnancy depends on the BP, gestational age, and the presence of associated maternal and foetal risk factors.

Most women with pre-existing hypertension and normal renal function have non-severe hypertension (140–159/90–109 mmHg) and are at low-risk for cardiovascular complications. Some are able to withdraw their medication in the first half of pregnancy because of the physiological fall in BP.

Evidence-based data regarding treatment of hypertension in pregnancy are lacking. The only trial of treatment of hypertension in pregnancy with adequate infant follow-up (7.5 years) was performed 40 years ago with $\alpha$-methyldopa.$^{371,372}$

In terms of treatment benefit, tight vs. less-tight control of hypertension in pregnancy is a control of Hypertension in Pregnancy Study was associated with less severe maternal hypertension, but no difference in the risk of adverse perinatal outcomes and overall serious maternal complications.$^{373}$ However, a secondary analysis of the data showed that women developing severe hypertension had higher rates of adverse maternal (pre-eclampsia, platelets $<100 \times 10^9$/L, elevated liver enzymes with symptoms, and maternal length of hospital stay $>10$ days) and perinatal outcomes (perinatal death, high-level neonatal care for $>48$ h, birth weight $<10$th percentile, pre-eclampsia, and pre-term delivery).$^{374}$ Thus, there is no evidence currently supporting target BP values in pregnancy.$^{373,375}$

#### 10.4.2 Non-pharmacological management

Non-pharmacological management of hypertension during pregnancy has a limited role to play, with randomized studies of dietary and lifestyle interventions showing minimal effects on pregnancy outcome.$^{376}$

Regular exercise might be continued with caution and obese women ($\geq 30$ kg/m$^2$) are advised to avoid a weight gain of more than 6.8 kg.$^{377}$

### 10.4.3 Pharmacological management

#### 10.4.3.1 Treatment of severe hypertension

There is no agreed definition of severe hypertension, with values ranging between 160–180 mmHg to $>110$ mmHg. This Task Force recommends considering an SBP $\geq 170$ mmHg or DBP $\geq 110$ mmHg in a pregnant woman an emergency, and hospitalization is indicated. The selection of the antihypertensive drug and its route of administration depend on the expected time of delivery. ACE inhibitors, ARBs, and direct renin inhibitors are strictly contraindicated (see section 12). Pharmacological treatment with i.v. labetalol, oral methyldopa, or nifedipine should be initiated; i.v. hydralazine is no longer the drug of choice as its use is associated with more perinatal adverse effects than other drugs.$^{378}$ However, hydralazine is still commonly used when other treatment regimens have failed to achieve adequate BP control as most obstetricians find its side effect profile acceptable.$^{379}$ Use of i.v. urapidil can also be considered. Sodium nitroprusside should only be used as the drug of last choice since prolonged treatment is associated with an increased risk of foetal cyanide poisoning.$^{51}$ The drug of choice when pre-eclampsia is associated with pulmonary oedema is nitroglycerin (glyceril trinitrate), given as an i.v. infusion of 5 $\mu$g/min, and gradually increased every 3–5 min to a maximum dose of 100 $\mu$g/min.

#### 10.4.3.2 Treatment of mild–moderate hypertension

Despite a lack of evidence, the European Guidelines$^{378,379}$ recommend the initiation of drug treatment in all women with persistent elevation of BP $\geq 150/95$ mmHg and at values $>140/90$ mmHg in women with:

- gestational hypertension (with or without proteinuria)
- pre-existing hypertension with the superimposition of gestational hypertension
- hypertension with subclinical organ damage or symptoms at any time during pregnancy.

Methyldopa, beta-blockers (most data available for labetalol), and calcium antagonists (most data available for nifedipine) are the drugs of choice.$^{380,381}$ Beta-blockers appear to be less effective than calcium antagonists and may induce foetal bradycardia, growth retardation, and hypoglycaemia; consequently, their type and dose should be carefully selected, with atenolol best avoided (see section 12 and Table 7). Women with pre-existing hypertension may continue their current antihypertensive medication unless on ACE inhibitors, ARBs, and direct renin inhibitors, which are contraindicated due to adverse foetal and neonatal outcomes. The plasma volume is reduced in pre-eclampsia, therefore diuretic therapy is best avoided unless in the context of oliguria, when low-dose furosemide may be considered. Delivery of i.v. magnesium sulfate is recommended for the prevention of eclampsia and treatment of seizures, but should not be given concomitantly with CCBs (there is a risk of hypotension due to potential synergism).$^{382}$

### 10.5 Delivery

Delivery is indicated in pre-eclampsia with visual disturbances or haemostatic disorders, and at 37 weeks in asymptomatic women.$^{383}$
10.6 Prognosis after pregnancy

10.6.1 Blood pressure post-partum
Post-partum hypertension is common in the first week. Methyldopa should be avoided because of the risk of post-partum depression.\(^{184}\)

10.6.2 Hypertension and lactation
Breastfeeding does not increase BP in the nursing mother. Cabergoline, rather than bromocriptine, is recommended for lactation suppression. However, there is some evidence that bromocriptine might be beneficial in PPCM,\(^ {264}\) although it may induce hypertension.

All antihypertensive agents taken by the nursing mother are excreted into breast milk.\(^ {385}\) Most of the antihypertensive drugs are present at very low concentrations, except for propranolol and nifedipine, which have breast milk concentrations similar to those in maternal plasma.

10.6.3 Risk of recurrence of hypertensive disorders in a subsequent pregnancy
Women experiencing hypertension in their first pregnancy are at increased risk in a subsequent pregnancy. The earlier the onset of hypertension in the first pregnancy, the higher the risk of recurrence in a subsequent pregnancy.

10.6.4 Long-term cardiovascular consequences of gestational hypertension
Women who develop gestational hypertension or pre-eclampsia are at increased risk of hypertension, stroke, and ischaemic heart disease in later adult life.\(^ {386,387}\) Lifestyle modifications are primarily indicated to avoid complications in subsequent pregnancies and to reduce maternal cardiovascular risk in the future. Therefore, annual visits to a primary care physician to check BP and metabolic factors are recommended.

10.6.5 Fertility treatment
There is no clear evidence that fertility treatment increases the risk of hypertension or pre-eclampsia.\(^ {188}\)

10.7 Recommendations

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class(^ a)</th>
<th>Level(^ b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low-dose aspirin (100–150 mg daily) is recommended in women at high or moderate risk of pre-eclampsia from week 12 to weeks 36–37.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>In women with gestational hypertension or pre-existing hypertension superimposed by gestational hypertension, or with hypertension and subclinical organ damage or symptoms, initiation of drug treatment is recommended at SBP &gt;140 mmHg or DBP &gt;90 mmHg.(^ {185}) In all other cases, initiation of drug treatment is recommended if SBP &gt;150 mmHg or DBP &gt;95 mmHg.(^ {348,375})</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>SBP ≥170 mmHg or DBP ≥110 mmHg in a pregnant woman is an emergency, and hospitalization is recommended.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Methyldopa (B), labetalol (C), and calcium antagonists (C) are recommended for the treatment of hypertension in pregnancy.</td>
<td>I</td>
<td>B (methyldopa) C (labetalol and calcium antagonists)</td>
</tr>
<tr>
<td>In women with gestational hypertension or mild pre-eclampsia, delivery is recommended at 37 weeks.(^ {383})</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>It is recommended to expedite delivery in pre-eclampsia and with adverse conditions such as visual disturbances or haemostatic disorders.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>In pre-eclampsia associated with pulmonary oedema, nitroglycerin given as an intravenous infusion is recommended.(^ {361})</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>In severe hypertension, drug treatment with intravenous labetalol, or oral methyldopa or nifedipine, is recommended.(^ {51})</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Limitation of weight gain to &lt;6.8 kg should be considered in obese women.(^ {177})</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>ACE inhibitors, ARBs, or direct renin inhibitors are not recommended.(^ {51,185,361})</td>
<td>III</td>
<td>C</td>
</tr>
</tbody>
</table>

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BP = blood pressure; DBP = diastolic blood pressure; SBP = systolic blood pressure.

\(^a\) Class of recommendation.

\(^b\) Level of evidence.
11. Venous thrombo-embolic disease during pregnancy and the puerperium

11.1 Epidemiology and maternal risk

VTE, encompassing PE and deep vein/venous thrombosis (DVT), represents a significant cause of pregnancy-related morbidity and mortality. Pregnancy and the puerperium are associated with an increased incidence of VTE occurring in around 0.05–0.20% of all pregnancies, and rates of PE of around 0.03%. PE is the most common cause of direct maternal death in the UK, with an incidence of 1.26 deaths per 100 000 pregnancies, and it is the fifth most common cause of maternal death overall. The case fatality rate is 3.5%. The risk of VTE is highest in the immediate post-partum period with rates of nearly 0.5% reported, and returns to the non-pregnant level after the sixth week post-partum. In women with previous VTE, recurrence rates are 7.6%, and in a high-risk population rates are 5.5% despite the use of LMWH. Consequently, a high index of suspicion and a low threshold for investigation must be maintained in pregnant women in general and in high-risk women specifically.

11.2 Risk factors for pregnancy-related venous thrombo-embolism and risk stratification

The presence of one risk factor increases the rate of VTE from 0.02 to 0.05%. Consequently, all women should undergo a documented assessment of risk factors for VTE before pregnancy or in early pregnancy. Based on this, women can be classified as being at high, intermediate, or low-risk of VTE and preventative measures applied accordingly. Previous unprovoked recurrent VTEs and previous VTE—unprovoked or oestrogen-related—are considered high-risk factors.

11.3 Prevention of venous thrombo-embolism

Prospective, non-randomized studies have shown that in women with risk factors not receiving anticoagulation, the recurrence rate of VTE ranged from 2.4–12.2%, in comparison with 0–5.5% in patients who did receive anticoagulation. LMWH has become the drug of choice for the prevention and treatment of VTE in pregnant patients. It causes less bone loss than UFH, and the osteoporotic fracture rate is lower (0.04% of pregnant women treated with LMWH). The initial dose of LMWH for thromboprophylaxis should be based on the booking weight (body weight at the first antenatal appointment with the gynaecologist, e.g. 8–10 weeks of pregnancy) since weight-based LMWH regimens have been shown to achieve prophylactic anti-Xa levels more effectively. Consequently, patients at high-risk for VTE should receive prophylactic enoxaparin at 0.5 IU/kg of body weight once daily, or another LMWH at equivalent doses, according to local practice. In morbidly obese women, weight-based dosing instead of fixed dosing is more appropriate in order to achieve adequate anti-Xa concentrations.

11.4 Management of acute venous thrombo-embolism

11.4.1 Pulmonary embolism

11.4.1.1 Clinical presentation

The symptoms and signs of PE during pregnancy are the same as in the non-pregnant state (dyspnoea, chest pain, tachycardia, haemoptysis, and collapse). However, subjective clinical assessment of PE is more difficult because dyspnoea and tachycardia are relatively common in normal pregnancy.

11.4.1.2 Diagnosis

Clinical prediction rules for assigning pre-test probabilities of VTE have been validated and diagnostic algorithms established in the non-pregnant patient. These include the use of D-dimer testing, compression ultrasonography, CT pulmonary angiography, and ventilation/perfusion lung scanning. This is not the case in pregnant women. A high index of suspicion is important, and all pregnant women with signs and symptoms suggestive of VTE should have objective testing performed urgently and receive therapeutic anticoagulation until the diagnosis is established.

D-dimer levels increase physiologically with each trimester. In one study, the mean [standard deviation (SD)] preconception D-dimer concentration was 0.43 (0.49) mg/L, and rose in the first, second, and third trimesters to 0.58 (SD 0.36), 0.83 (SD 0.46), and 1.16 (SD 0.57) mg/L, respectively, indicating a 39% relative increase in D-dimer concentration for each trimester. Thus, a positive D-dimer test in pregnancy is not necessarily indicative of VTE and further objective testing is required. A negative D-dimer test helps to exclude VTE outside pregnancy, but normal D-dimer concentrations have been reported in pregnant women with VTE, meaning that imaging remains the diagnostic test of choice during pregnancy. Currently, the optimal diagnostic approach for the pregnant patient with suspected PE is uncertain. A modified Wells score may be useful alone or in combination with D-dimer testing to stratify women into those needing imaging, allowing the remainder to avoid unnecessary radiation exposure, but this awaits further study.

If the index of suspicion of DVT remains high, then compression ultrasound should be performed, and if this is abnormal then anticoagulation is indicated. If compression ultrasonography is negative, then further testing is required and MRI should be performed. Where PE is suspected and all other investigations are normal, low-dose CT should be undertaken.

1.4.1.3 Treatment

**LMWH**: LMWH has become the drug of choice for the treatment of VTE in pregnancy and the puerperium. In suspected DVT or PE, therapeutic LMWH should be given until the diagnosis is excluded by objective testing.

**Dosage**: The recommended therapeutic dose is calculated on early pregnancy body weight (e.g. enoxaparin 1 mg/kg body weight twice daily, dalteparin 100 IU/kg body weight twice daily, or tinzaparin 175 IU/kg), aiming for 4–6 h peak anti-Xa values of 0.6–1.2 IU/mL.
Monitoring (see section 12).

**UFH:** Typically, UFH is used in the acute treatment of massive pulmonary emboli. For details on management, see section 12.

**Thrombolysis:** Thrombolitics should only be used in patients with severe hypotension or shock. When thrombolysis has been given, the loading dose of UFH should be omitted and an infusion started at a rate of 18 U/kg/h. After stabilization of the patient, UFH can be switched to LMWH.

**Fondaparinux:** Fondaparinux (7.5 mg once a day in normal-weight pregnant women) can be considered if there is an allergy or adverse response to LMWH (see section 12).

**Vena cava filters:** Indications for vena cava filters are the same as in non-pregnant patients. However, there is limited experience with their use and the risk associated with the procedure may be increased. Post-partum management: In patients with recent PE, pre-partum heparin treatment should be restarted 6 h after a vaginal birth and 12 h after a caesarean delivery, if no significant bleeding has occurred, with subsequent overlap with VKAs for at least 5 days. VKAs may be started on the second day after delivery and continued for at least 3 months, or for 6 months if PE occurred late in pregnancy. The INR should be between 2 and 3 and needs regular monitoring, ideally every 1–2 weeks. VKAs do not enter the breast milk in active forms and are safe for nursing mothers.

**11.4.2 Acute deep vein thrombosis**

11.4.2.1 Clinical presentation

Leg swelling is a frequent finding in pregnancy, giving rise to the suspicion of DVT. Since DVT is left-sided in >85% of cases, due to compression of the left iliac vein by the left iliac artery and the gravid uterus, swelling of the left leg is more suspicious. Iliac vein thrombosis may manifest with isolated pain in the buttock, groin, flank, or abdomen. Three clinical variables—left leg presentation, >2 cm calf circumference difference, and first trimester—allowed a negative predictive value of 100% (95% CI 95.8–100%) if none of the three variables was present and ultrasound of the legs was negative. However, this clinical decision rule needs to be validated in prospective studies.

11.4.2.2 Diagnosis

D-dimer: See section 11.4.1.2.

**Compression ultrasound leg vein imaging:** Compression ultrasound is the diagnostic imaging procedure of choice for suspected DVT in pregnancy with a high sensitivity and specificity for proximal DVT, but less so for distal and pelvic DVTs. Serial compression ultrasound evaluations at days 0, 3, and 7 in pregnancy give a high negative predictive value of 99.5% (95% CI 97–99%). Women with a suspected DVT in pregnancy can be evaluated with D-dimer testing (see above) and compression ultrasonography. If a proximal DVT is detected, treatment should be continued. If the initial compression ultrasound is negative, then magnetic resonance venography may be considered to exclude a pelvic DVT. If the clinical suspicion is high and the initial compression ultrasonography negative, then anticoagulation should be continued and compression ultrasonography repeated on days 3 and 7. If the initial clinical suspicion is low, then anticoagulation can be stopped and compression ultrasonography repeated on days 3 and 7. If compression ultrasonography is persistently negative, a DVT can be excluded.

**11.4.2.3 Treatment**

In acute DVT, treatment with therapeutic doses of weight adjusted LMWH should be given twice daily (see treatment of PE).

**11.5 Recommendations**

11.5.1 Management of delivery

In women on therapeutic LMWH, delivery should be planned at around 39 weeks to avoid the risk of spontaneous labour while fully anticoagulated, as LMWH can only be partially reversed with protamine sulfate.

In high-risk women on therapeutic LMWH, LMWH should be converted to UFH at least 36 h prior to delivery and the infusion stopped some 4–6 hours prior to anticipated delivery. A normalized aPTT should guide the use of regional anaesthesia.

In low-risk women on therapeutic LMWH or women on high dose prophylaxis, assuming a typical twice-a-day regimen, the evening LMWH dose should be omitted and induction or caesarean section performed the next morning, with regional anaesthesia started more than 24 h after the last dose of LMWH and if no other drugs with impairment of coagulation are used.

Therapeutic anticoagulation is associated with an increased risk of post-partum haemorrhage, so the third stage of labour should always be actively managed with modified dose oxytocin. Recently, the effect of adding 2 IU oxytocin over 5 min to a standard treatment of low-dose infusion for 4 h [10 U of oxytocin in 500 mL of normal saline given i.v. at 36 mL/h for 4 h (12 mL/min)] was analysed. The addition of 2 IU of oxytocin was not associated with any greater derangement in cardiovascular measures, but with a significantly lower volume of blood loss. We would advise using this regimen.
12. Drugs during pregnancy and breastfeeding

12.1 General principles
This section summarizes all pertinent drugs and their potential use during pregnancy and breastfeeding. There are no uniform recommendations for the treatment of pregnant women yet. This also concerns the timing of treatment initiation and the selection of medications. Prescribing information for drugs on specific databases for pregnancy and lactation (for internet databases see section 12.3) should be consulted. As drug treatment in pregnancy concerns the mother and the foetus, optimum treatment of both must be targeted. Whether drug treatment is necessary is dependent on the urgency of the indication.

In case of emergency, drugs that are not recommended by international agencies for use during pregnancy and breastfeeding should not be withheld from the mother. The potential risk of a drug and the possible benefit of the therapy must be weighed against each other.

12.1.1 Pharmacokinetics in pregnancy
During pregnancy, profound physiological changes occur that potentially change the absorption, distribution, metabolism, and excretion of drugs. The following list provides a summary of these changes:

- **Cardiovascular system, lungs and blood:**
  - increases in plasma volume, CO, stroke volume, and heart rate
  - decreases in serum albumin concentration and serum colloid osmotic pressure
  - increases in coagulation factors and fibrinogen
  - compression of the inferior vena cava by the uterus
  - increase in tidal volume and minute ventilation.

- **Liver, stomach, and intestines:**
  - changes in oxidative liver enzymes, such as increased activity of cytochrome P450 enzymes e.g. CYP2D6 and CYP3A4 nausea and vomiting
  - delayed gastric emptying
  - prolonged small bowel transit time
  - gastrointestinal reflux.

- **Kidneys:**
  - increases in renal blood flow and glomerular filtration rate.

Different sources of evidence can be used for the risk classification of drugs applied during pregnancy.
12.1.2 Drug classes in pregnancy

12.1.2.1 Anticoagulants

VKA and LMWH have advantages and disadvantages during pregnancy, which are also discussed in the sections related to specific indications. However, comparison between studies is hampered by reporting differences, and conclusions concerning the safety of low-dose VKA (warfarin <5 mg daily) in the current literature are controversial. VKAs cross the placenta and their use in the first trimester can result in embryopathy (limb defects and nasal hypoplasia) in 0.6–10% of cases. Substitution of a VKA with UFH or LMWH in weeks 6–12 almost eliminates the risk of embryopathy. There is evidence that the embryopathy risk with VKA is also dose-dependent. The risk was 0.45–0.9% in pregnancies with low-dose warfarin according to two recent systematic reviews. In addition to the risk of embryopathy that is limited to the first trimester, there is a 0.7–2% risk of foetocephaly (e.g. ocular and central nervous system abnormalities and intracranial haemorrhage) when VKAs are used in the second and third trimesters. Foetocephaly has also been described with UFH but not with LMWH throughout pregnancy. Vaginal delivery while the mother is on VKAs is contraindicated because of the risk of foetal intracranial bleeding. Haemorrhagic complications in the mother occur with all regimens.

The efficacy and safety of several LMWH preparations was shown in a review of 2777 pregnant women treated for DVT or PE. The risk of recurrent VTE with therapeutic doses of LMWH was 1.15%. The observed rate of major bleeding was 1.98%. Heparin-induced thrombocytopenia is markedly lower with LMWH than with UFH, as is heparin-induced osteoporosis (0.04%). Clinically suspected DVT or PE, therapeutic LMWH should be given until the diagnosis is excluded by objective testing.

Monitoring is essential in patients treated with LMWH with mechanical valves (see section 6), but the evidence is less clear in patients with VTE. Given the need for dose increase as pregnancy progresses to maintain a certain therapeutic anti-Xa level (peak: 0.7–1.2 U/mL), it seems reasonable to also determine anti-Xa peak levels during pregnancy in patients with VTE. This appears particularly justified in view of the fact that PE occurred in women receiving prophylactic doses of LMWH. As with the use of LMWH in women with mechanical valves, using trough levels and adjusting the dosage frequency may be necessary to achieve adequate anticoagulation.

UFH does not cross the placenta either, but is associated with more thrombocytopenia (platelet levels should be measured every 2–3 days), osteoporosis, and more frequent dosing when given subcutaneously compared with LMWH. Typically, UFH is used in the acute treatment of massive pulmonary emboli. It is also used around the time of delivery if the maintenance of anticoagulation is critical and when the ability to reverse anticoagulation urgently using protamine is advantageous. In this circumstance, LMWH should be switched to i.v. UFH at least 36 h before the induction of labour or caesarean delivery is planned. UFH should be discontinued 4–6 h before anticipated delivery and restarted 6 h after delivery if there are no bleeding complications.

12.1.2.2 Thrombolytics

Thrombolytics are considered to be relatively contraindicated during pregnancy and peripartum, and should only be used in high-risk patients with severe hypotension or shock. The risk of haemorrhage, mostly from the genital tract, is around 8%. There are more than 200 reported patients in whom streptokinase was mostly used and, more recently, recombinant tissue plasminogen activator (alteplase). Neither of these thrombolytics crosses the placenta in significant amounts. Foetal loss in 6% and pre-term delivery in 6% of cases were reported. When thrombolysis is given, the loading dose of UFH should be omitted and an infusion started at a rate of 18 U/kg/h, and carefully adjusted according to the aPTT level. After stabilization of the patient, UFH can be switched to LMWH.

12.1.2.3 Factor Xa and thrombin inhibitors

No adequate, well-controlled studies in pregnant women are available.

Fondaparinux indirectly inhibits factor Xa activity via ATIII binding. There are a few observational studies on the use of fondaparinux in pregnancy, with the largest reporting good outcomes for 65 pregnancies managed with fondaparinux. Its use can be considered if there is an allergy or adverse response to LMWH. One study showed minor transplacental passage of fondaparinux, and more work is required to assess the risk of congenital malformations.

Rivaroxaban, a direct factor Xa inhibitor, crosses the placental barrier and therefore is not recommended in pregnancy. A systematic review of 137 pregnancies with pregnancy outcome data revealed a miscarriage rate of 23% (n = 31), elective terminations in 29% (n = 39) of cases, and possible embryopathy in 2.2% (n = 3) of cases.

Most cases were on rivaroxaban, and in most pregnancies the duration of use was limited to the first trimester. Rivaroxaban is currently not recommended in pregnant patients. Other direct factor Xa inhibitors—such as apixaban, edoxaban, and the direct oral thrombin inhibitor dabigatran—should not be used in pregnant patients.

12.1.2.4 Beta-adrenergic blocking agents

Beta-adrenergic blocking agents are generally safe in pregnancy, but may be associated with increased rates of foetal growth restriction and also hypoglycaemia. Beta-1-selective drugs are preferred, except in TdP (see section 9), as they are less likely to affect uterine contraction and peripheral vasodilation, and they have exhibited lower rates of foetal growth retardation. Examples are metoprolol and bisoprolol. Unselective beta-blockers such as atenolol have been associated with higher rates of foetal growth retardation. Among the alpha/beta-blockers, labetalol is a drug of choice for hypertension in pregnancy, and carvedilol used for HF therapy did not show any association with foetal growth retardation in a recently published small study with 13 patients receiving this drug.

12.1.2.5 Renin–angiotensin–aldosterone system inhibitors: ACE inhibitors, ARBs, ARNIs, and aldosterone antagonists

ACE inhibitors and ARBs are teratogenic and contraindicated during pregnancy. Renal or tubular dysplasia, renal failure, oligohydramnios, growth retardation, ossification disorders of the skull, lung hypoplasia, contractures, large joints, anaemia, and intraterine foetal death have been described. In a systematic review, 48% of 118 foetuses exposed to ACE inhibitors and 87% of foetuses exposed to ARBs had complications related to the use of these medications. These recommendations and data also apply to ARNIs (sacubitril/valsartan), since they contain ARBs.
Spironolactone is not advised in humans during pregnancy. Eplerenone has been associated with post-implantation losses at the highest administered doses in rabbits, and should only be used in pregnancy if clearly needed.

12.1.2.6 Calcium channel blockers
CCBs do not seem to be associated with an increased incidence of congenital anomalies in humans. In one study with 721 pregnancies exposed to CCBs during the third trimester, an increased risk (relative risk 3.6, 95% CI 1.3–10.4) of neonatal seizures with CCBs was reported. Diltiazem is teratogenic in animals and only limited data in humans exist; thus, its use is only recommended in pregnancy if the potential benefit justifies the potential risk to the foetus. Verapamil is considered to be fairly safe during pregnancy, and is recommended as a second-line drug for rate control in AF and for the treatment of idiopathic sustained VTs in pregnant women.

12.1.2.7 Statins
Statins should not be prescribed in pregnancy or during breastfeeding to treat hyperlipidaemia since their harmlessness is not proven. However, in a review published in 2012, no evidence of teratogenicity of statins was found, but a harmful effect could not be ruled out due to small sample sizes. In a prospective case-control study of 249 foetuses exposed to statins, the rate of birth defects did not differ significantly between cases and controls.

12.2 US Food and Drug Administration classification
On 30 June 2015, the US Food and Drug Administration (FDA) changed the previously used classification system for the counselling of pregnant women and nursing mothers requiring drug therapy. The former A to X categories have been replaced by the Pregnancy and Lactation Labelling Rule (PLLRR), which provides a descriptive risk summary and detailed information on animal and clinical data. PLLRR applies immediately for prescription drugs approved after 30 June 2015, and the former FDA categories have to be removed for all other drugs until 29 June 2018. However, the former FDA categories will be present in the literature for a longer period of time, therefore Table 7 provides information on both systems. For detailed up-to-date information on drugs used during pregnancy and breastfeeding, please see the Supplementary Data/Web version of the guidelines. Detailed information can also be found on www.ema.europa.eu, www.accessdata.fda.gov, http://www.embryotox.de, or from prescription labels provided by manufacturers.

The previous classification consisted of category A (safest) to X (known danger: do not use!). The following categories were used for drugs during pregnancy and breastfeeding, as outlined in the 2011 Guidelines.

Category A: adequate and well-controlled studies have failed to demonstrate a foetal risk in the first trimester (and there is no evidence of risk in the later trimesters).

Category B: either animal reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women, or animal reproduction studies have shown an adverse effect that was not confirmed in controlled studies in women.

Category C: either studies in animals have revealed adverse effects on the foetus and there are no controlled studies in women, or studies in women and animals are not available. Drugs should be given only if potential benefits justify the potential risk to the foetus.

Category D: there is evidence of human foetal risk, but the benefits from use in a pregnant woman may be acceptable despite the risk (e.g. treatment of life-threatening conditions).

Category X: studies in animals or humans have demonstrated foetal abnormalities, there is evidence of foetal risk based on human experience, or both, and the risk of drug use in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

12.3 Internet databases
The authors of the database www.embryotox.de of the Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie of the Berliner Betrieb für Zentrale Gesundheitliche Aufgabe base their recommendations on a combination of scientific sources, expert opinion that is mainly based on observational data, and personal experiences of women during pregnancy and breastfeeding.

The English database www.safefetus.com is arranged in a similar fashion to the German database.

12.4 Pharmaceutical industry
Manufacturers’ instructions are mainly based on the fact that drugs are not tested sufficiently during pregnancy and breastfeeding. For this and for legal reasons, drugs are frequently considered prohibited during pregnancy and breastfeeding.

12.5 Recommendations

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before pharmacological treatment in pregnancy is started, it is recommended to</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>check Table 7 for clinical safety data.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>In the absence of clinical safety data, it is recommended to check the electronic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>drug table (<a href="http://www.safefetus.com">www.safefetus.com</a>) for pre-clinical safety data.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>In the absence of adequate human safety data, decision-making should be based on</td>
<td></td>
<td></td>
</tr>
<tr>
<td>individual drug efficacy and safety profiles, and the available animal data, and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>the decision must be made together with the patient.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decision-making based on former FDA categories alone is no longer recommended.</td>
<td>IIa</td>
<td>C</td>
</tr>
</tbody>
</table>

FDA = US Food and Drug Administration.
Class of recommendation.
Level of evidence.
### Table 7  Drugs and safety data

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Classification (Vaughan Williams for antiarrhythmic drugs)</th>
<th>Former FDA category</th>
<th>Placenta permeable</th>
<th>Transfer to breast milk (foetal dose)</th>
<th>Pre-clinical/clinical safety data</th>
</tr>
</thead>
</table>
| Abciximab                    | Monoclonal antibody with antiplatelet effects               | C                   | Unknown            | Unknown                              | Inadequate human studies  
  - use only if potential benefit outweighs potential risk  
  Animal data:  
  - no animal reproduction studies                                                                                           |
| ACE inhibitors*              | ACE inhibitor                                                | D                   | Yes                | Yes\(^b\) (maximum of 1.6%)          | Contraindicated  
  - renal or tubular dysplasia, oligohydramnios, growth retardation, ossification disorders of skull, lung hypoplasia, contractures, large joints, anaemia, intrauterine foetal death                                                                 |
| Acenocoumarol                | Vitamin K antagonist                                         | D                   | Yes                | Yes (no adverse effects reported)    | Embryopathy (mainly first trimester), bleeding (see discussion in section 5)                                                                                                                                   |
| Acetylsalicylic acid (low dose) | Antiplatelet drug                                           | B                   | Yes                | Well tolerated                      | No teratogenic effects  
  - there is insufficient clinical experience regarding the use of doses between 100–500 mg/day                                                                                                              |
| Adenosine\(^c\)              | Antiarrhythmic                                              | C                   | No                 | No                                   | No foetal adverse effects reported (limited human data)                                                                                                                                                 |
| Alirocumab                   | Lipid-lowering drug (monoclonal antibody)                    | -                   | Yes                | Unknown                              | No human data: not recommended  
  Animal data:  
  - no adverse effects on foetal growth or development in rats and monkeys  
  - maternal toxicity in rats  
  - weaker secondary response to antigen challenge in the offspring of monkeys                                                                                                                      |
| Aliskiren                    | Renin inhibitor                                              | D                   | Unknown            | Yes (secreted in rat milk)          | No use in first trimester; contraindicated in second and third trimesters  
  - see other RAAS blockers  
  Animal data:  
  - no evidence of embryofetal toxicity or teratogenicity at doses ≤600 mg/kg/day in rats or 100 mg/kg/day in rabbits  
  - fertility, pre-natal development, and post-natal development were unaffected in rats at doses ≤250 mg/kg/day. The doses in rats and rabbits provided systemic exposures of 1–4 × and 5 × MRHD                                                                 |

*Note:  
\(^a\) ACE inhibitor  
\(^b\) embryo-fetal toxicity or embryonic death  
\(^c\) antiarrhythmic  
\(^d\) lipid-lowering drug  
\(^e\) renin inhibitor
<table>
<thead>
<tr>
<th>Drug</th>
<th>Category</th>
<th>Contraindicated</th>
<th>Animal data</th>
<th>Human data</th>
<th>Foetal data</th>
</tr>
</thead>
</table>
| Ambrisentan | Endothelin receptor antagonist | X | Unknown | Unknown (contraindicated during breastfeeding) | Contraindicated  
  - no human data  
| | | | | | Animal data:  
  - teratogenic in rats (≥ 15 mg/kg/day) and rabbits (≥ 7 mg/kg/day). In both species, abnormalities of lower jaw, hard/soft palate, heart and vascular malformation, thymus and thyroid abnormalities, ossification of the basisphenoid bone, displacement of the umbilical artery |
| Amiloride | Diuretic (potassium-sparing) | B | Yes | Yes (secreted in rat milk) | Inadequate human data  
| | | | | | Animal data:  
  - no harm to foetus in teratogenicity studies in rabbits (20 × RHD) and mice (25 × RHD)  
| | | | | |  
  - no impaired fertility in rats (20 × RHD)  
| | | | | |  
  - decreased rat pup growth and survival (5 × or higher RHD) |
| Amiodarone | Antiarrhythmic (Class III) | D | Yes | Yes | Thyroid insufficiency (9%), hyperthyroidism, goitre, bradycardia, growth retardation, premature birth |
| ARB (sartans) | ARB | D | Unknown | Unknown | Contraindicated  
  - renal/tubular dysplasia, oligohydramnios, growth retardation, ossification disorders of skull, lung hypoplasia, contractures, large joints, anaemia, intrauterine foetal death |
| Penicillin, ampicillin, amoxicillin, erythromycin,mezlocillin,cephalosporins | Antibiotics | B | Yes | Yes | No foetal adverse effects reported |
| Vancomycin, imipenem, rifampicin, teicoplanin | Antibiotics | C | Unknown | Unknown | Limited data |
| Aminoglycosides, quinolones tetracyclines | Antibiotics | D | Unknown | Unknown | Foetal risk: use only when benefit outweighs risk |
| Apixaban | Anticoagulant | - | Transplacental passage in ex vivo studies of placental transfer | Extensive secretion into rat milk with the parent drug as the major component | No human data; not recommended  
| | | | | | Animal data:  
  - no direct/indirect reproductive toxicity in animal studies  
| | | | | |  
  - no foetal malformation in rodents  
| | | | | |  
  - increased maternal bleeding incidence in rodents |
<table>
<thead>
<tr>
<th>Drug</th>
<th>Class</th>
<th>Category</th>
<th>Pregnancy Category</th>
<th>Carcinogenicity</th>
<th>Teratogenicity</th>
<th>Mutagenicity</th>
<th>Animal Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atenolol</td>
<td>Beta-blocker (Class II)</td>
<td>D</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td>Hypospadias (first trimester), birth defects, low birth weight, bradycardia and hypoglycaemia in foetus (second and third trimesters)</td>
</tr>
<tr>
<td>Beraprost</td>
<td>Prostacyclin analogue</td>
<td>-</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td></td>
<td>No human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• no lethal or teratogenic effects in rats (&lt;2.0 mg/kg/day) or rabbits (&lt;1 mg/kg/day)</td>
</tr>
<tr>
<td>Bendroflumethiazide</td>
<td>Diuretic (thiazide)</td>
<td>C</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td>Inadequate human data</td>
</tr>
<tr>
<td>Bisoprolol</td>
<td>Beta-blocker (Class II)</td>
<td>C</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td>Foetal bradycardia and hypoglycaemia</td>
</tr>
<tr>
<td>Bosentan</td>
<td>Endothelin receptor antagonist</td>
<td>X</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td></td>
<td>Contraindicated</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• no human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• teratogenic in rats (≥ 60 mg/kg/day; 2 × MRHD), malformations of the head, mouth, face, and large blood vessels; increased stillbirths and pup mortality (60/300 mg/kg/day; 2 × and 10 × MRHD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• no birth defects in rabbits (&lt;1500 mg/kg/day)</td>
</tr>
<tr>
<td>Bumetanide</td>
<td>Diuretic (loop)</td>
<td>C</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td></td>
<td>Inadequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• in rodents, no teratogenicity with oral application</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• no teratogenic effects with i.v. application (rats/mice: 140 × MRHD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• moderate growth retardation and increased incidence of delayed ossification of sternae in rats (at 3400 × oral MRHD; not seen at 1000 × oral MRHD)</td>
</tr>
<tr>
<td>Cangrelor</td>
<td>Antiplatelet drug</td>
<td>C</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td></td>
<td>No human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• no malformations in rat or rabbit, no teratogenicity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• foetal growth retardation in rats (at 5 × less than the MRHD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• increased incidence of abortion and intrauterine losses, and foetal growth retardation in rabbits (12 × MRHD)</td>
</tr>
<tr>
<td>Carvedilol</td>
<td>Alpha/beta-blocker</td>
<td>C</td>
<td>Yes (data from rats; no human data available)</td>
<td>Yes</td>
<td></td>
<td>Yes</td>
<td>No adequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• bradycardia and hypoglycaemia in foetus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• use only if potential benefit outweighs potential risk</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• increased post-implantation loss, decrease in foetal body weight, and delayed skeletal development in rats (50 × MRHD). No developmental toxicity in rats at 10 × MRHD</td>
</tr>
<tr>
<td>Drug</td>
<td>Type</td>
<td>Pregnancy Class</td>
<td>Teratogenicity</td>
<td>Lactation Considerations</td>
<td>Toxicity in Rabbits</td>
<td>Human Data</td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------------</td>
<td>-----------------</td>
<td>----------------</td>
<td>--------------------------</td>
<td>---------------------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>Antiplatelet drug</td>
<td>B</td>
<td>Unknown</td>
<td>Yes (secreted in rat milk)</td>
<td>Increased post-implantation loss in rabbits (25× MRHD). No developmental toxicity in rabbits at 5× MRHD. No adequate human data.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animal data:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No impaired fertility or foetotoxicity in rats (65× MRHD) and rabbits (78× MRHD).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colestipol, cholestyramine</td>
<td>Lipid-lowering drugs</td>
<td>C</td>
<td>Unknown</td>
<td>Yes (lowering fat-soluble vitamins)</td>
<td>May impair absorption of fat-soluble vitamins, e.g. vitamin K → cerebral bleeding (neonatal)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animal data:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female fertility: decrease in implantations/increase in pre-implantation loss (plasma exposure five-fold higher compared with patients).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decrease in foetal body weight and embryofoetal viability in rodents (plasma exposure 5- to 10-fold higher compared with patients).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased maternal bleeding (vaginal/uterine) in rodents.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dabigatran</td>
<td>Anticoagulant</td>
<td>-</td>
<td>Transplacental passage in ex vivo studies of placental transfer</td>
<td>Unknown</td>
<td>No human data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animal data:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female fertility: decrease in implantations/increase in pre-implantation loss (plasma exposure five-fold higher compared with patients).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decrease in foetal body weight and embryofoetal viability in rodents (plasma exposure 5- to 10-fold higher compared with patients).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased maternal bleeding (vaginal/uterine) in rodents.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Danaparoid</td>
<td>Anticoagulant</td>
<td>B</td>
<td>No</td>
<td>No</td>
<td>Limited human data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animal data:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No impaired fertility or foetotoxicity in rats (8.7× RHD) and rabbits (6× RHD).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digoxin</td>
<td>Cardiac glycoside</td>
<td>C</td>
<td>Yes</td>
<td>Yes&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Serum levels unreliable, safe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dihydralazine</td>
<td>Vasodilator</td>
<td>-</td>
<td>Unknown</td>
<td>Yes</td>
<td>Maternal side effects: reflex tachycardia, headache, tachyphylaxis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animal data:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lupus-like symptoms (maternal/foetal).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diltiazem</td>
<td>Calcium channel blocker (Class IV)</td>
<td>C</td>
<td>No</td>
<td>Yes&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Possible teratogenic effects</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animal data:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Embryo and foetal lethality in mice, rats, and rabbits (4–6× RHD), and abnormalities of the skeleton, heart, retina, and tongue.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mice, rats, or rabbits: reductions in early individual pup weights and pup survival, prolonged delivery, and increased incidence of stillbirths.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>b</sup>Serum levels unreliable, safe.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Class</th>
<th>Pregnancy Category</th>
<th>Use During Pregnancy</th>
<th>Animal Data</th>
</tr>
</thead>
</table>
| Disopyramide (Class IA)      | C                      | Yes               | Yes<sup>b</sup>       | Uterine contractions  
  - use only when benefit outweighs risk  
  Animal data:  
  - no teratogenicity  
  - decreased implantation sites, decreased pup growth and survival (20x RHD) |
| Dronedarone (Class III)      | -                      | Yes (data from animals; no human data available) | Yes (data from animals; no human data available) | Not recommended: limited human data  
  Animal data:  
  - reproductive toxicity (post-implantation losses, reduced foetal and placental weights, and external, visceral and skeletal malformations) |
| Edoxaban Anticoagulant       | -                      | Unknown            | Animal studies show excretion in breast milk; contraindicated in breastfeeding | Contraindicated:  
  - human data: Hokusai-VTE study: 10 cases with exposure in first trimester, for up to 6 weeks. Results: six live births (four full term and two pre-term), one first trimester spontaneous abortion, and three elective terminations  
  Animal data:  
  - reproductive toxicity (gallbladder variations, increased post-implantation losses (49–65x MRHD)  
  - vaginal haemorrhage at higher doses in rats/rabbits |
| Enoximone Phosphodiesterase inhibitor | -                      | Unknown            | Unknown               | Inadequate human studies  
  - use only if necessary |
| Eplerenone Aldosterone antagonist | B                      | Unknown            | Yes (data from animals; no human data available) | Inadequate human data  
  - should be used during pregnancy only if clearly needed  
  Animal data:  
  - no teratogenic effects in rats or rabbits (exposures up to 32 and 31 times the human AUC, respectively);  
  - decreased body weight in maternal rabbits  
  - increased rabbit foetal resorptions and post-implantation loss at the highest administered dose |
| Epoprostenol Prostacyclin analogue | B                      | Unknown            | Unknown               | Inadequate human data  
  Animal data:  
  - no impaired fertility or foetal harm in rats (2.5x RHD) and rabbits (4.8x RHD) |
| Evolocumab Lipid-lowering drug (monoclonal antibody) | -                      | Yes (data in monkeys; no human data available) | Unknown               | Inadequate human data  
  - not recommended  
  Animal data:  
  - no adverse effects on foetal growth or development in monkeys  
  - reduced T cell-dependent antibody response in monkeys immunized with KLH |

<sup>b</sup> Use only if necessary.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Category</th>
<th>Use in Pregnancy</th>
<th>Use in Breastfeeding</th>
<th>Embryotoxicity</th>
<th>Teratogenicity</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ezetemibe</td>
<td>Lipid-lowering drug</td>
<td>-</td>
<td>Yes (data in rats and rabbits; no human data available)</td>
<td>Unknown (increased plasma concentration in nursing rat pups)</td>
<td>Inadequate human data</td>
<td>• use only when benefit outweighs risk</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
<td>• no evidence of embryolethal effects in rats and rabbits</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
<td>• increased incidence of common foetal skeletal findings in rats (at ~10 × the human exposure at 10 mg/day)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
<td>• increased incidence of extra thoracic ribs in rabbits (at 150 × the human exposure at 10 mg/day)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
<td>• combination with statins in rats and rabbits during organogenesis results in higher ezetimibe and statin exposure</td>
</tr>
<tr>
<td>Fenofibrate</td>
<td>Lipid-lowering drug</td>
<td>C</td>
<td>Yes</td>
<td>Yes</td>
<td>Inadequate human data</td>
<td>• use only when benefit outweighs risk</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
<td>• embryocidal and teratogenic in rats (7–10 × MRHD) and embryocidal in rabbits (9 × MRHD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
<td>• in rats (9 × MRHD before and throughout gestation): delayed delivery, increased post-implantation loss, decreased litter size, decreased birth weight, 40% survival of pups at birth, 4% survival of pups as neonates, 0% survival of pups to weaning, increase in spina bifida</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
<td>• increase in foetal gross, visceral, and skeletal findings in rats (10 × MRHD on day 6–15 of gestation)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
<td>• delayed delivery, 40% decrease in live births, 75% decrease in neonatal survival, decreased pup weight in rats (7 × MRHD from day 15 of gestation through weaning)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
<td>• abortions in 10–25% of dams (9–18 × MRHD), death in 7% of foetuses (18 × MRHD).</td>
</tr>
<tr>
<td>Flecainide</td>
<td>Antiarrhythmic (Class IC)</td>
<td>C</td>
<td>Yes</td>
<td>Yes</td>
<td>Inadequate human data</td>
<td>• teratogenic effects (e.g. club paws, sternebral and vertebral abnormalities, pale hearts with contracted ventricular septa) and an embryotoxic effect (e.g. increased resorptions) in one breed of rabbit (New Zealand White) but not in another (Dutch Belted) (4 × MRHD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
<td>• no teratogenic effects in rats or mice (at 50 and 80 mg/kg/day, respectively), but delayed sternebral and vertebral ossification at high dose in rats</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
<td>• embryocidal and teratogenic in one breed of rabbit (New Zealand White) but not in another (Dutch Belted) (4 × MRHD)</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Drug</th>
<th>Category</th>
<th>Pregnancy Outcome</th>
<th>Maternal Outcomes</th>
<th>Animal Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fondaparinux</td>
<td>Anticoagulant</td>
<td>-</td>
<td>Yes (maximum of 10%)</td>
<td>Yes (excreted in rat milk) Inadequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• studies in rats/rabbits: subcutaneous doses up to 10 mg/kg/day in rats (about 32 × RHD based on body surface area) and at subcutaneous doses up to 10 mg/kg/day in rabbits (about 65 × RHD based on body surface area) revealed no evidence of impaired fertility or harm to the foetus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• should not be prescribed to pregnant women unless clearly necessary (see also discussion in section 11)</td>
</tr>
<tr>
<td>Furosemide</td>
<td>Diuretic (loop)</td>
<td>C</td>
<td>Yes</td>
<td>Adequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• unexplained maternal deaths and abortions in rabbits (2, 4, and 8 × MRHD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• increased incidence and severity of hydronephrosis in mice and rabbits</td>
</tr>
<tr>
<td>Gemfibrozil</td>
<td>Lipid-lowering drug</td>
<td>C</td>
<td>Yes</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• rats: increase in stillborns, slight reduction in pup weight, increased skeletal variations, and, rarely, anophthalmia (0.6 and 2 × RHD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• rabbits: decreased litter size (1 and 3 × RHD) and increased incidence of parietal bone variations (3 × RHD)</td>
</tr>
<tr>
<td>Glyceryl trinitrate</td>
<td>Nitrate</td>
<td>C</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• rats and rabbits (with nitroglycerin ointment): no teratogenic effects</td>
</tr>
<tr>
<td>Heparin (low molecular weight)</td>
<td>Anticoagulant</td>
<td>B</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Long-term use less osteoporosis and thrombocytopenia than UFH, increased risk of maternal bleeding (see discussion in section 3 for use during pregnancy)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Human data: retrospective cohort study with 693 live births: no increased risk of major developmental abnormalities</td>
</tr>
<tr>
<td>Heparin (unfractionated)</td>
<td>Anticoagulant</td>
<td>B</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• rats/rabbits: no evidence of teratogenic effects or foetotoxicity</td>
</tr>
</tbody>
</table>

*Continued*
<table>
<thead>
<tr>
<th>Drug</th>
<th>Class</th>
<th>Category</th>
<th>Pregnancy Category</th>
<th>Lactation</th>
<th>Maternal side effects</th>
<th>Animal data:</th>
<th>Oligohydramnios</th>
<th>Fetal side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydralazine</td>
<td>Vasodilator</td>
<td>C</td>
<td>Yes</td>
<td>Yes (1%)</td>
<td>maternal side effects: lupus-like symptoms, foetal tachyarrhythmia</td>
<td>teratogenic in mice (20–30 × MRHD) and rabbits (10–15 × MRHD); cleft palate, malformations of facial and cranial bones; no teratogenicity in rats</td>
<td>impaired foetal-placental perfusion, foetal and neonatal effects like icterus, disturbance of electrolyte balance, and thrombocytopenia</td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>Diuretic (thiazide)</td>
<td>B</td>
<td>Yes</td>
<td>Yes; milk production can be reduced</td>
<td>Animal data:</td>
<td>No such digital anomalies or other gross structural abnormalities in Sprague-Dawley rats or monkeys. In Sprague-Dawley rats, iloprost clathrate (13% iloprost) significantly increased the number of non-viable foetuses at a maternally toxic oral dosage of 250 mg/kg/day, and in Han-Wistar rats it was found to be embryolethal in 15 of 44 litters at an i.v. dosage of 1 mg/kg/day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iloprost</td>
<td>Prostacyclin analogue</td>
<td>C</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Inadequate human data</td>
<td>Animal data:</td>
<td>No evidence of impaired fertility or foetal harm in rats, mice, or rabbits (6.25 × MRHD), and unaffected post-natal development in rats and mice</td>
<td></td>
</tr>
<tr>
<td>Indapamide</td>
<td>Diuretic (thiazide)</td>
<td>B</td>
<td>Yes</td>
<td>Unknown</td>
<td>Inadequate human data</td>
<td>Animal data:</td>
<td>No dose-related increase in embryotoxicity (excess mummified pups) in rabbits at 70 mg/kg (12 × MRHD)</td>
<td></td>
</tr>
<tr>
<td>Isosorbide dinitrate</td>
<td>Nitrate</td>
<td>B</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Bradycardia</td>
<td>Animal data:</td>
<td>Inadequate human data</td>
<td></td>
</tr>
<tr>
<td>Isradipine</td>
<td>Calcium channel blocker</td>
<td>C</td>
<td>Yes</td>
<td>Unknown</td>
<td>Inadequate human data</td>
<td>Animal data:</td>
<td>No teratogenicity (up to 150 × MRHD)</td>
<td></td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th><strong>Medication</strong></th>
<th>Type</th>
<th>Category</th>
<th>Excretion</th>
<th>Human Data</th>
<th>Animal Data</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ivabradine</strong></td>
<td>I-channel blocker</td>
<td>-</td>
<td>Yes</td>
<td>Inadequate human data</td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Yes (transferred to placenta in rats)</td>
<td>• contraindicated</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Yes (animal studies show excretion in breast milk; contraindicated in breastfeeding)</td>
<td>• exposure close to therapeutic doses showed a higher incidence of foetal cardiac defects in the rat and a small number of foetuses with ectrodactyly in the rabbit drug of choice for hypertension</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• intrauterine growth retardation (second and third trimesters), neonatal bradycardia and hypoglycaemia (used near term), hypoglycaemia</td>
</tr>
<tr>
<td><strong>Labetalol</strong></td>
<td>α/β-blocker</td>
<td>C</td>
<td>Yes</td>
<td>Yes b</td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• rats and rabbits (4× or 6× MRHD): no foetal malformations</td>
</tr>
<tr>
<td><strong>Levosimendan</strong></td>
<td>Calcium sensitizer</td>
<td>-</td>
<td>Unknown</td>
<td>Inadequate human data</td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• generalized reduction in the degree of ossification in rat and rabbit foetuses, with anomalous development of the supraoccipital bone in the rabbit</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• administration before and during early pregnancy decreased the number of corpora lutea, implantations, and pups per litter, and increased the number of early resorptions and post-implantation losses in the female rat (effects were seen at clinical exposure levels)</td>
</tr>
<tr>
<td><strong>Lidocaine</strong></td>
<td>Antiarrhythmic (Class IB)</td>
<td>C</td>
<td>Yes</td>
<td>Yes b</td>
<td>Foetal bradycardia, acidosis, central nervous system toxicity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• reproduction studies in rats (6× RHD): no evidence of harm to the foetus</td>
</tr>
<tr>
<td><strong>Macitentan</strong></td>
<td>Endothelin receptor antagonist</td>
<td>X</td>
<td>Unknown</td>
<td>Contraindicated</td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• no human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• teratogenic in rabbits and rats at all doses tested, cardiovascular and mandibular arch fusion abnormalities</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• reduced pup survival and impairment of reproductive capability of offspring (6× RHD during late pregnancy/lactation)</td>
</tr>
<tr>
<td><strong>Methyldopa</strong></td>
<td>Central alpha-agonist</td>
<td>B</td>
<td>Yes</td>
<td>Yes b</td>
<td>Mild neonatal hypotension</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• no teratogenic effects in recently published prospective observational cohort study (first trimester exposure, n = 261), but higher risk of pre-term birth</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• mice (16.6× MRHD), rats (1.7× MRHD), and rabbits (3.3× MRHD): no evidence of foetal harm</td>
</tr>
</tbody>
</table>

**Continued**
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Category</th>
<th>C</th>
<th>B</th>
<th>Inadequate human data</th>
<th>Animal data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metolazone</td>
<td>Diuretic (thiazide)</td>
<td>B</td>
<td>Yes</td>
<td>Yes</td>
<td>• treatment of male rats prior to mating with untreated females: birth weight of offspring was decreased and the pregnancy rate was reduced in dams mated with males from the 10 and 50 mg/kg groups</td>
</tr>
<tr>
<td>Metoprolol</td>
<td>Beta-blocker (Class II)</td>
<td>C</td>
<td>Yes</td>
<td>Yes&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Bradycardia and hypoglycaemia in foetus</td>
</tr>
<tr>
<td>Mexiletine</td>
<td>Antiarrhythmic (Class IB)</td>
<td>C</td>
<td>Yes</td>
<td>Yes&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Inadequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• foetal bradycardia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• use only when benefit outweighs risk</td>
</tr>
<tr>
<td>Milrinone</td>
<td>Phosphodiesterase inhibitor</td>
<td>C</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Inadequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• in rats/rabbits, no teratogenicity after oral or i.v. application</td>
</tr>
<tr>
<td>Nadolol</td>
<td>Beta-blocker (Class II)</td>
<td>C</td>
<td>Unknown</td>
<td>Yes</td>
<td>Foetal bradycardia and hypoglycaemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• evidence of embryo- and foetotoxicity was found in rabbits, but not in rats or hamsters, at doses 5–10× MRHD; no teratogenic potential was observed in any of these species</td>
</tr>
<tr>
<td>Nesiritide</td>
<td>Recombinant B-type natriuretic peptide</td>
<td>C</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Inadequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• use only when benefit outweighs risk</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data</td>
</tr>
</tbody>
</table>

<sup>b</sup> Use only if clearly needed.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Class</th>
<th>Dose</th>
<th>Tocolytic</th>
<th>Fetal Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nifedipine</td>
<td>Calcium channel blocker</td>
<td>C</td>
<td>Yes</td>
<td>Yes (maximum of 1.8%) Tocolytic; sublingual application and potential synergism with magnesium sulfate may induce hypotension (mother) and foetal hypoxia. Clinical studies: first trimester (n = 34 and n = 76): no teratogenic effects. However, increased perinatal asphyxia, caesarean delivery, prematurity, and intrauterine growth retardation. Animal data: Rodents, rabbits, and monkeys: embryotoxic, placentotoxic, teratogenic, and foetal toxic effects: stunted foetuses (rats, mice, and rabbits), digital anomalies (rats and rabbits), rib deformities (mice), cleft palate (mice), small placentas and underdeveloped chorionic villi (monkeys), embryonic and foetal deaths (rats, mice, and rabbits), prolonged pregnancy (rats; not evaluated in other species), and decreased neonatal survival (rats; not evaluated in other species).</td>
</tr>
<tr>
<td>Nitroprusside</td>
<td>Vasodilator</td>
<td>C</td>
<td>Yes</td>
<td>Inadequate human data. Use only if needed. Animal data: No adequate, well-controlled studies. Foetal cyanide levels were shown to be dose-related to maternal levels of nitroprusside. In pregnant ewes, metabolic transformation led to fatal levels of cyanide in the foetuses; infusion of 25 mg/kg/min for 1 h in pregnant ewes resulted in the death of all foetuses. Infusion with 1 mg/kg/min for 1 h delivered normal lambs. Effects of administering sodium thiosulfate in pregnancy, either alone or in combination with sodium nitroprusside, are unknown.</td>
</tr>
<tr>
<td>Phenprocoumon</td>
<td>Vitamin K antagonist</td>
<td>D</td>
<td>Yes</td>
<td>Inadequate human data. Coumarin embryopathy, bleeding (see discussions in sections 3 and 5). Animal data: No malformations in rats and rabbits. At very high dose (&gt;240 × RHD), effects on maternal body weight and/or food consumption, and a slight decrease in offspring body weight (relative to controls), was documented. In pre- and post-natal rat studies (240 × RHD), maternal treatment had no effect on the behavioural or reproductive development of the offspring.</td>
</tr>
<tr>
<td>Prasugrel</td>
<td>Antiplatelet drug</td>
<td>-</td>
<td>Unknown</td>
<td>Inadequate human data. Animal data: No malformations in rats and rabbits. At very high dose (&gt;240 × RHD), effects on maternal body weight and/or food consumption, and a slight decrease in offspring body weight (relative to controls), was documented. In pre- and post-natal rat studies (240 × RHD), maternal treatment had no effect on the behavioural or reproductive development of the offspring.</td>
</tr>
<tr>
<td>Drug</td>
<td>Pharmacological Class</td>
<td>C</td>
<td>No Animal Data</td>
<td>Animal Data</td>
</tr>
<tr>
<td>--------------------</td>
<td>-----------------------</td>
<td>---</td>
<td>----------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Procainamide</td>
<td>Antiarrhythmic (Class IA)</td>
<td>C</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Unknown</td>
<td>(limited experience)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>No animal data</td>
<td></td>
</tr>
<tr>
<td>Propafenone</td>
<td>Antiarrhythmic (Class IC)</td>
<td>C</td>
<td>Yes</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Unknown</td>
<td>(limited experience)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>No animal data</td>
<td></td>
</tr>
<tr>
<td>Propranolol</td>
<td>Beta-blocker (Class II)</td>
<td>C</td>
<td>Yes</td>
<td>Yes&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Unknown</td>
<td>Bradycardia and hypoglycaemia in foetus</td>
</tr>
<tr>
<td>Quinidine</td>
<td>Antiarrhythmic (Class IA)</td>
<td>C</td>
<td>Yes</td>
<td>Yes&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Unknown</td>
<td>Thrombocytopenia, premature birth, eighth nerve toxicity</td>
</tr>
<tr>
<td>Ranolazine</td>
<td>K&lt;sub&gt;a&lt;/sub&gt;-channel blocker</td>
<td></td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Unknown</td>
<td>Inadequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>No animal data</td>
<td></td>
</tr>
<tr>
<td>Riociguat</td>
<td>Guanylate cyclase stimulator</td>
<td></td>
<td>Unknown</td>
<td>Yes (present in rat milk)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Unknown</td>
<td>Contraindicated</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>Anticoagulant</td>
<td></td>
<td>Yes</td>
<td>Yes (data from animals indicate secretion in milk)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Unknown</td>
<td>Inadequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>contraindicated</td>
<td></td>
</tr>
</tbody>
</table>

Animal data:
- rabbits (3 × MRHD) and rats (6 × MRHD): embryotoxic (decreased survival)
- rats (1 × MRHD): increases in maternal deaths, and reductions in neonatal survival, body weight gain, and physiological development at 4 × MRHD
- rats (1 × MRHD): embryotoxicity (reduced litter size, increased resorption rates) and toxicity (deaths)
- rabbits (5 × MRHD): no embryo or neonatal toxicity
- signs of embryonal and maternal toxicity at doses <400 mg/kg/day (2–2.7 × MRHD) in rats and 150 mg/kg/day (1.5–2 × MRHD) in rabbits, misshapen sternebrae and reduced ossification in offspring; these doses in rats and rabbits were associated with an increased maternal mortality rate
- rats: teratogenic and embryotoxic, increased rate of cardiac ventricular septal defect at 8 × MRHD, increased post-implantation loss at 2 × MRHD;
- rabbits: increased abortions (4 × MRHD) and foetal toxicity (13 × MRHD)
- in rats: embryofetal toxicity (post-implantation loss, retarded/progressed ossification, and hepatic multiple light-coloured spots), increased incidence of common malformations, and placental changes observed at clinically relevant concentrations; maternal haemorrhagic complications

Continued
<table>
<thead>
<tr>
<th>Drug</th>
<th>Class</th>
<th>Animal data</th>
<th>Human data</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sacubitril/valsartan</td>
<td>Angiotensin receptor neprilysin inhibitor</td>
<td>- No teratogenicity, embryotoxicity, or foetotoxicity in rats (20 × MRHD) and rabbits (40 × MRHD) during organogenesis</td>
<td>Yes (excreted in the milk of lactating rats)</td>
<td>Contraindicated: can cause foetal harm; sacubitril: inadequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- rabbits: decreased foetal body weight and skeletal malformations (5.7 × MRHD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- rats: no embryofoetal toxicity or teratogenicity at 2.2 × MRHD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- valsartan: renal or tubular dysplasia, oligohydramnion, growth retardation, ossification disorders of skull, lung hypoplasia, contractures, large joints, anaemia, and intrauterine foetal death</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- sacubitril/valsartan: rats/rabbits: increased embryofoetal toxicity, low incidence of foetal hydrocephaly with maternally toxic doses, cardiomegaly (rabbits) at maternally non-toxic doses, foetal skeletal variations (rabbits)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- adverse embryofoetal effects are attributed to ARBs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selexipag</td>
<td>IP-receptor agonist</td>
<td>- No teratogenicity, embryotoxicity, or foetotoxicity in rats (20 × MRHD) and rabbits (40 × MRHD) during organogenesis</td>
<td>Unknown</td>
<td>Inadequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- rats: no adverse developmental effects in the foetus up to 47 × MRHD, slight reduction in foetal and maternal body weight at the high dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- rabbits: no adverse developmental effects in the foetus up to 50 × MRHD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sildenafil</td>
<td>Phosphodiesterase type 5 inhibitor</td>
<td>- No teratogenicity, embryotoxicity, or foetotoxicity in rats (20 × MRHD) and rabbits (40 × MRHD) during organogenesis</td>
<td>Unknown</td>
<td>Inadequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- rats: no adverse developmental effects in the foetus up to 50 × MRHD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- rabbits: no adverse developmental effects in the foetus up to 50 × MRHD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sotalol</td>
<td>Antiarrhythmic (Class III)</td>
<td>B No teratogenic potential in rats (9 × MRHD) and rabbits (7 × MRHD)</td>
<td>Yes</td>
<td>Yes: Bradycardia and hypoglycaemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- no teratogenic potential in rats (9 × MRHD) and rabbits (7 × MRHD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- rabbits: a high dose of sotalol hydrochloride (6 × MRHD) produced a slight increase in foetal death, likely due to maternal toxicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- rabbits (18 × MRHD): increased number of early resorptions</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Medication</th>
<th>Description</th>
<th>ADR Class</th>
<th>OTC</th>
<th>Pregnancy</th>
<th>Lactation</th>
<th>Inadequate Human Data</th>
<th>Animal Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spironolactone</td>
<td>Aldosterone antagonist</td>
<td>D</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td>Antiandrogenic effects, oral clefts (first trimester)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(1.2%); milk production can be reduced</td>
<td></td>
<td></td>
<td>• inadequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• mice (dose below the MRHD): no teratogenic or other embryotoxic effects</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• rabbits (dose approximately MRHD): increased rate of resorption and lower number of live foetuses</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• rats (200 mg/kg/day): feminization of male foetuses; exposure during late pregnancy (50/100 mg/kg/day) led to dose-dependent decreases in ventral prostate and seminal vesicle weights in males, and enlarged ovaries and uteri in females</td>
</tr>
<tr>
<td>Statins</td>
<td>Lipid-lowering drugs</td>
<td>X</td>
<td>Yes</td>
<td>Yes</td>
<td>Unknown</td>
<td></td>
<td>Congenital anomalies</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• mice (dose below the MRHD): no teratogenicity, embryotoxicity, or foetotoxicity. One of two studies in rats showed decreased post-natal pup survival (at doses &gt;10× MRHD)</td>
</tr>
<tr>
<td>Tadalafil</td>
<td>Phosphodiesterase type 5 inhibitor</td>
<td>B</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td>Inadequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• rats and mice (up to 11× MRHD): no teratogenicity, embryotoxicity, or foetotoxicity.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• rats: slight delay in hepatic maturity and skeletal development at maternal non-toxic doses</td>
</tr>
<tr>
<td>Ticagrelor</td>
<td>Antiplatelet drug</td>
<td>C</td>
<td>Yes</td>
<td>Yes</td>
<td>Unknown</td>
<td></td>
<td>Inadequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• rats: minor developmental anomalies at maternal toxic doses; rabbits: slight delay in hepatic maturity and skeletal development at maternal non-toxic doses</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• rats/rabbits: slightly reduced maternal body weight, reduced neonatal viability and birth weight with delayed growth</td>
</tr>
<tr>
<td>Ticlopidine</td>
<td>Antiplatelet</td>
<td>C</td>
<td>Unknown</td>
<td>Yes</td>
<td>Unknown</td>
<td></td>
<td>Inadequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• mice (200 mg/kg/day), rats (400 mg/kg/day), and rabbits (up to 100 mg/kg/day): no teratogenic potential</td>
</tr>
<tr>
<td>Torasemide</td>
<td>Diuretic (loop)</td>
<td>B</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td></td>
<td>Inadequate human data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• no foetotoxicity or teratogenicity in rats (at 15× human dose of 20 mg/day) or rabbits (at 5× human dose of 20 mg/day): decrease in average body weight, increase in foetal resorption, delayed foetal ossification at 4× (rabbits) and 5× (rats) higher doses</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Drug</th>
<th>Class/Action</th>
<th>Pregnancy Category</th>
<th>Use</th>
<th>Excretion</th>
<th>Animal Data</th>
<th>Human Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treprostinil</td>
<td>Prostacyclin analogue</td>
<td>B</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Inadequate human data</td>
<td>use only if needed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• rabbits (subcutaneous) at dose higher than RHD: increased incidence of foetal skeletal variations</td>
<td></td>
</tr>
<tr>
<td>Tiamterene</td>
<td>Diuretic (potassium-sparing)</td>
<td>C</td>
<td>Yes</td>
<td>Yes (excretion shown in animal milk)</td>
<td>Inadequate human data</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• no foetal harm in rats (at 6 × MRHD)</td>
<td></td>
</tr>
<tr>
<td>Urapidil</td>
<td>A1 receptor-1-blocker/5-HT1A agonist</td>
<td>-</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Inadequate human data</td>
<td></td>
</tr>
<tr>
<td>Vardenafil</td>
<td>Phosphodiesterase type 5 inhibitor</td>
<td>B</td>
<td>Unknown</td>
<td>Yes (in rats)</td>
<td>Inadequate human data</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• rats (100 × MRHD) and rabbits (20 × MRHD): no teratogenicity, embryotoxicity, or foetotoxicity; retarded physical development of pups in rats at 1 (= MRHD) and 8 mg/kg/day</td>
<td></td>
</tr>
<tr>
<td>Verapamil oral</td>
<td>Calcium channel blocker (Class IV)</td>
<td>C</td>
<td>Yes</td>
<td>Yesb</td>
<td>Well tolerated</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• rabbits (oral, 1.5 × RHD): no teratogenicity; rats (oral, 6 × RHD): no teratogenicity, but embryocidal, retarded foetal growth and development, and hypotension</td>
<td></td>
</tr>
<tr>
<td>Verapamil i.v.</td>
<td>Calcium channel blocker (Class IV)</td>
<td>C</td>
<td>Yes</td>
<td>Yesb</td>
<td>i.v. use is associated with a greater risk of hypotension and subsequent foetal hypoperfusion</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• see verapamil oral</td>
<td></td>
</tr>
<tr>
<td>Vernakalant</td>
<td>Antiarrhythmic</td>
<td>-</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Inadequate human data</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Animal data:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• rats: malformations (misshapen/absent/fused skull bones including cleft palates, bent radius, bent/misshapen scapula, constricted trachea, absent thyroid, and undescended testes) and increased embryofetal lethality at exposure levels higher than the single i.v. dose in humans</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Category</td>
<td>Human Data</td>
<td>Animal Data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>----------</td>
<td>------------</td>
<td>-------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vorapaxar</td>
<td>Antiplatelet</td>
<td>Yes (excretion shown in rat milk)</td>
<td>Inadequate human data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• rats/rabbits: no defects in embryofoetal development (rats: 56 × RHD; rabbits 26 × RHD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• transient effects on sensory function and neurobehavioural development in pups at 67 × RHD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• decreased memory in female pups at 31 × RHD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• pre- and post-natal studies: rat pups had decreased survival and body weight gain (at 67 × RHD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warfarin</td>
<td>Vitamin K antagonist</td>
<td>D</td>
<td>Yes (maximum of 10%), well tolerated as inactive metabolite</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Coumarin embryopathy, bleeding (see discussion in sections 3 and 5 for use during pregnancy)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For older substances, the former FDA classification is given wherever available; for newer substances released after 30 June 2015, the FDA classification has been replaced with detailed information from www.ema.europa.eu, www.accessdata.fda.gov, http://www.embryotox.de, or from prescription labels provided by manufacturers. ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; AUC = area under the curve; FDA = US Food and Drug Administration; 5-HT₁₅A = 5-hydroxytryptamine (serotonin); i.v. = intravenous; KLH = keyhole limpet haemocyanin; MRHD = maximum recommended human dose; RAAS = renin–angiotensin–aldosterone system; RHD = recommended human dose; UFH = unfractionated heparin; VTE = venous thrombo-embolism.

a The available data on first trimester use do not strongly support teratogenic potential. 45–62 Because ACE inhibitors, ARBs, aldosterone antagonists, and renin inhibitors should be avoided during pregnancy and breastfeeding the risk category is D. Positive outcomes with ACE inhibitors have been described and pregnancy does not have to be terminated if the patient was exposed to these medications, but should be followed-up closely.
b Breastfeeding is possible if the mother is treated with the drug. 37

Adenosine Most experiences with this drug are in the second and third trimesters. Its short half-life may prevent it from reaching the foetus.

Atenolol is classified D by the FDA, 48 although some authors classify it as C. 813

Digoxin The experience with digoxin is extensive, and it is considered to be the safest antiarrhythmic drug during pregnancy. A prophylactic antiarrhythmic efficacy has never been demonstrated.

Statins These should not be prescribed in pregnancy and during breastfeeding since their harmlessness is not proven. There are no expected disadvantages to the mother from a temporary interruption of the therapy during pregnancy.
13. Gaps in evidence

Epidemiological data
European epidemiological (e.g. registers such as ROPAC) data on women with CVDs and their outcomes, and the foetal risk during pregnancy and in the peripartum period, are important sources of information. However, there is also a clear need for randomized controlled trials. In women with specific aortic diseases, the outcome is not well studied and the impact of treatment with beta-blockers during pregnancy is lacking.

The impact of pregnancy in a woman with congenital or aortic disease on the long-term maternal and foetal outcome is not well studied.

The impact of fertility treatment on pregnancy complications and maternal outcomes remains unknown.

Mechanical valve prostheses
In women with mechanical valve prostheses, no prospective studies are available that compare different anticoagulation regimens. There are unresolved questions concerning LMWH, including optimal anti-Xa levels, the importance of peak vs. pre-dose levels, the best time intervals for anti-Xa monitoring, and the duration of use (first trimester or throughout pregnancy).

Coronary artery disease
In women with CAD, the required delay of a subsequent pregnancy following MI is unknown. Furthermore, optimal management and follow-up of patients with P-SCAD is a burning clinical problem. This includes the decision for interventional therapy as well as counselling on the recurrence risk for repeated pregnancies.

Drugs
The safety of antiplatelet agents used after PCI in pregnancy is not well known.

There is a lack of randomized trials on the use of antiarrhythmic drugs and interventions during pregnancy.

Data based on prospective randomized clinical trials in pregnant women to assess drug efficacy and safety are very limited. They will stay limited in some areas due to accepted ethical limitations. However, greater efforts can be made by prospective registries to answer burning treatment questions.

Studies investigating the pharmacokinetic changes during pregnancy that modify clinical drug efficacy are required.

Cardiomyopathies
The pathophysiology of PPCM has still to be explored in more detail. PPCM includes LV dysfunction due to several different causes and thus PPCM is not a well-described entity. The potential for recovery is often unclear and the risks of subsequent pregnancies are not well defined. For acute HF in the context of pregnancy there are almost no evidence-based treatments. More research is clearly needed.

Cardiac transplantation
Evidence is also limited for pregnancies in patients post-cardiac transplantation.

Delivery
Trials evaluating the level of surveillance at delivery and the warranted monitoring level after delivery are needed. Furthermore, the optimal mode of delivery is not clear for high-risk situations.

Hypertension
It is still unclear whether mild–moderate hypertension in pregnancy should be pharmacologically treated. The current guidelines are based on expert consensus regarding thresholds to initiate antihypertensive medication. Prospective studies, even observational, in this area are needed.

Diagnostic pathways
More data are needed on diagnostic pathways, specifically the place of D-dimers, in VTE. The value of monitoring anti-Xa values in patients with VTE (treatment) is unknown. Studies are needed on the benefit of using the combination of peak and trough levels. The lack of data regarding the length of anticoagulation after delivery is an unmet need.

14. Key messages

- Risk estimation should be individualized depending on the underlying cardiac diagnosis, ventricular and valvular function, functional class, presence of cyanosis, PAPs, and other factors.
- Indications for intervention (surgical or catheter) in the majority of patients do not differ in women who consider pregnancy compared with other patients. There are a few exceptions, such as some degree of aortic dilatation and severe asymptomatic MS.
- In women with a moderate or high-risk of complications during pregnancy (mWHO II–III, III, and IV), pre-pregnancy counselling and management during pregnancy and around delivery should be performed in an expert centre by a multidisciplinary team: the pregnancy heart team.
- All women with congenital or other possibly genetic heart disease should be offered foetal echocardiography in weeks 19–22 of pregnancy.
- A delivery plan should be made between 20–30 weeks of pregnancy detailing induction, management of labour, delivery, and post-partum surveillance.
- Induction of labour should be considered at 40 weeks of gestation in all women with cardiac disease.
- Vaginal delivery is the first choice for the majority of patients.
- Indications for caesarean section are:
  - pre-term labour in patients on OACs
  - aggressive aortic pathology
  - acute intractable HF
  - severe forms of PH (including Eisenmenger’s syndrome)
- Pregnancy termination should be discussed if there is a high-risk of maternal morbidity or mortality, and/or of foetal abnormality.
- Pregnancy, and consequently fertility treatment, is contraindicated in women with mWHO class IV.
- All patients with known cardiac or aortic disease need investigations and counselling about the risks of pregnancy pre-pregnancy or before assisted reproductive therapy.
- The following patients should be counselled against pregnancy:
  - with a Fontan operation and additional comorbidities (ventricular dysfunction, arrhythmias, or valve regurgitation)
– with PAH
– severe systemic ventricular dysfunction (EF <30% or NYHA class III–IV).
– severe (re-)coarctation
– systemic right ventricle with moderate or severely decreased ventricular function
– with vascular Ehlers-Danlos
– with severe aortic dilatation or (history of) aortic dissection
– with severe MS (even when asymptomatic)
– Patients with severe AS who are symptomatic, or asymptomatic patients with impaired LV function or a pathological exercise test
– if LVEF does not normalize in women with previous PPCM.

• Women with a mechanical valve prosthesis are at high-risk of maternal morbidity (especially valve thrombosis and bleeding) and even mortality, and should be managed by a pregnancy heart team in expert centres.

• LMWH should only be used when weekly monitoring of anti-Xa levels with dose adjustment is available.

• Women with HF during pregnancy should be treated according to current guidelines for non-pregnant patients, respecting contraindications for some drugs in pregnancy (see table ‘Recommendations for drug use in pregnancy’). When inotropes or more advanced treatment is necessary, transport to an expert centre is recommended.

• It is recommended to inform women with DCM and HFrEF about the risk of deterioration of the condition during gestation and peripartum.

• In women with PPCM and DCM, subsequent pregnancy is not recommended if LVEF does not normalize.

• Patients with congenital LQTS and catecholaminergic polymorphic VT are recommended beta-blockers during pregnancy and post-partum.

• Initiation of antihypertensive drug treatment is recommended in all women with persistent elevation of BP ≥150/95 mmHg and at values ≥140/90 mmHg in women with:
  – gestational hypertension (with or without proteinuria)
  – pre-existing hypertension with the superimposition of gestational hypertension
  – hypertension with subclinical organ damage or symptoms at any time during pregnancy.

• Women at high or moderate risk of pre-eclampsia should be advised to take 100–150 mg of acetylsalicylic acid daily from week 12 to week 36–37 in addition to their hypertension treatment.

• Methyldopa, labetalol, and calcium antagonists are recommended for the treatment of hypertension in pregnancy.

• LMWH is the agent of choice for VTE prophylaxis and treatment.

• Thrombolytics to treat thrombo-embolism should only be used in patients with severe hypotension or shock.

• In the case of an emergency, drugs that are not recommended by the pharmaceutical industry during pregnancy and breastfeeding should not be withheld from the mother. The potential risk of a drug and the possible benefit of the therapy must be weighed against each other.
15. ‘What to do’ and ‘what not to do’ messages from the Guidelines

<table>
<thead>
<tr>
<th><strong>Recommendations</strong></th>
<th><strong>Class</strong></th>
<th><strong>Level</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General recommendations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-pregnancy risk assessment and counselling is indicated in all women with known or suspected congenital or acquired cardiovascular and aortic disease.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>It is recommended to treat high risk patients in specialized centres by a multidisciplinary team: the pregnancy heart team.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Echocardiography is recommended in any pregnant patient with unexplained or new cardiovascular signs or symptoms.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Vaginal delivery is recommended as first choice in most patients; for most important exceptions see below.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Prophylactic antibiotic therapy to prevent endocarditis during delivery is not recommended.</td>
<td>III</td>
<td>C</td>
</tr>
<tr>
<td><strong>Recommendations for pregnancy and pulmonary hypertension or congenital heart disease</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right heart catheterization is recommended to confirm the diagnosis of PAH (group 1). This can be performed during pregnancy but with very strict indications, optimal timing, and shielding of the foetus.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Pregnancy is not recommended in patients with PAH.</td>
<td>III</td>
<td>B</td>
</tr>
<tr>
<td>Pregnancy is not recommended in patients after Fontan operation and any associated complication.</td>
<td>III</td>
<td>C</td>
</tr>
<tr>
<td><strong>Recommendations for the management of aortic disease</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All aortic diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imaging of the entire aorta (CT/MRI) is recommended before pregnancy in patients with a genetically proven aortic syndrome or known aortic disease.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>When a woman with known aortic dilatation, (history of) dissection, or genetic predisposition for dissection becomes pregnant, strict blood pressure control is recommended.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Repeated echocardiographic imaging every 4–12 weeks (depending on the diagnosis and severity of dilatation) is recommended during pregnancy and 6 months post-partum in patients with ascending aorta dilatation.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>It is recommended to deliver all women with aortic dilatation or (history of) aortic dissection in an experienced centre with a pregnancy heart team, where cardiothoracic surgery is available.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>In patients with an ascending aorta &lt;40 mm, vaginal delivery is recommended.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Specific syndromes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy is not recommended in patients with vascular Ehlers–Danlos syndrome.</td>
<td>III</td>
<td>C</td>
</tr>
<tr>
<td><strong>Recommendations for the management of native valvular heart disease</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitral stenosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>In patients with symptoms or pulmonary hypertension, restricted activities and beta-1-selective blockers are recommended.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>Diuretics are recommended when congestive symptoms persist despite beta-blockers.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>Continued</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intervention is recommended before pregnancy in patients with MS and valve area &lt;1.0 cm².</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Therapeutic anticoagulation using heparins or VKA is recommended in case of AF, left atrial thrombosis, or prior embolism.</td>
<td>I</td>
<td>C</td>
</tr>
</tbody>
</table>

**Aortic stenosis**

| Intervention is recommended before pregnancy in patients with severe AS if they are symptomatic. | I  | B |
| Intervention is recommended before pregnancy in patients with severe AS if LV dysfunction (LVEF <50%) is present. | I  | C |
| Intervention is recommended before pregnancy in patients with severe AS when they develop symptoms during exercise testing. | I  | C |

**Chronic regurgitant lesions**

| Surgical treatment is recommended before pregnancy in patients with severe aortic or mitral regurgitation and symptoms, impaired ventricular function, or ventricular dilatation. | I  | C |
| Medical therapy is recommended in pregnant women with regurgitant lesions when symptoms occur. | I  | C |

**Recommendations for the management of prosthetic heart valves**

| It is recommended to choose the valve prosthesis in women contemplating pregnancy in consultation with a pregnancy heart team. | I  | C |
| It is recommended to manage pregnancy in women with mechanical valves in a centre with a pregnancy heart team. | I  | C |
| If delivery starts while on VKA or in less than 2 weeks after discontinuation of a VKA, caesarean section is indicated. | I  | C |
| It is recommended to discontinue VKA and start adjusted-dose intravenous UFH (aPTT ≥2× control) or adjusted-dose LMWH (see separate recommendations) at the 36th week of gestation. | I  | C |
| It is recommended to anticipate the timing of delivery to ensure safe and effective peripartum anticoagulation. | I  | C |
| Immediate echocardiography is indicated in women with mechanical valves presenting with dyspnoea and/or an embolic event. | I  | C |
| During the second and third trimesters until the 36th week, VKAs are recommended in women needing a low dose. | I  | C |

**Recommendations for the management of coronary artery disease**

| ECG and measurement of troponin levels is recommended when a pregnant woman has chest pain. | I  | C |
| Primary coronary angioplasty is recommended as the preferred reperfusion therapy for STEMI during pregnancy. | I  | C |
| Breastfeeding is not recommended in mothers who take antiplatelet agents other than low-dose aspirin due to a lack of data (see section 12). | III | C |

**Recommendations for the management of cardiomyopathies and heart failure**

| Anticoagulation is recommended in patients with intracardiac thrombus detected by imaging or with evidence of systemic embolism. | I  | A |
| It is recommended to treat women with heart failure during pregnancy according to current guidelines for non-pregnant patients, respecting contraindications for some drugs in pregnancy (see Table 7). | I  | B |
| It is recommended to inform women with HFrEF about the risk of deterioration of the condition during gestation and peripartum. | I  | C |
| Therapeutic anticoagulation with LMWH or VKAs according to stage of pregnancy is recommended for patients with AF. | I  | C |
| In HFrEF, it is recommended that beta-blockers are continued in women who used them before pregnancy, or that they are installed with caution if symptoms persist. | I  | C |
| In patients with PPCM and DCM, counselling for recurrence risk during subsequent pregnancy is recommended in all cases, even after recovery of LV function. | I  | C |

Continued
### Recommendations for the management of arrhythmias

#### Acute management (intravenous administration of drugs) of SVT and AF

Immediate electrical cardioversion is recommended for any tachycardia with haemodynamic instability and for pre-excited AF.\(^1\),\(^2\),\(^1\)06\(^6\) I C

#### Long-term management (oral administration of drugs) of SVT and AF

- Beta-1-selective blockers or verapamil\(^b\) are recommended for the prevention of SVT in patients without pre-excitation on resting ECG.\(^1\),\(^2\),\(^2\)7\(^7\) I C
- Flecaïnide\(^c\) or propafenone\(^c\) are recommended for the prevention of SVT in patients with WPW syndrome.\(^1\) I C
- Beta-1-selective blockers are recommended for rate control of AT or AF.\(^1\) I C

#### Acute management (intravenous administration of drugs) of ventricular tachyarrhythmias

Immediate electrical cardioversion is recommended for both sustained unstable and stable VT.\(^7\)2 I C

#### Long-term management (oral administration of drugs) of ventricular tachyarrhythmias

Beta-blocking agents are recommended during pregnancy and post-partum in patients with long QT syndrome or catecholaminergic polymorphic ventricular tachycardia.\(^7\)2 I C

### Recommendations for the management of hypertension

#### Low-dose aspirin (100–150 mg daily) is recommended in women at high or moderate risk of pre-eclampsia from week 12 to week 36 - 37.\(^3\)47,\(^3\)48 I A

#### In women with gestational hypertension or pre-existing hypertension superimposed by gestational hypertension, or with hypertension and subclinical organ damage or symptoms, initiation of drug treatment is recommended at SBP >140 mmHg or DBP >90 mmHg. In all other cases, initiation of drug treatment is recommended at SBP >150 mmHg or DBP >95 mmHg.\(^3\)48,\(^3\)75 I C

#### SBP >170 mmHg or DBP >110 mmHg in a pregnant woman is an emergency, and hospitalization is recommended. I C

Methyldopa, labetalol, and calcium antagonists are the drugs of choice for the treatment of hypertension in pregnancy.\(^5\),\(^1\)379,\(^3\)89 I C

It is recommended to expedite delivery in pre-eclampsia, and with adverse conditions such as visual disturbances or haemodynamic disorders. I C

In severe hypertension, drug treatment with intravenous labetalol, oral methyldopa, or nifedipine is recommended.\(^5\) I C

### Recommendations for the management of venous thrombo-embolism

LMWH is recommended for the prevention and treatment of VTE in pregnant patients.\(^1\)3 I B

For high-risk women, it is recommended to give a weight-related prophylactic dose of LMWH (e.g. enoxaparin 0.5 mg/kg once daily).\(^1\) I B

It is recommended that the therapeutic dose of LMWH is based on body weight.\(^1\)4 I C

Thrombolytics to manage patients with pulmonary embolism are only recommended in patients with severe hypotension or shock.\(^5\) I C

In high-risk women, it is recommended to convert LMWH to UFH at least 36 h prior to delivery and to stop the UFH infusion 4 - 6 h prior to anticipated delivery. aPTT should be normal before regional anaesthesia.\(^2\)2 I C

Continued
Class III drugs should not be used in prolonged QTc. Cardioversion of AF and atrial flutter should generally be preceded by anticoagulation (see below).146 AF = atrial fibrillation; APTT = activated partial thromboplastin time; AS = aortic stenosis; AT = atrial tachycardia; CT = computed tomography; DBP = diastolic blood pressure; DCM = dilated cardiomyopathy; ECG = electrocardiogram; FDA = US Food and Drug Administration; HCM = hypertrophic cardiomyopathy; HFrEF = heart failure with reduced ejection fraction; LMWH = low molecular weight heparin; LV = left ventricular; LVEF = left ventricular ejection fraction; MRI = magnetic resonance imaging; MS = mitral stenosis; PAH = pulmonary arterial hypertension; PPM = peripartum cardiomyopathy; SBP = systolic blood pressure; STEMI = ST-elevation myocardial infarction; SVT = supraventricular tachycardia; UFH = unfractionated heparin; VKA = vitamin K antagonist; VT = ventricular tachycardia; VTE = venous thrombo-embolism; WPW = Wolff–Parkinson–White.

1Low-dose VKA: warfarin <5 mg/day, phenprocoumon <3 mg/day, or acenocoumarol <2 mg/day. High-dose VKA: warfarin >5 mg/day, phenprocoumon >3 mg/day, or acenocoumarol >2 mg/day.

2AV nodal blocking agents should not be used in patients with pre-excitation on resting ECG or pre-excited AF.

3Recaainde and propafenone should be combined with AV nodal blocking agents for certain atrial tachycardias, but structural heart disease, reduced left ventricular function, and bundle branch block should be excluded.

16. Appendix

ESC Committee for Practice Guidelines (CPG): Stephan Windecker (Chairperson) (Switzerland), Victor Aboyans (France), Stefan Agewall (Norway), Emanuele Barbato (Italy), Héctor Bueno (Spain), Antonio Coca (Spain), Jean-Philippe Collet (France), Ioan Mircea Coman (Romania), Veronica Dean (France), Victoria Delgado (The Netherlands), Donna Fitzsimons (UK), Oliver Gaemperli (Switzerland), Gerhard Hindricks (Germany), Bernard Jung (France), Peter Jüni (Canada), Hugo A. Katus (Germany), Juhani Knutti (Finland), Patrizio Lancellotti (Belgium), Christophe Leclercq (Switzerland), Theresa A. McDonagh (UK), Piotr Ponikowski (Poland), Dimitrios J. Richter (Greece), Peter Jucló (Switzerland), Evgeny Shlyakhto (Russia), Iain A. Simpson (UK), Miguel Sousa-Uva (Portugal), Jose Luis Zamorano (Spain).

ESC National Cardiac Societies actively involved in the review process of the 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: Algeria: Algerian Society of Cardiology, Naima Hammoudi; Armenia: Armenian Cardiologists Association, Armen Piruzyan; Austria: Austrian Society of Cardiology, Julia Mascherbauer; Azerbaijan: Azerbaijan Society of Cardiology, Fuad Samadov; Belarus: Belarusian Scientific Society of Cardiologists, Andrei Prystrom; Belgium: Belgian Society of Cardiology, Agnes Pasquet; Bosnia and Herzegovina: Association of Cardiologists of Bosnia and Herzegovina, Jasmin Caluk; Bulgaria: Bulgarian Society of Cardiology, Nina Gotcheva; Croatia: Croatian Cardiac Society, Bosko Skoric; Cyprus: Cyprus Society of Cardiology, Hera Heracleous; Denmark: Danish Society of Cardiology, Niels Vejlstrup; Estonia: Estonian Society of Cardiology, Maarja Maser; Finland: Finnish Cardiac Society, Risto Juhani Kaaja; The Former Yugoslav Republic of Macedonia: Macedonian FYR Society of Cardiology, Elizabeta Srbivoska-Kostovska; France: French Society of Cardiology, Claire Mouiner-Vehler; Georgia: Georgian Society of Cardiology, Tamar Vakhtangadze; Germany: German Cardiac Society, Karin Rybak; Greece: Hellenic Society of Cardiology, George Giannakoulas; Hungary: Hungarian Society of Cardiology, Robert Gabor Kiss; Iceland: Icelandic Society of Cardiology, Inga S. Thrandsdottir; Ireland: Irish Cardiac Society, R John Erwin; Israel: Israel Heart Society, Avital Porter; Italy: Italian Federation of Cardiology, Giovanna Geraci; Kosovo: Kosovo Society of Cardiology, Pranvera Ibrahimi; Kyrgyzstan: Kyrgyz Society of Cardiology, Olga Lunegovia; Latvia: Latvian Society of Cardiology, Iveta Mintale; Lebanon: Lebanese Society of Cardiology, Zeina Kadri; Libya: Libyan Cardiac Society, Hisham Benlami; Lithuania: Lithuanian Society of Cardiology, Jurate Barysiene; Luxembourg: Luxembourg Society of Cardiology, Cristiana A. Banu; Malta: Maltese Cardiac Society, Maryanne Caruana; Moldova: Moldavian Society of Cardiology, Cristina Grattì; Morocco: Moroccan Society of Cardiology, Laila Haddour; The Netherlands: Netherlands Society of Cardiology, Berto J. Bouma; Norway: Norwegian Society of Cardiology, Mette-Elise Estensen; Poland: Polish Cardiac Society, Piotr Hoffman; Romania: Romanian Society of Cardiology, Antoniu Octavian Petris; Russian Federation: Russian Society of Cardiology, Olga Moiseeva; San Marino: San Marino Society of Cardiology, Luca Bertelli; Serbia: Cardiology Society of Serbia, Bosiljka Vujisic Tesic; Slovakia: Slovak Society of Cardiology, Juraj Dubrava; Slovenia: Slovenian Society of Cardiology, Mirta Kozelj; Spain: Spanish Society of Cardiology, Raquel Prieto-Arévalo; Sweden: Swedish Society of Cardiology, Eva Furenäs; Switzerland: Swiss Society of Cardiology, Markus Scherzermann; Tunisia: Tunisian Society of Cardiology and Cardio-Vascular Surgery, Mohamed Sami Mourali; Turkey: Turkish Society of Cardiology, Necla Ozer; Ukraine: Ukrainian Association of Cardiology, Olena Mitshenko; United Kingdom: British Cardiovascular Society, Catherine Nelson-Piercy.


ESC Guidelines


258. Morales A, Painter T, Li R, Siegfried JD, Li D, Norton N, Hershberger RE. Rare

259. van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, Hilfiker-Kleiner D,

260. Burchill LJ, Lameijer H, Roos-Hesselink JW, Grewal J, Ruys TP, Kulikowski JD,

258. Tweet MS, Hayes SN, Gulati R, Rose CH, Best PJ. Pregnancy after spontaneous

259. Colletti PM, Lee KH, Elkayam U. Cardiovascular imaging of the pregnant

262. Bagg W, Henley PG, Macpherson P, Cundy TF. Pregnancy in women with dia-

266. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, Maggioni AP, Laroche C,

271. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K,

272. Walenta K, Schwarz V, Schirmer SH, Kindermann I, Friedrich EB, Solomayer EF,

262. Bagg W, Henley PG, Macpherson P, Cundy TF. Pregnancy in women with dia-

266. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, Maggioni AP, Laroche C,

270. van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, Hilfiker-Kleiner D,

260. Burchill LJ, Lameijer H, Roos-Hesselink JW, Grewal J, Ruys TP, Kulikowski JD,

266. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, Maggioni AP, Laroche C,

271. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K,

272. Walenta K, Schwarz V, Schirmer SH, Kindermann I, Friedrich EB, Solomayer EF,

262. Bagg W, Henley PG, Macpherson P, Cundy TF. Pregnancy in women with dia-

266. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, Maggioni AP, Laroche C,

271. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K,

272. Walenta K, Schwarz V, Schirmer SH, Kindermann I, Friedrich EB, Solomayer EF,

262. Bagg W, Henley PG, Macpherson P, Cundy TF. Pregnancy in women with dia-

266. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, Maggioni AP, Laroche C,

271. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K,

272. Walenta K, Schwarz V, Schirmer SH, Kindermann I, Friedrich EB, Solomayer EF,

262. Bagg W, Henley PG, Macpherson P, Cundy TF. Pregnancy in women with dia-

266. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, Maggioni AP, Laroche C,

271. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K,

272. Walenta K, Schwarz V, Schirmer SH, Kindermann I, Friedrich EB, Solomayer EF,


298. Duncker D, Konig T, Hohmann S, Bauersachs J, Veltmann C. Avoiding untimely implantable cardioverter/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter/defibrillator-the PROLONG study. J Am Heart Assoc 2017;6:e004512.


333. Friddy KP, Moak JP, Fries MH, Iqbal SN. Catecholaminergic ventricular tachycar-


339. Natalie A, Davidson T, Geiger MJ, Newby K. Implantable cardioverter-


342. Saltzberg MT, Szymkiewicz S, Bianco NR. Characteristics and outcomes of peri-
partum versus nonperipartum cardiomyopathy in women using a wearable car-


348. National. Collaborating Centre for Women’s and Children’s Health (UK) Hypertension in pregnancy: The management of hypertensive disorders during preg-


350. Hofmeyr GJ, Lawrie TA, Atalah AN, Duley L, Tolrani MR. Calcium supplemen-


domised trial of supplementation with vitamins C and E among pregnant women at high-risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG 2009;116:780–788.


354. Poston L, Birley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VITIP). Randomised placebo-


